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Abstract
The development of new methods that provide mechanistic information on the
structural dynamics of proteins represents a significant challenge in the field of
biochemistry. Fluorescence spectroscopy is a highly sensitive technique that is ideally
suited for monitoring protein movement in situ. However, the most commonly used
fluorophores generally yield poor structural resolution, due to their relatively large size
compared to the protein of interest. Research in our laboratory has demonstrated that a
thioamide, a single atom-substitution of the peptide backbone, is capable of quenching a
wide array of fluorophores in a distance-dependent fashion. We have shown that
thioamide quenching of tyrosine and tryptophan can be used to monitor biological
interactions, such as ligand binding to the protein Calmodulin (CaM). To expand the
utility of the thioamide group as a spectroscopic probe, our laboratory has developed
semi-synthesis techniques for its installation into full-length proteins. Having validated
thioamide quenching of intrinsic protein fluorescence in our model system, we then
applied this technique to monitoring the misfolding of the amyloidogenic protein Î±synuclein (Î±S), implicated in the pathogenesis of Parkinsonâ??s Disease. In order to
determine which of our spectroscopic pairs best behaves in accordance with our theoretical models, we
also examined thioamide quenching of Cnf using our CaM model
system. For intramolecular studies with Cnf/thioamide FRET pairs, we combined
unnatural amino acid mutagenesis with native chemical ligation to access double-labeled Î±S using a
minimum of chemical synthesis. We have also shown that we can combine unnatural amino acid
mutagenesis with expressed protein ligation at methionine to incorporate the probe pair in an entirely
traceless manner. Using thioamide/Cnf FRET of our constructs, we were able to monitor conformational
changes of monomeric Î±S with unprecedented structural resolution. In addition to our work using
thioamides, we have also developed efficient strategies for producing variants of singly and doublylabeled Î±S containing red-shifted fluorophores for fluorescence polarization (FP) and other FRET based
assays, respectively. Most recently, we have shown that we can use site specifically labeled Î±S in
conjunction with FP to glean mechanistic insight into the processes of aggregation and disaggregation.
Ultimately, these labeled constructs will allow us to study these processes in vivo.
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ABSTRACT

MINIMALLY PERTURBING FLUORESCENCE PROBE PAIRS FOR THE STUDY
OF PROTEIN FOLDING AND MISFOLDING

Rebecca Wissner
E. James Petersson
The development of new methods that provide mechanistic information on the
structural dynamics of proteins represents a significant challenge in the field of
biochemistry. Fluorescence spectroscopy is a highly sensitive technique that is ideally
suited for monitoring protein movement in situ. However, the most commonly used
fluorophores generally yield poor structural resolution, due to their relatively large size
compared to the protein of interest. Research in our laboratory has demonstrated that a
thioamide, a single atom-substitution of the peptide backbone, is capable of quenching a
wide array of fluorophores in a distance-dependent fashion. We have shown that
thioamide quenching of tyrosine and tryptophan can be used to monitor biological
interactions, such as ligand binding to the protein Calmodulin (CaM). To expand the
utility of the thioamide group as a spectroscopic probe, our laboratory has developed
semi-synthesis techniques for its installation into full-length proteins. Having validated
thioamide quenching of intrinsic protein fluorescence in our model system, we then
applied this technique to monitoring the misfolding of the amyloidogenic protein αsynuclein (αS), implicated in the pathogenesis of Parkinson’s Disease. In order to
determine which of our spectroscopic pairs best behaves in accordance with our
viii

theoretical models, we also examined thioamide quenching of Cnf using our CaM model
system. For intramolecular studies with Cnf/thioamide FRET pairs, we combined
unnatural amino acid mutagenesis with native chemical ligation to access double-labeled
αS using a minimum of chemical synthesis. We have also shown that we can combine
unnatural amino acid mutagenesis with expressed protein ligation at methionine to
incorporate the probe pair in an entirely traceless manner. Using thioamide/Cnf FRET of
our constructs, we were able to monitor conformational changes of monomeric αS with
unprecedented structural resolution. In addition to our work using thioamides, we have
also developed efficient strategies for producing variants of singly and doubly-labeled αS
containing red-shifted fluorophores for fluorescence polarization (FP) and other FRETbased assays, respectively. Most recently, we have shown that we can use sitespecifically labeled αS in conjunction with FP to glean mechanistic insight into the
processes of aggregation and disaggregation. Ultimately, these labeled constructs will
allow us to study these processes in vivo.
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Chapter 1 : Introduction

1

§1.1 Preamble
Proteins, the most diverse and structurally varied macromolecules inside of cells,
play a vital role in all of the biological processes that are required to sustain life. All
living cells require thousands of proteins, linear chains of linked amino acids, for various
complex functions such as catalysis of metabolic reactions, regulation of signaling
processes, cellular architecture, and small molecule transport. The amino acids that
comprise full-length proteins are connected to one another via amide bonds (composed of
carbon, oxygen, and nitrogen) and the universal genetic code consists of only twenty
naturally-occurring amino acids. These twenty building blocks are strung together in
different orders to assemble all of the proteins required for life, from the simplest
unicellular organisms up to humans.
Full length proteins generally twist and fold into three-dimensional structures.
Pioneering studies performed by Christian B. Anfinsen and coworkers demonstrated that
a protein’s fold is dictated by the order of its constituent amino acids and the noncovalent interactions that occur between them.1 Several decades of biochemical research
have since established that the efficient formation and maintenance of the correct overall
structure is required for proper protein function. Misfolded proteins, which fail to adopt
their correctly folded or “native state” structure, are biologically inactive.2 Furthermore,
misfolded proteins can be detrimental to cell health in that they have a tendency to
interact unfavorably with other proteins or components of the cell. In the crowded interior
of a cell, properly folded proteins are only marginally stable, and misfolding occurs
frequently. However, most cells possess a system of safeguards to prevent misfolded
proteins from persisting. In some cases, misfolding is reversible. Certain proteins inside
of cells, known as molecular chaperones, can specifically bind to misfolded proteins,
2

shield them from their environment, and enable their refolding. Alternatively, a misfolded
protein can be selectively targeted for degradation.3,4
Although these distinct quality control mechanisms may render a protein
misfolding event harmless, certain types of misfolded proteins can evade this protective
machinery and cause disease. An increasing number of neurodegenerative disorders, such
as Alzheimer’s, Parkinson’s, and Huntington’s disease have been attributed to a specific
kind of protein misfolding known as amyloidogenesis.2,5 Amyloid formation has also
been implicated in a number of other nonneuropathic diseases, including amyotrophic
lateral sclerosis, type II diabetes, and familial renal amyloidosis.2,5 Upon an initial
misfolding event, single, monomeric amyloidogenic proteins associate with each other to
form larger aggregates of multiple proteins in a self-templating fashion (Figure 1.1).
These aggregates undergo further assembly to form highly-ordered structures known as
amyloid fibrils, which ultimately deposit in the form of plaques in the brain.

Figure 1.1 Proposed Model of Amyloid Formation.
Monomers under a conformational change that leads to oligomerization and the formation of
insoluble amyloid fibrils.

Many species along this pathway (from small aggregates to fully mature fibrils)
exhibit neurotoxic properties, but it remains unclear how and why these proteins misfold
in the first place. A detailed structural understanding of the misfolding of amyloidogenic

3

proteins could ultimately result in the rational design of therapeutic strategies to combat
the formation of these toxic intermediates.
§1.2 Application of Fluorescence Spectroscopy to the Study of Protein Folding
The development of new methods to ascertain mechanistic information on the
structural dynamics of proteins remains an enduring challenge in the field of
biochemistry. The most common techniques used to study protein structure are X-ray
crystallography and nuclear magnetic resonance (NMR) spectroscopy. These methods
require large amounts of highly purified and well-folded proteins. Although these
powerful tools allow one to determine protein structures at atomic resolution, the static
images obtained cannot explain how a protein moves over time in order to perform its
function. Additional dynamic experiments must be performed that either corroborate or
disprove any mechanistic insight that is implied by the observed structure.
Fluorescence spectroscopy represents a highly sensitive technique that is ideally
suited for analyzing protein movement in solution.6,7 Since fluorescence data can be
obtained on the sub-microsecond timescale, structural information from these
experiments can be acquired in real-time. In order to perform fluorescence spectroscopy,
the protein molecule of interest must contain a fluorophore. Two natural amino acids,
tyrosine and tryptophan, are fluorescent. However, proteins typically contain multiple
copies of these amino acids, which convolute data interpretation, as the fluorescent
emissions from duplicate residues are relatively indistinguishable from one another.
Therefore, it is often useful to attach to a protein an unnatural fluorescent tag that emits
light with a unique wavelength compared to the other amino acids in the protein.
If a fluorescent tag is sensitive to changes in its local environment, it can be used
to detect overall protein motion.8 Such a fluorophore is defined as solvatochromatic.
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Solvatochroism effects arise from changes in the polarity of the surrounding environment
that lead to alterations in the fluorophore's emissive properties. For example, a
fluorescent tag may emit more brightly when it faces the non-polar interior of a protein
than when it is exposed to the hydrophilic exterior. In this case, when the protein
undergoes a change in structure that places the tag towards the interior, a shift in
fluorescence will be detected, and one can infer that protein motion has occurred (Figure
1.2). Although this type of experiment could be used to determine whether a global
conformational change has taken place, it cannot reveal how one region of the protein
moves with respect to another region of the protein (i.e., how the protein folds).

Figure 1.2 Cartoon Representation of Environmentally Sensitive Fluorophores for
Monitoring Protein Motion.
The protein calmodulin (CaM) undergoes a substantial conformational rearrangement upon
peptide binding. A strategically placed environmentally sensitive fluorophore could be used to
report on this structural change.

In order to gain a more detailed depiction of movement, one must label the
protein of interest with two tags that can interact in a distance-dependent manner. In
some cases, the light emitted by one fluorophore can be attenuated by a second chemical
species called a quencher (Figure 1.3).6 The extent to which the quencher reduces the
intensity of the emitted light can be used to measure the distance between the two probes.
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Figure 1.3 Cartoon Representation of Distance-Dependent Fluorescence Quenching.
Two fluorophores that interact in a distance-dependent manner can be used to measure the
distance between two different locations in a protein.

Clearly, the overall shape of a protein cannot be determined by obtaining a single
distance measurement between two fixed locations. However, many distance
measurements between several different pairs of points can be obtained by generating a
diverse set of labeled proteins that contain the probe pair at different locations (Figure
1.4). Using this strategy, one can map out the key folding interactions that give rise to the
protein’s overall shape, then take these individual snapshots and compile them into a
series in order to examine how these interactions change during protein movement.
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Figure 1.4 Cartoon Representations of Labeled Proteins for FRET Analyses.
Individual distance measurements obtained using a diverse set of labeled proteins can be used to
map out protein structure.

There are multiple distinct mechanisms by which fluorescence quenching can
occur between two probes in a distance-dependent manner. Förster resonance energy
transfer (FRET) is a non-radiative process by which energy is transferred from an
electronically excited donor fluorophore to a nearby acceptor chromophore (which may
or may not be fluorescent) by means of long-range dipole-dipole coupling interactions
between chromophores.9 In order for FRET to occur, the fluorescence emission spectrum
of the donor must overlap with the absorption spectrum of the acceptor chromophore.
Additionally, the relative orientations of the donor and acceptor transition dipole
moments must be favorably aligned. A further requirement for FRET is that the
fluorescence lifetime of the donor must be long enough to permit the energy transfer
event to occur. If these criteria are satisfied, the efficiency of energy transfer between a
given FRET pair will strongly depend on their spatial separation. According to Förster
theory, the efficiency of energy transfer (E) between a donor and an acceptor
7

chromophore depends on the inverse sixth power of the distance between them (r) by the
following equation:
6
0
6
0
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(Eq. 1.1)

where R0 is the Förster radius, the distance at which energy transfer is 50% efficient. The
R0 of a particular FRET pair can be calculated using:
9000(ln 10) 2 Q D J
R 
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(Eq. 1.2)

where QD is the quantum yield of the donor, n is the index of refraction of the solvent, NA
is Avogadro’s number, and J is the spectral overlap integral. κ2 is a geometrical factor
(defined in the Materials and Methods sections of Chapter 3) that relates the relative
orientation of the donor and acceptor transition moment dipoles. For a freely rotating
FRET pair, this value is often approximated as κ2 = 2/3. Conveniently, FRET can be used
to measure distances in a range that is extremely useful for studies of protein folding (10
– 100 Å).
Quenching mechanisms that occur over shorter distances, such as Dexter electron
exchange and photoinduced electron transfer (PET) can likewise be exploited for studies
in protein folding.10 Similar to FRET, Dexter and PET quenching mechanisms occur in a
non-radiative fashion, meaning that energy transfer from the excited state donor to a
nearby acceptor does not involve the emission or absorption of a photon. Dexter energy
transfer occurs when an electronically excited donor exchanges an electron with a nearby
acceptor in a concerted manner. This event returns the donor to its ground state while
leaving the acceptor in the excited state. Since orbital overlap is a requirement of electron
exchange, Dexter energy transfer only occurs over very short distances (< 10 Å) and
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drops off exponentially at longer distances. Experimentally, FRET and Dexter
mechanisms can be difficult to discern from each other. However, it is reasonable to
assume that both processes are likely to occur at short donor/acceptor pair distances.
While spectral overlap between the donor and acceptor is a requirement for FRET
and Dexter energy transfer, PET quenching is governed by redox chemistry.11 PET
occurs when an electronically excited fluorophore donates to or accepts an electron from
a nearby molecule, leading to the formation of a charge-separated complex. This complex
can return to the ground state without emission of a photon by spontaneous back electron
transfer (also known as charge recombination). Alternatively, this charge-separated
complex can return to the ground state by exciplex emission. The direction of electron
transfer in the excited state is dictated by the oxidation and reduction potentials of the
interacting pair. In order for PET quenching to occur, the formation of the charge
separated complex must be energetically favorable upon electronic excitation. The
change in Gibbs free energy (ΔG˚) resulting from PET can be evaluated using the RehmWeller formalism:
G ET  F E Ox (D)  E Red (A)  E0, 0  C

(Eq. 1.3)

where F is the Faraday constant, E˚Ox(D) and E˚Red(A) are the oxidation and reduction
potentials of the electron donor and acceptor molecules, respectively, E0,0 is the zero
vibrational electronic excitation energy of the fluorophore, and C is a term accounting for
Coulombic interactions, which is typically assumed to be negligible in water.12 Since
molecular collisions are requisite for efficient electron transfer, quenching is only likely
to occur when the donor and acceptor moieties are in close spatial proximity (< 15 Å).
However, the distance-dependence of PET quenching is difficult to predict for a given
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donor/acceptor pair. Although PET quenching can report on short-range interactions, this
method is not appropriate for the accurate determination of interchromophore distances.
Both long and short-range fluorescence quenching mechanisms have been applied
to the study of protein folding. Whereas FRET can be exploited to accurately measure the
distances between donor and acceptor probes in the 10 to 100 Å range, PET can be used
to determine whether two distinct regions of a protein approach molecular contact. In
general, FRET is more useful for monitoring large-scale conformational changes.
However, genetically encodable FRET labels (such as variants of the Green Fluorescent
Protein, GFP) are often quite large relative to the protein being studied.13 On the other
hand, producing heterogeneous, double-labeled proteins for FRET studies containing
extrinsic probes is a challenge in its own right. Fortunately, new methods for generating
site-specifically double-labeled proteins for FRET studies are rapidly emerging.
§1.3 Recent Strategies for the Dual Incorporation of Fluorescent Labels into
Proteins.
Over the past two decades, FRET has emerged as a powerful tool for studying
protein dynamics.14 Despite the widespread use of this technique, the site-specific
labeling of proteins with a suitable pair of donor and acceptor dyes remains a significant
challenge in the field of chemical biology. The genetically incorporable green fluorescent
protein and its multicolor variants are commonly employed as labels for FRET studies.
However, fluorescent protein tags are often quite large relative to the protein being
studied and are therefore limited in the number of positions in which they can be placed,
reducing the amount and quality of data that can be obtained from these experiments.13
In order to circumvent the disadvantages associated with fluorescent proteins,
several post-translational strategies have been developed for transferring smaller
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fluorescent labels onto proteins at specific amino acid sequences. Tsien and coworkers
demonstrated that a genetically incorporable tetracysteine motif can be selectively labeled
using a bisarsenical fluorescein derivative known as FlAsH.15 FlAsH can be administered
as a non-fluorescent complex with ethanedithiol (EDT). Displacement of EDT by the
tetracysteine motif leads to a dramatic increase in the fluorescence quantum yield of the
dye, rendering this system fluorogenic. Alternatively, several groups have developed
chemoenzymatic protein labeling methods that capitalize on the selectivity of certain
enzymes for specific amino acid sequences. For example, the enzyme sortase, which
catalyzes a transpeptidase reaction at an internal recognition motif, can be used to
conjugate fluorescent labels to the protein termini.16,17 Other enzymes, such as biotin
ligase and lipoic acid ligase, can be used to attach fluorophores to amino acid
sidechains.18,19 However, all of these methods require the insertion of a 5-15 amino acid
recognition motif that may ultimately be disruptive to native protein structure and
function.
Fluorescent dyes can also be introduced into a protein by chemical modification
of amino acid functional groups such as the nucleophilic cysteine (Cys) thiol. Solvent
accessible Cys residues can be readily labeled using fluorophores that are conjugated to
alkyl halides or maleimide handles (Figure 1.5).20
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Figure 1.5 Chemical Modification of Cys Residues.
Cys can be readily labeled using probes attached to maleimide (top) or alkyl halide (bottom)
handles. The yellow star represents a fluorescence probe.

Although Cys modification is extremely useful for introducing a single
fluorescent label into a protein, attempts to place two labels on two independent,
engineered Cys residues lead to heterogeneously labeled populations that are not optimal
for use in FRET studies.21 Moreover, this strategy is only appropriate for proteins that
either lack endogenous Cys or for those that are tolerant to Cys replacement with an
unreactive amino acid.
Recently, several groups have reported improved strategies for producing
homogeneous, doubly-labeled proteins for FRET studies using unnatural amino acids
(Uaas). The site-specific incorporation of Uaas into full-length proteins can be achieved
using a method known as nonsense suppression. The nonsense codons, Opal (UGA),
Amber (UAG), and Ochre (UAA), signal the termination of protein translation by serving
as binding sites for ribosomal release factors. Pioneering studies performed by Schultz
and coworkers demonstrated that an unnatural tRNA bearing an anticodon cognate to an
intrinsic stop signal can suppress the termination of translation (Figure 1.6).22 In order to
facilitate the ribosomal incorporation of a Uaa in response to a stop codon, the suppressor
tRNA must first be charged with the Uaa of interest.
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Figure 1.6 Ribosomal Incorporation of Uaas.
Uaa-tRNACUA (X = Uaa side chain, Z = AA side chain) can suppress the termination of translation
in response to UAG stop codons transcribed in the mRNA message.

Uaa-tRNA can be produced in vitro using semi-synthetic methods. However,
semi-synthetic Uaa-tRNAs are generally restricted to use in cell-free translation systems
that are costly and low-yielding in comparison to in vivo protein expression. Enzymatic
acylation of a suppressor tRNA can be accomplished using an evolved mutant aminoacyl
tRNA synthetase (aaRS) that is selective for the Uaa of interest.23 In order to perform
nonsense suppression in vivo, the aaRS/tRNA pair must be orthogonal to the endogenous
cellular machinery. This requirement can be met by importing an evolved aaRS/tRNA
pair derived from one organism into an alternative expression host. To date, over 150
Uaas have been incorporated into recombinant proteins for various structural and
functional studies.24 Two types of genetically incorporable Uaas are useful for generating
doubly-labeled proteins for FRET studies: those that are intrinsically fluorescent and
those that contain a selective reactive handle for further modification. A wide variety of
Uaas that meet these criteria have been reported and several examples will be described
herein.
Uaas bearing reactive moieties that can be selectively modified in the presence of
biological functional groups are described as bioorthogonal.25 Several research groups
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have shown that bioorthogonal Uaas can be used in conjunction with Cys to produce
doubly-labeled proteins for FRET studies. Previously, it had been shown that a mutant
TyrRS/tRNA

pair

derived

from

the

archea

Methanococcus

jannaschi

(MjTyrRS/tRNACUA) can be used to incorporate a variety of p-substituted Phe analogs
into proteins in response to an amber stop codon in live E. coli cells.26,27 In 2008, Brustad
et al. used this pair to incorporate p-acetylphenylalanine (pAcF) into a variant of
bacteriophage T4 lysozyme containing a single Cys residue.28 pAcF contains a ketone
group that can undergo a selective reaction with an alkoxyamine to form an oxime
linkage. Labeling of protein-incorporated pAcF with Alexa488-alkoxyamine proceeded
with high yields and was followed by Cys modification using Alexa545-maleimide.
Single-molecule FRET measurements obtained using two distinct doubly-labeled T4
lysozyme constructs were in good agreement with distances observed in the reported
crystal structure. Additionally, the authors examined denaturant-mediated unfolding of
the protein, and found that expansion of the N- and C-termini occurs prior to the
unfolding transition.

Figure 1.7 Dual Labeling of pAcF and Cys.
pAcF can undergo a selective reaction with an alkoxyamine to form an oxime linkage. Labeling of
pAcF can be followed by Cys modification with a maleimide. The green star represents Alexa488
(donor). The red star represents Alexa545 (acceptor).

Seo et al. also used the MjTyrRS/tRNACUA pair to incorporate a different Tyr
analog, p-azidophenylalanine (pAzF) into maltose binding protein (MBP) containing a
single Cys residue.21 In the presence of Cu(I), azides undergo 1,3-dipolar cycloaddition
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with alkynes to form stable 1,4-disubstituted triazole linkages (commonly referred to as
Cu(I)-catalyzed click chemistry).29 However, the reported labeling yield of pAzF in this
study was quite low (66%), which could likely be attributed to in vivo reduction of the
aryl azide group to an unreactive amine (Figure 1.8).

Figure 1.8 Dual Labeling of pAzF and Cys.
pAzF can undergo a selective reaction with an alkyne in the presence of Cu(I) to form a 1,4disubstituted triazole linkage. Cu(I)-mediated cycloaddition can be followed by Cys modification
with a maleimide. However, in vivo reduction of pAzF to the unreactive amine leads to a mixture
of products. The green star represents fluorescein (donor). The red star represents
tetramethylrhodamine (acceptor).

Recently,

the

pyrrolysyl

aaRS

derived

from

Methanosarcina

barkeri

(MbPylRS)—an archea that naturally incorporates pyrrolysine into proteins—has
emerged as an extremely useful aaRS that can be evolved to incorporate a variety of
bioorthogonal Uaas.24,30 In 2011, Nguyen et al. reported the genetic incorporation of a
Uaa containing a masked 1,2-aminothiol, Nε-L-Thiaprolyl-L-lysine. Upon deprotection of
the thiazolidine ring, the 1,2-aminothiol can condense with a cyanobenzothiazole (CBT)
in a bioorthogonal manner.31 In order to demonstrate that 1,2-aminothiols can be used to
produce double-labeled proteins, the authors introduced the masked Uaa into a mutant of
the protein calmodulin (CaM) containing a single Cys. First, the Cys residue was labeled
using

rhodamine-maleimide.

Next,

the
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1,2-aminothiol

was

deprotected

using

methoxyamine and then treated with CBT-fluorescein. Although the ultimate doublylabeled protein was indeed homogeneous, this method requires an additional deprotection
step that may not be compatible with proteins that are sensitive to treatment with high
concentrations of methoxyamine.

Figure 1.9 Dual Labeling of an Engineered 1,2-Aminothiol and Cys pair.
Cys labeling is performed prior to deprotection of Nε-L-Thiaprolyl-L-lysine. The deprotected 1,2aminothiol can undergo a selective condensation reaction with a cyanobenzothiazole. The green
star represents fluorescein (donor). The red star represents tetramethylrhodamine (acceptor).

Uaa mutagenesis can be combined with labeling at Cys to afford doubly-labeled
constructs, but this strategy is still not compatible with proteins that contain multiple Cys
residues. In order to incorporate two distinct Uaas into a single protein, an additional
blank codon must be introduced. In 2010, the Liu group demonstrated that the
Methanosarcina maize PylRS-tRNA pair (MmPylRS-tRNA) can be modified to suppress
the ochre codon and that this protocol can be coupled with MjTyrRS/tRNACUA to
incorporate two Uaas into a single protein in a site-specific manner.32 As an initial proof
of principle, Wan et al. used this strategy to incorporate an azide (pAzF) as well as an
alkyne-containing amino acid (Nε-propargyloxycarbonyl-L-lysine) into GFP. Dual
labeling was achieved by performing two sequential copper mediated azide-alkyne
cycloaddition reactions using propargyl-conjugated fluorescein to label the azide and 3azido-7-hydroxycoumarin to label the alkyne. Although the cross-reactivity of the Uaa
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pair was suppressed by using an excess of dye in the first labeling step, this pair may not
be suitable for labeling positions that are in close spatial proximity.

Figure 1.10 Dual Labeling of pAzF and Nε-propargyloxycarbonyl-L-lysine.
Sequential Cu(I)-mediated 1,3-dipolar cycloaddition reactions can be performed to label the
ribosomally incorporated azide and alkyne handles. However, if the probe pair is placed in close
proximity, an intramolecular cyclization reaction may occur. The blue star represents
hydroxycoumarin (donor). The green star represents fluorescein (acceptor).

To overcome this limitation, Wu et al. used a similar dual suppression system to
incorporate a different bioorthogonal pair, pAzF and 2-amino-8-oxononanoic acid (an
alternative ketone-containing Uaa), into glutamine binding protein (QBP).33 In this case,
strain-promoted azide-alkyne cycloaddition (SPAAC) could be used to effect the click
reaction in the absence of a metal catalyst. Specifically, it had been reported that
dibenzocyclooctyne (DBCO), which is highly strained about its carbon-carbon triple
bonds, can undergo efficient 1,3-dipolar cycloadditions with azides, driven by the relief
of ring strain that results upon triazole formation.34 Catalyst-free double-labeling of QBP
in one pot was performed by simply incubating the protein with fluorescein-DBCO and
7-diethylaminocoumarin-3-alkoxyamine. Quantitative conversion to the dual-labeled
construct was achieved by allowing the reaction to proceed overnight. However, it is
important to note that in vivo reduction of pAzF is typically problematic; it is unclear
why higher labeling yields were observed in this specific case.
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Figure 1.11 Dual Labeling of pAzF and 2-Amino-8-Oxononanoic acid.
Dual labeling was achieved by incubating the modified protein with alkoxyamine and DBCOconjugated fluorophores in a single pot. The blue star represents diethylaminocoumarin (donor).
The green star represents fluorescein (acceptor).

In order to demonstrate that dual-labeled QBP could be used for folding studies,
denaturant-mediated unfolding of the protein was examined by FRET. Crystallographic
studies have shown that upon binding to glutamine, QBP undergoes a significant
structural rearrangement. Curiously, FRET signals of the dual-labeled protein in the
presence and absence of glutamine were similar. The authors of the study proposed that
the lack of observed changes in FRET could reflect the existence of a dynamic
conformational ensemble in solution that cannot be detected using crystallographic
techniques. However, further studies must be performed in order to fully explain this
unexpected observation.
Recently, the Chin and Mehl laboratories reported an elegant alternative strategy
for incorporating two Uaas into a single protein.35 Previous studies have shown that UaatRNAs with expanded four-base anticodons (tRNAXXXX) can read through a four-base
codon inserted into the standard mRNA reading frame.36 In theory, introduction of a fourbase pair codon system should provide up to 256 blank codons. However, natural
ribosomes do not efficiently process quadruplet codons as they are not well
accommodated by the decoding center. Prior to this work, the Chin laboratory had
18

developed orthogonal ribosomes that translate mRNA messages with altered ShineDalgarno sequences, which cannot be recognized by natural ribosomes.37 Since
orthogonal ribosomes are not responsible for expressing or maintaining the cellular
proteome, they can be engineered to perform new functions. In 2012, the Chin group
evolved an orthogonal ribosome (ribo-Q1) capable of efficiently decoding quadruplet
codons and demonstrated that two mutually orthogonal aaRS/tRNA pairs, MjTyrRStRNAUCCU and MbPylRS-tRNACUA, can direct the site-specific installation of two Uaas
into a single protein.38
In 2014, Wang et al. reported an optimized orthogonal ribosome system for the
dual incorporation of bioorthogonal Uaas.39 In order to enhance the read-through of
quadruplet codons, a library of Pyl tRNAXXXX mutants was screened to identify those
exhibiting improved translation efficiencies. Presumably, the evolved tRNAXXXX mutants
contain expanded anticodon loops that can bind more efficiency to quadruplet codons in
the mRNA message. Although the authors were able to direct the incorporation of two
distinct Uaas in response to two different quadruplet codons, higher incorporation
efficiencies were observed by coupling the evolved MbPylRS/tRNAUACU pair with
MjTyrRS/tRNACUA. With this improved system in hand, the authors were able to
demonstrate that several chemically distinct pairs of Uaas can be site-specifically
installed into full-length proteins with improved yields.
Next, the authors identified a Uaa pair that could be used to efficiently doublelabel a protein in a one-pot reaction in the absence of any additional catalyst. Prior work
had shown that Uaas containing functional groups that participate in inverse electrondemand Diels-Alder reactions can be labeled in a bioorthogonal manner.40-42 Tetrazine
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groups rapidly undergo this type of cycloaddition reaction with strained alkenes and
alkynes. Chin and coworkers identified a Uaa pair, norbornyl-lysine (NorK) and
tetrazinyl-phenylalanine (TetPhe), that can be labeled using a tetrazine and alkyneconjugated probe, respectively. Importantly, this Uaa pair is only minimally crossreactive. CaM containing both Uaas was produced in E. coli cells harboring plasmids for
ribo-Q1 as well as aaRS/tRNA pairs selective for NorK and TetPhe. Quantitative doublelabeling was achieved by sequentially incubating the expressed protein with BODIPYTMR-tetrazine and BODIPY-fluorescein-bicyclononyne.

Figure 1.12 Dual Labeling of NorK and TetPhe.
Dual labeling was achieved by performing two sequential inverse electron demand Diels Alder
reactions. The green star represents BODIPY-FL (donor). The red star represents BODIPY-TMR
(acceptor).

CaM is a 140-amino acid neuronal signaling protein that undergoes a
conformational rearrangement upon binding four Ca2+ ions.43 In an initial proof of
principle experiment, urea denaturation of folded CaM containing the donor/acceptor pair
at the N- and C-termini was monitored using FRET. As expected, global unfolding of
CaM resulted in a decrease in FRET efficiency between the two dyes. In order to monitor
local conformational changes of the N-terminal domain in response to increasing
amounts of Ca2+, CaM was labeled with the donor/acceptor probe pair at positions 1 and
40, respectively. FRET measurements revealed that the N-terminal domain undergoes
two distinct structural transitions upon the first and last equivalents of Ca2+.
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Recently, Sachdeva et al. used the quadruplet decoding orthogonal ribosome
system to incorporate an optimized Uaa pair to double-label proteins with increased
efficiency.44 Prior to this work, the Chin group evolved PylRS to incorporate a 1,3
disubstituted cyclopropene containing amino acid that can be rapidly modified using a
tetrazine probe.45 This Uaa was installed into CaM along with o-propargyl Tyr (Ppy) such
that the mutant protein could be labeled using a combination of Cu(I)-mediated
azide/alkyne cycloaddition and inverse electron demand Diels-Alder reactions. Doublelabeling was performed in a single pot by incubating the mutant CaM with BODIPY-FLazide and BODIPY-TMR-tetrazine in the presence of click reaction catalysts. By using
20 equivalents of each dye, quantitative dual modification was complete within 30
minutes.

Figure 1.13 Dual Labeling of Ppy and a 1,3-Disubstituted Cyclopropene.
Efficient one-pot labeling was achieved by incubating the protein with tetrazine and alkyneconjugated fluorescence probes in the presence of Cu(I). The green star represents BODIPY-FL
(donor). The red star represents BODIPY-TMR (acceptor).

In 2013, Chen et al. reported an alternative efficient strategy for producing
labeled proteins for FRET studies.46 Prior to this work, other groups had shown that Uaas
containing fluorescent side chains can be genetically incorporated into proteins and used
as FRET partners with Trp or Tyr.47,48 However, this method is not compatible with
proteins containing multiple copies of these residues. In order to incorporate two
fluorescent Uaas into a single protein, two distinct blank codons must be suppressed as
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previously described. In this study, amino acyl tRNAs containing 4-biphenyl-Lphenylalanine (BpPhe-tRNACCCG) and L-(7-hydroxycoumarin-4-yl)ethylglycine (HCoutRNACUA) were prepared using semi-synthesis. In this system, BpPhe serves as a low
excitation (280 nm) donor fluorophore. Dual suppression of each cognate codon was
achieved during in vitro translation of a message encoding the enzyme dihydrofolate
reductase (DHFR). DHFR undergoes a modest conformational change upon binding its
inhibitor trimethoprim (TMP). In order to monitor this transition, DHFR was prepared
containing BpPhe and HCou at positions 17 and 115, respectively. Next, changes in
FRET were monitored as a function of TMP concentration. Despite its elegance, the
method suffers from various drawbacks. The production of semi-synthetic tRNAs is time
consuming and the amount of protein generated by in vitro translation is usually limited
to µgram quantities. Additionally, BpPhe cannot be selectively excited in the presence of
Trp or Tyr. Despite these disadvantages, this important work has set the stage for
devising an optimized strategy for producing proteins containing intrinsically fluorescent
Uaa pairs.
To summarize, Uaa-based methods for the production of doubly fluorescently
labeled proteins have undergone dramatic improvements in a short period of time. These
new technologies are efficient, facile, and remarkably versatile. In the future, these
strategies will enable researchers to generate vast libraries of doubly-labeled constructs
for mapping out protein conformational changes in real-time with residue-level precision.
§1.4 Introduction to α-Synuclein.
Parkinson’s disease (PD), a debilitating movement disorder whose sufferers
exhibit resting tremors, muscular rigidity, bradykinesia, and postural instability, is the
second most common aging-related neurodegenerative disease.49 Histologically, PD is
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characterized by dopaminergic nerve cell death in the substantia nigra of the brain and by
the presence of insoluble proteinaceous inclusions in the remaining neurons of the same
region.50 These intracellular inclusions, known as Lewy bodies (LBs) and Lewy neurites,
were found to contain a filamentous form of the protein α-synuclein (αS).51 αS is a small
(14.5 kDa) intrinsically disordered protein that is abundantly expressed in the brain.
Although the precise physiological role of αS is unknown, several lines of evidence
implicate a function for the protein in synaptic vesicle trafficking.52 Moreover, αS has
been clearly shown to play a role in the pathogenesis of PD. While most cases of PD are
sporadic, point mutations (A30P, E46K, A53T, H50Q), duplications, and triplications of
the αS gene have all been linked to familial forms of early-onset PD.53 Expression of
human wild-type or mutant αS in transgenic animal models produces age-related motor
defects as a result of neuronal cell death.54,55 Recently, it has been reported that
intracerebral injections of αS fibrils induce the formation of intracellular inclusions in the
brains of nontransgenic mice.56 These studies revealed that misfolded copies of αS can
recruit native protein and convert it into a pathogenic form, thus demonstrating that they
are the causative agent in the spread of PD.
αS has three distinct domains: an N-terminus comprised of seven imperfect repeat
sequences bearing the hexamer motif KTKEGV, a central hydrophobic region known as
the nonamyloid-β component (NAC) domain, and a flexible, negatively-charged Cterminus (Figure 1.14).
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Figure 1.14 Primary Structure of αS.
Top: αS is comprised of three distinct domains. Bottom: αS FASTA sequence color coded to
correspond to each domain above.

It is generally accepted that αS exists as a disordered monomer in vivo; however
some controversial studies suggest that the physiologically relevant form of αS is actually
a metastable tetramer.57 Although it is possible that native αS is folded, the protein
nonetheless exhibits remarkable structural plasticity.58 Upon binding to membrane lipids,
αS monomers can adopt α-helical conformations. Misfolding of monomeric αS leads to a
conformational change that triggers aberrant oligomerization. Transient αS oligomers
with β-sheet character eventually mature into insoluble cross-β strand fibrils. Despite
increasing research in this area, the precise, molecular details of αS misfolding have yet
to be described. Accordingly, a more complete picture of the dynamic structural changes
of αS upon misfolding would greatly facilitate our understanding of the pathogenesis of
PD.
§1.5 Structural Studies of Monomeric α-Synuclein.
αS was originally characterized as an intrinsically disordered protein using a
variety of structural methods. Analysis of its CD spectrum revealed that the protein is
predominantly random coil in solution.59 FTIR measurements (which are generally more
sensitive for the detection of β-sheet structure) confirmed that αS does not contain any
significant secondary structure. However, small-angle X-ray scattering studies showed
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that αS has a radius of gyration (Rg) that is smaller than expected for a fully extended
random-coil conformation (40 vs. 52 Å), but larger than predicted for a folded globular
protein of equivalent chain length (15 Å).60
Several groups have investigated the structure of monomeric αS using
multidimensional heteronuclear NMR spectroscopy.61,62 A variety of NMR experiments
performed using 13C and 15N labeled αS confirmed that the monomer is largely unfolded
and devoid of any stable secondary structure. However, it was also observed that the first
100 amino acids exhibit a slight preference towards adopting helical torsion angles,
particularly between residues 6 and 37. Whereas this transient helical structure was
detected in the N-terminus, the C-terminal region was less well defined and is therefore
considered to adopt a fully extended conformation in solution.
Although it has been established that purified recombinant αS exists as a
disordered monomer, recent reports have argued that the use of harsh purification
protocols have prevented researchers from correctly identifying the native state of αS.57,63
Moreover, it is possible that the structure of αS is influenced by macromolecular
crowding in the cellular milieu. In a recent study, Binolfi et al. acquired high quality 2D
NMR spectra of labeled αS in intact E. coli cells.64 The obtained NMR spectra were
remarkably similar to spectra acquired in vitro, indicating that αS is predominantly
disordered in a crowded cellular environment. Although these studies do not rule out the
possibility that native αS is folded in eukaryotic cells, they do confirm that αS is capable
of adopting extended, disordered conformations in vivo.
Despite the fact that αS lacks fully formed α-helices and β-sheets, the
hydrodynamic radius of αS is smaller than that expected for a random coil structure,
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suggesting that long-range tertiary contacts may have a role in the compaction of the
protein. In order to investigate this phenomenon, Dedmon et al. performed paramagnetic
relaxation enhancement (PRE) NMR experiments.65 PRE measurements are based on the
altered relaxation rates of nuclei that are in close proximity to paramagnetic probes (also
referred to as spin labels) and can be used to identify interatomic distances up to 25 Å
apart. A library of spin-labeled αS mutants was prepared by selectively labeling
engineered Cys mutants with a nitroxide paramagnetic probe known as MTSL (S-(1oxyl-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl methanesulfonothioate). By
applying distance constraints to molecular dynamics (MD) simulations, the authors found
that the native αS ensemble samples a variety of non-random, compact conformations.

Figure 1.15 Labeling of αS with a Nitroxide Spin Label.
Cys residues react with MTSL to form a disulfide linkage.

Intriguingly, long-range contacts were observed between the C-terminal tail and
the central region of the protein. PRE experiments performed by a different laboratory
confirmed this initial finding and also revealed significant contact between N- and Cterminal residues.66 Thus, the authors proposed that long-range interactions, especially
those mediated by the C-terminus, may function to shield the highly hydrophobic region
of the protein and thereby prevent its assembly into oligomeric species. This notion is
consistent with the experimental observation that C-terminally truncated variants of αS
form fibrils more rapidly than full-length αS.67
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Furthermore, FRET experiments have been used to probe the structure and
dynamics of monomeric αS. In 2004, Lee et al. measured distance distributions in αS
using Trp/3-NitroTyr (W/Y-NO2) as a donor/acceptor (DA) pair.68 The Förster distance
of this DA pair is approximately 26 Å. Since native αS does not contain any Trp residues,
site-directed mutagenesis can be performed to produce single Trp-containing proteins. In
order to convert particular Tyr residues into their nitrated forms, the expressed protein
was treated with tetranitromethane. To prevent chromophore cross-talk, all Tyr residues
aside from the chosen acceptor site were mutated to Phe. Distance measurements were
obtained using a total of six DA pairs spanning the entire length of the protein. Distance
distributions extracted from time-resolved Trp fluorescence measurements revealed that
while the protein is highly dynamic, compacted conformers also contribute to the
population of the ensemble.
The Rhoades laboratory has shown that single-molecule FRET (smFRET) can
also be used to study the conformational behavior of monomeric αS.69-71 The use of
smFRET is particularly advantageous for studying monomeric αS as it allows one to
directly probe the structure of αS at extremely low concentrations. Therefore, the
acquired FRET data are unlikely to be complicated by intermolecular interactions arising
from populations of oligomeric species. Heterogeneously double-labeled αS for smFRET
experiments can be produced by sequential labeling of engineered Cys residues with
maleimide-conjugated Alexa Fluor dyes. While the smFRET data suggest that αS
undergoes substantial conformational rearrangements in solution, significant interactions
between the N- and C-termini were observed at physiological pH. Notably, significant
compaction of αS was observed at low pH.71 Since low pH conditions are known to
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accelerate aggregation, the authors of this study postulated that this collapsed structure
represents the pathogenic, aggregation-prone conformation. smFRET data were later used
to guide computational studies of αS structure. By applying the experimentally
determined distances as constraints in MD simulations, the authors were able to generate
a model of the disordered ensemble in solution. Remarkably, the dimensions of the
computationally-derived ensemble were in excellent agreement with experimental
measurements of Rg.
§1.6 Lipid Induced Folding of Monomeric α-Synuclein.
Upon binding to negatively charged lipid membranes or membrane-mimetic
detergent micelles, αS adopts a well-folded helical structure. Detailed NMR analyses
revealed that the micelle-bound form of αS consists of two non-interacting antiparallel
helices in the N-terminal region connected by a short linker between residues 38-44
(Figure 1.16).72 However, in the presence of unilamellar vesicles, αS has been shown to
adopt an extended helical conformation by smFRET.73 In either conformation, the Cterminal domain of αS is predicted to remain disordered. The lipid-bound conformations
of αS have been extensively probed by several groups using a variety of biophysical
techniques including NMR and smFRET.62 While the details of these reported structures
slightly vary, there appears to be a general consensus that the nature of the fold is likely
to be dependent upon the size of the vesicles employed.
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Figure 1.16 Solution NMR Structure of αS Bound to SDS Micelles.
PDB Code: 1XQ8

§1.7 TMAO Induced Folding of Monomeric α-Synuclein.
Osmolytes are naturally-occurring small organic molecules that have the capacity
to alter the physicochemical environment of biological systems. Broadly, these molecules
are categorized by their effect on protein folding. A protecting osmolyte is known to
enhance protein stability, whereas a destabilizing osmolyte causes proteins to unfold.
Trimethylamine N-oxide (TMAO) is the most efficient protecting osmolyte studied to
date. Previous studies have shown that the addition of TMAO can induce
thermodynamically unstable proteins to fold and regain their functional activity in
vitro.74,75 Additionally, TMAO has been shown to counteract the destabilizing effects of
the denaturant urea.76 More recently, Bandyopadhyay et al. have shown that TMAO can
even promote the folding of mutation-destabilized globular proteins in live E. coli cells.77
The exact molecular mechanism by which TMAO and other protecting osmolytes
enhance protein folding is currently under investigation. One mechanistic scenario has
been presented by Zou et al., who measured the transfer free energy of a model peptide
backbone from water to TMAO.78 The authors proposed that an unfavorable interaction
of TMAO with the protein backbone results in a stabilizing effect on proteins. In other
words, TMAO destabilizes the unfolded state of a polypeptide chain and shifts the
folding equilibrium to the native state. This phenomenon is referred to as the

29

“osmophobic effect”. Others have proposed that TMAO induces protein folding simply
by acting as a macromolecular crowding reagent through excluded volume effects.79
Since it had been reported that TMAO can promote the folding of other IDPs,
Uversky et al. examined the effect of TMAO on the structural properties of αS.80 CD
measurements revealed that αS adopts a predominantly helical conformation in high
concentrations of TMAO. Next, the authors probed the TMAO-induced structure of αS
using fluorescence spectroscopy. 8-Anilinonaphthalene-1-sulfonic acid (ANS) is an
environmentally-sensitive dye that binds to hydrophobic surfaces of partially folded
proteins, resulting in a concomitant increase in fluorescence intensity. In the presence of
αS, ANS fluorescence increased as a function of TMAO concentration. Although this
result may be consistent with the formation of a partially folded intermediate, the authors
did not examine the effect of TMAO on ANS fluorescence in the absence of αS.
Additionally, folding of αS was examined using acrylamide as a contact-dependent
quencher of Tyr fluorescence. In TMAO, acrylamide quenching of Tyr fluorescence was
reduced, indicating that these residues are somewhat protected from solvent in the
TMAO-induced conformation. However, acrylamide quenching of free Tyr in the
presence and absence of TMAO was not reported. Although these results are interesting,
they must be considered with caution, as both experiments lack an appropriate control
that would be required to fully interpret the reported data.
In 2012, Ferreon et al. used smFRET to study the effect of osmolytes on the
structure of monomeric αS.81 Double-labeled αS for smFRET experiments was produced
by sequential labeling of engineered Cys residues at positions 7 and 84 with maleimideconjugated Alexa Fluor dyes. In buffer, the average EFRET value measured was 0.47,
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corresponding to a distance of approximately 61 Å. The measured EFRET between the two
labels decreased as a function of TMAO concentration (Figure 1.17). At 4 M TMAO, the
average EFRET value measured was 0.86, which corresponds to a distance of
approximately 44 Å. These results corroborate earlier findings suggesting that TMAO
induces folding of αS.

Figure 1.17 Compaction of αS in TMAO.
Left: Cartoon representation of αS compaction in the presence of TMAO. Right: FRET efficiency
as a function of TMAO concentration. Figure adapted from Ferreon et al.81

In a subsequent publication, Moosa et al. performed a more rigorous titration of
TMAO with double-labeled αS.82 A plot of FRET efficiency as a function of TMAO
concentration revealed a sigmoidal transition profile suggestive of a two-state folding
process. In addition to monitoring folding by smFRET, the authors of this study
performed CD spectroscopy measurements, which were also consistent with a
cooperative two-state folding transition to a helical structure. Although it is unknown
whether the TMAO-induced structure is related to the native conformation of αS in vivo,
these studies demonstrate that αS can be induced to fold into a compact helical structure
in the absence of lipids.
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Figure 1.18 TMAO-Induced Two-State Folding of αS.
Left: FRET efficiency as a function of TMAO concentration for to a two-state linear extrapolation
model. Right: TMAO-induced folding measured by CD spectroscopy fit to a two-state linear
extrapolation model. U represents the unfolded protein and T represents the protein in the
presence of TMAO. Figure adapted from Moosa et al.82

§1.8 Structural Studies of α-Synuclein Fibrils.
The observation that LBs consist of an insoluble, filamentous form of αS
prompted numerous investigations aimed at characterizing the molecular details of this
structure. Early transmission electron microscopy (TEM) studies revealed that purified
recombinant αS readily assembles into fibrils with overall morphologies that are similar
to those extracted from PD patients post-mortem.83 By TEM, αS fibrils appear long (1-10
µm), straight, and unbranched with an average diameter of roughly 5-10 nm. CD
measurements revealed that αS undergoes a conformational change from random coil to
β-sheet upon aggregation. X-ray and electron fibril diffraction patterns confirmed that αS
fibrils consist of a β-sheet structure and that the individual β-strands are stacked
perpendicular to the long fiber axis.

84

High-resolution cryoelectron microscopy images

revealed that αS filaments are comprised of two individual fibril strands that assemble
into both straight and twisted structures. Whereas the strands of the fibrils in the straight
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filaments are separated by 1.5 nm, the fibrils in the twisted filaments are separated by up
to 3 nm at their widest points.85
A variety of experimental approaches have been taken to obtain more detailed
information on the fold of αS fibrils. In 2003, Der-Sarkissian et al. investigated the
structural organization of αS fibrils using electron paramagnetic resonance (EPR)
spectroscopy.86 Like PRE, EPR studies require the incorporation of a nitroxide spin label.
Whereas PRE experiments are based on the relaxation rates of nuclei that are in close
proximity to the nitroxide probe, EPR measurements directly report on the structural
environment of the label itself. In this initial study, fibrils were prepared from a total of
36 spin-labeled αS mutants. Analysis of the obtained EPR spectra suggested that the core
region of the fibrils consists of 68 amino acids spanning residues 34 to 101. These data
were consistent with proteolytic digestion studies suggesting that the core region extends
into the N-terminal region beyond the hydrophobic NAC domain.87 A thorough analysis
of intermolecular spin-spin interactions between adjacent nitroxide labels revealed that βsheets in the core region are organized in an in-register, parallel fashion. Although the
fibril core appears to be well-folded by EPR, the N-terminal region showed a
heterogeneous, less-ordered structure, and the C-terminal region was determined to be
entirely disordered. In a subsequent study, Chen et al. prepared a library of 83 spinlabeled αS mutants for EPR studies.88 In addition to confirming the previous findings, the
authors were able to detect flexible regions within the tightly-packed core that likely
correspond to loop regions between neighboring β-strands.
Several groups have studied the structure of αS fibrils using advanced NMR
techniques. In 2005, Heise et al. reported the first solid-state NMR-derived structure of

33

the αS fibril core.89 In order to obtain resonance assignments corresponding to specific
amino acid residues, the authors performed a variety of multidimensional crosscorrelation experiments using isotope-labeled αS. Overall, the results of the NMR
experiments were in good agreement with the EPR studies. Residues 39‒95 were
determined to comprise the β-sheet rich fibril core, whereas the C-terminal tail was
characterized as disordered. Although seven distinct β-strands were identified, their
overall topology was not described.
In 2008, Vilar et al. performed hydrogen/deuterium (H/D) exchange as well as
solid-state NMR experiments to further characterize the fold of αS fibrils.85 Backbone
amide protons can readily exchange with solvent deuterons provided that they are
sufficiently solvent exposed. Otherwise, the process of H/D exchange occurs slowly
(seconds compared to hours). H/D exchange experiments revealed that the amide residues
between amino acids 30-110 are protected from solvent, whereas residues at both termini
were determined to be solvent exposed. Within the identified core, five segments of
amino acid residues were found to undergo H/D exchange more slowly than any other
observed regions. Taking these results as well as previous EPR studies into account, the
authors proposed that the fibril core consists of five distinct β-strands connected by small
loops that fold into a β-sandwich (Figure 1.19).
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Figure 1.19 Proposed Fold of αS Fibrils.
The fibril core is predicted to consist of at least five β-strands (shown as individual colors)
connected by small loops that fold into a β-sandwich.

Since these initial reports, other groups have used solid-state NMR to investigate
the structure of αS fibrils.90,91 Although the details of each reported structure vary, each
study predicts the formation of a core region that contains at least five β-strands.

Figure 1.20 Summary of Solid State NMR Measurements of αS Fibrils.
Top: Amino acid residues residing within the fibril core. Bottom: Arrows represent β-strand
regions identified by solid state NMR spectroscopy. Note that is Heise et al. two different fibril
forms (orange and yellow) were identified. Figure adapted from Pornsuwan et al.92

Recently, Pornsuwan et al. carried out a series of double electron-electron
resonance (DEER) experiments with dually spin-labeled mutants of αS to ascertain the
distances between individual β-strands.92 These preliminary inter-strand measurements
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suggest that the overall fold may be more complex than the predicted β-sandwich model.
Although EPR and NMR studies have helped to shed light on the fold of αS fibrils,
neither technique has been used to describe structural details involving the termini.
Moreover, since these measurements can only be obtained at the end of the aggregation
process, they cannot be used to resolve conformational changes that occur in real-time.
§1.9 Structural Studies of α-Synuclein Oligomers.
Although fibrils are known to induce pathology, an increasing number of reports
suggest that soluble oligomeric intermediates of αS are toxic to neurons. However, the
transient nature of these heterogeneous oligomers renders them exceedingly difficult to
isolate and study. Although several different methods have been reported for generating
αS oligomers in vitro, none have been proven to produce species that are physiologically
relevant. Regardless, several groups have examined their structure using a variety of
experimental techniques.
Apetri et al. examined the structural features of oligomeric αS using Raman and
atomic force microscopy (AFM).93 In this study, αS oligomers were produced by simply
allowing the protein to incubate at 37 ºC without agitation for several weeks. After 21
days, spheroidal oligomers ranging from 1.4 – 7.5 nm in height were observed by AFM.
Spheroidal oligomers do not enhance the fluorescence of ThT, indicating that these
intermediates lack the crossed β-sheet structure that is characteristic of amyloid fibrils.
Longer periods of incubation led to the formation of filamentous αS (Figure 1.21). In
order to gain insight into the changes in secondary structure accompanying the formation
of spheroidal oligomers, Raman microscopy measurements were performed at each stage
of the aggregation process. Upon oligomerization, the observed Raman amide I band
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profiles were consistent with increasing β-sheet content and decreasing extended β-strand
and polyproline II structure.

Figure 1.21 AFM Images of αS at Various Stages of Aggregation.
Left: AFM images obtained at 21 (left), 32 (middle), and 42 (right) days of incubation at 37 ºC.
Right: ThT binding assays corresponding to each stage of the aggregation process demonstrate
that spheroidal oligomers lack amyloid content. Figure adapted from Apetri et al.93

In order to probe the conformation of αS oligomers using fluorescence
spectroscopy, Rooijen et al. prepared αS mutants containing single Trp residues (F4W,
Y39W, A69W, A90W, A124W, and A140W).94 Solvent exposed Trp residues typically
emit from 340 – 355 nm. In a more hydrophobic environment, Trp emission undergoes a
blue-shift to yield a maximum closer to 335 nm. Stable oligomers were prepared by resuspending dried monomeric αS in buffer. Oligomers formed from F4W, Y39W, A69W,
and A90W exhibited significantly blue-shifted Trp fluorescence in comparison to each
respective monomer (~348 nm to ~337 nm). No blue-shift in Trp emission was detected
for oligomers formed from A124W and A140W, indicating that the C-terminus of the
protein remains solvent exposed. Upon binding to lipid vesicles, a similar pattern in Trp
fluorescence was observed. Overall, these studies suggest that the N-terminal and NAC
domains constitute the folded core of the spheroidal oligomer.
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Figure 1.22 Spectral Analysis of αS Trp Mutants.
The observed emission maximum of αS was plotted as a function of the position of the inserted
Trp residue. Figure adapted from Rooigen et al.94

Recently, Mysling et al. analyzed the structure of αS oligomers using H/D
exchange monitored by mass spectroscopy (HDX-MS).95 In this work, oligomeric αS
was isolated using size-exclusion chromatography. First, H/D exchange was performed
by diluting oligomeric αS into D2O. Following the exchange reaction, the oligomers were
digested with pepsin, and the resultant peptide fragments were analyzed using LC/MS.
Efficient backbone exchange was observed for the C-terminal domain (residues 94-140),
consistent with Trp fluorescence studies suggesting that the acidic tail remains solvent
exposed in αS oligomers. In the remainder of the protein, three regions that were strongly
protected from H/D exchange (residues 4-17, 39-54, and 70-89) were interspersed by two
relatively more dynamic segments (residues 18-38 and 55-76). These results are
consistent with the notion that intermolecular associations between αS monomers are
driven by hydrophobic amino acids residing in the NAC domain (residues 65-90).
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Figure 1.23 Heat Map of Local H/D Exchange Patterns Observed in αS Oligomers.
Peptides are color-coded according to fractional deuterium uptake. Figure adapted from Mysling
et al.95
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conformationally dynamic and solvent exposed in αS fibrils. However, both Trp
fluorescence and HDX-MS experiments suggest that the N-terminus of αS resides in a
less polar, less solvent exposed environment in αS oligomers. Thus, it is possible that
structural rearrangements of the N-terminal domain play a critical role in the maturation
of αS fibrils.
§1.10 Monitoring α-Synuclein Dynamics using Fluorescence Spectroscopy.
It is well established that misfolding of αS leads to the formation of β-sheet rich
fibrils, but the molecular mechanisms underlying the conversion of αS into neurotoxic
species remain poorly understood.96 Fluorescence spectroscopy is a highly sensitive
technique that is ideally suited for monitoring dynamic protein behavior in situ. Several
fluorescence-based approaches have been applied to the study of αS. Commonly used
amyloid dyes, such as Thioflavin T (ThT), can be used to detect the presence of αS
fibrils. ThT is a small benzothiazole dye that exhibits a dramatic increase in fluorescence
upon binding to amyloid fibrils. In solution, the emission of ThT is quenched by a
process known as twisted intramolecular charge transfer (TICT). TICT occurs when
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rotation about the central C-C bond orients the benzothiazole and dimethylaminobenzene
rings perpendicular to one another. Upon binding to fibrils, this bond can no longer
rotate, resulting in a substantial increase in the quantum yield of the dye.97 Although ThT
and other extrinsic dyes are routinely employed to monitor the kinetics of amyloid
formation, they cannot be used to yield structural details of this process at the residue
level. Moreover, the most commonly used extrinsic probes are insensitive to the
formation of early αS oligomers.

Figure 1.24 Thioflavin T Binds to Amyloid Fibrils.
Left: Chemical structure of Thioflavin T. Rotation about the central C-C bond leads to twisted
intramolecular charge transfer. Right: Structure of Thioflavin T bound to amyloid fibrils comprised
of β-2 microglobulin (PDB Code 3MYZ).

In order to directly monitor αS dynamics using fluorescence spectroscopy, a
fluorescent moiety must be installed into the protein. Several groups have incorporated
environmentally-sensitive fluorophores into αS for monitoring the various stages of
aggregation. Dusa et al. introduced a Trp mutation into position 39 to generate an
intrinsic fluorescence probe for monitoring αS dynamics.98 Upon aggregation, Trp
fluorescence increased with a rate that was similar to ThT binding. Curiously, the
emission maximum was similar in the monomeric and fibrillized forms (346-355 nm),
indicating that residue 39 remains somewhat solvent exposed upon aggregation. This
result is surprising in light of NMR and EPR studies predicting that residue 39 is
embedded within the fibril core.
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In order to incorporate unnatural fluorescence probes into αS, several groups have
turned to site-directed labeling of engineered Cys residues. In 2008, Thirunavukkuarasu
et al. prepared three mutants of αS labeled with a pyrene group at positions 18, 90, and
140.99 The high extinction coefficient, long lifetime, and solvent-sensitivity of pyrene
render it a particularly useful probe for studying αS dynamics. Additionally, pyrene
groups that are in close spatial proximity have a tendency to form pi-stacked complexes;
upon electronic excitation, these complexes can form excimers that exhibit unique
emission bands. Since near-molecular contact is required for excimer formation to occur,
it can be used to evaluate short distances within or between proteins. Over the course of
aggregation, several parameters of pyrene fluorescence were examined including steadystate, lifetime, and anisotropy measurements. Together, these experiments allowed the
authors to detect the formation of early αS oligomers. Intriguingly, the emission
properties of pyrene-labeled αS containing familial PD point mutations were different
from those of labeled wild-type. Although this observation is interesting, the authors were
unable to rationalize the origin of these distinctive features.

Figure 1.25 Site-Specific Pyrene Labels for Monitoring Aggregation.
Left: Cys-containing labeled with pyrene maleimide. Right: Example of aggregation monitored by
pyrene fluorescence. Figure adapted from Thirunavukkuarasu et al.99

In 2010, Yushchenko et al. introduced 3-hydroxychromones (3HCs) as probes for
monitoring αS oligomerization.100 Upon excitation, 3HCs undergo a process known as
41

excited-state intramolecular proton transfer (ESPIT) that results in emission from two
chemically distinct excited states referred to as the normal excited state N* and the
ESPIT phototautomer product T*. The ratio (T*/N*) of the emission band intensity is
extremely sensitive to the polarity and hydrogen bonding capacity of the surrounding
environment. Therefore, the authors reasoned that 3HCs are uniquely well-suited for
detecting changes in the local microenvironment of αS residues during early stages of its
aggregation. In this study, αS was labeled with 2-(2-furyl)-3-hydroxychrome (FC) at
position 140. During aggregation, the FC emission band ratio underwent a dramatic
change that was consistent with the probe moving into a less protic and less polar
environment. Kinetics measured by the change in FC fluorescence preceeded those
obtained using ThT, indicating that FC was more sensitive for detecting the formation of
αS oligomers. Although the C-terminal domain of αS is characterized as
conformationally-mobile and solvent exposed, this study suggests that its local
environment is markedly different in fibrils.

Figure 1.26 Ratiometric Hydroxychomone Probe for Monitoring αS Aggregation.
Left: Cys-containing αS labeled with 2-(2-furyl)-3-hydroxychomone maleimide (MFC). Right:
Aggregation of αS140MFC. Figure adapted from Yushchenko et al.100

In order to detect structural changes involving the N- and C-termini upon
aggregation, Yap et al. generated a small library of αS mutants labeled with an
environmentally sensitive dansyl (Dns) probe.101 Aggregation was monitored with

42

mutants labeled at the termini (7 and 136) as well as with mutants labeled at sites next to
the predicted fibril core (26 and 100). Upon aggregation, the fluorescence of each Dns
probe changed in a manner that was consistent with being transferred into a more
hydrophobic environment. Surprisingly, kinetic studies revealed that changes in Dns
fluorescence at the termini preceded those occurring at sites closer to the fibril core. In
order to determine whether this effect was nucleation-dependent, these assays were
repeated in the presence of a wild-type αS seed, and a similar trend was observed (Figure
1.27). Together, these data suggest that the first steps in αS fibrillization involve
conformational rearrangements occurring at the N- and C-termini.

Figure 1.27 Site-Specific Dansyl Labels for Monitoring αS Aggregation.
Left: Cys-containing αS labeled with dansyl probe. Right: Aggregation kinetics monitored by Dns
fluorescence and light scattering.

Although environmentally-sensitive fluorophores are useful for monitoring
aggregation, the information obtained from these experiments is limited. Alternatively,
FRET can be employed to define the structural details regarding the oligomeric
conformations of αS. Whereas smFRET experiments can be performed using mixtures of
doubly-labeled proteins, ensemble FRET measurements require the preparation of
homogeneous site-specifically labeled material. Due to the challenging nature of
producing doubly-labeled αS containing optimal labels for FRET studies, there are only a
few reports in the literature describing the use of this technique at the ensemble level.
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Perhaps the simplest way to produce homogeneous doubly-labeled proteins for
FRET studies is to take advantage of intrinsic protein fluorescence. In 2005, Kaylor et al.
generated a mutant of αS containing a single Tyr donor and Trp acceptor
(Y125W/Y133F/Y136F) at positions 39 and 125, respectively.102 Significant energy
transfer from Tyr to Trp was observed in monomeric αS, indicating that these regions are
separated by an average 25 Å distance in the disordered ensemble. Over the course of
aggregation, an increase in FRET was observed in the soluble fractions, suggesting that
early oligomers adopt more compact conformations. However, since the authors did not
dilute the doubly-labeled protein into a label-free mixture (such as an all Phe mutant), it
is not possible to distinguish inter vs. intramolecular FRET interactions from the obtained
spectra. Although FRET was detected at the oligomeric stage, energy transfer between
Tyr and Trp was not observed in the fibrillar state. The authors attribute this finding to a
possible lack of FRET between the pair, but they also note that Tyr emission is
significantly quenched at position 39 in fibrils lacking the Trp acceptor. Despite these
areas of concern, this report is still often cited as evidence for the compaction of αS upon
aggregation.
In 2010, Nath et al. prepared αS containing a red-shifted donor/acceptor probe
pair for FRET studies.103 First, a mutant of αS containing an engineered Cys residue at
position 140 was labeled with tetramethylrhodamine (TMR) maleimide. Since the pKa of
the N-terminus is lower than that of lysine (~ 7.7 vs ~ 10.5) semi-selective modification
of the N-terminus can be achieved at low pH (~ 6.5). Following an initial round of
purification, the singly labeled protein was reacted with Alexafluor-488 succinimidyl
ester to afford the doubly-labeled construct. However, the authors note that the
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measurements revealed that the donor/acceptor ratio in the final product was nearly 2:1.
Additionally, fluorescence correlation spectroscopy measurements revealed that
oligomers had formed during the course of the labeling reactions. Despite these issues,
intramolecular misfolding events were monitored by diluting the labeled construct into a
molar excess of unlabeled protein. Steady-state and time-resolved fluorescence
measurements suggested that compaction of the termini increased upon further
oligomerization. However, due to the heterogeneity of the sample, the authors were
unable to use FRET to quantify the actual change in distance that occurred.
§1.11 Conspectus
Distance-dependent fluorophore interactions such as FRET and PET are wellsuited for studying the misfolding of αS. However, the production of homogeneously
double-labeled αS is a challenge in its own right. Furthermore, in order for the labels to
be useful, they must not perturb the misfolding and/or aggregation process. The Petersson
laboratory develops new fluorescence-based technologies to study the dynamic behavior
of proteins using a combination of synthetic chemistry, molecular biology, and
biophysical techniques. In this thesis, I will describe how we have applied our unique,
minimally perturbing fluorescence probe – the thioamide – to the study of protein
folding. Next, I will discuss our development of novel semi-synthetic strategies for
installing thioamide/fluorophore probe pairs into full-length αS for folding studies.
Finally, I will describe alternative methods for producing labeled αS for various
aggregation and disaggregation experiments. Together, these studies have generated
unique insight into the conformational dynamics of αS that will be described in detail
herein
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Chapter 2 : Applications of Thioamide Quenching of Intrinsic Protein
Fluorescence to Studies of Folding and Binding
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Adapted with permission from (Jacob M. Goldberg, Rebecca F. Wissner, Alyssa M.
Klein, and E. James Petersson. Chem Comm. 2012, 48, 1550–1552). Copyright (2012)
Royal Society of Chemistry and from (Solongo Batjargal, Yanxin J. Wang, Jacob M.
Goldberg, Rebecca F. Wissner, and E. James Petersson, J. Am. Chem. Soc. 2012, 134,
9172-9182). Copyright (2012) American Chemical Society and from (E. James
Petersson, Jacob M. Goldberg, Rebecca, F. Wissner, Phys. Chem. Chem. Phys. 2014, 16,
6827-6837). Copyright (2014) Royal Society of Chemistry.
§ 2.1 Thioamide Quenching of Protein Fluorescence
Intrinsic protein fluorescence, which chiefly arises from excitation of tryptophan
(Trp) or tyrosine (Tyr) residues, has been used extensively to probe protein folding,
conformational rearrangements, and ligand binding.6 Many of these studies employ
distance-dependent quenching of Trp and Tyr through energy transfer to an extrinsic
probe, but data interpretation in these experiments is often limited by the size of the
acceptor chromophore. If a chromophore were sufficiently compact to be incorporable at
any position in a protein without severely perturbing native structure, the structural
resolution of these experiments could be greatly improved. Here, we show that a
thioamide – a single atom substitution of the peptide backbone - can quench Trp and Tyr
fluorescence in a distance-dependent fashion. We also show that this technique can be
used to monitor protein/protein interactions in vitro.
Thioamide Properties. Thioamides are nearly isosteric with the natural
oxoamides found in the peptide backbone. However, this single-atom substitution results
in subtle differences between the two functional groups. Sulfur has a larger van der
Waals radius than oxygen (1.85 Å vs. 1.40 Å) and is considerably less electronegative
(2.58 vs 3.44).104 The thiocarbonyl bond is longer than the oxocarbonyl bond (1.71 Å vs.
1.23 Å), whereas the carbon-nitrogen (C-N) bond is slightly shorter in a thioamide (1.35
Å vs 1.37 Å).105 The NH pKa is substantially lower for the thioamide than the oxoamide
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(12 vs 17).106 Additionally, the barrier to rotation about the C-N bond is higher for
thioamides (22 kcal/mol vs. 17 kcal/mol).107
In order to rationalize these properties, Wiberg et al. have argued that the relative
contribution of resonance structure B is greater for thioamides than for oxoamides
(Figure 2.1).107 Since oxygen is more electronegative than sulfur, dipolar structure B may
seem more important for oxoamides. However, computational electron density maps
revealed greater transfer of π electron density from N to S in thioformamide than from N
to O in formamide. It can therefore be reasoned that the energetic penalty for further
polarization due to charge transfer from nitrogen is higher for oxoamides than for
thioamides. Furthermore, the larger size of sulfur allows it to better accommodate
negative charge, and weakens overlap with carbon p orbitals in the C=S bond.

Figure 2.1 Dipolar Resonance Structure of Oxoamides and Thioamides.
The relative contribution of resonance structure B is greater for thioamides than for oxoamides.

In general, the thioamide NH is a stronger hydrogen bond donor than the
oxoamide NH, while the sulfur is a slightly weaker hydrogen bond acceptor than the
corresponding oxygen.108,109 Although thioamides are weaker hydrogen bond acceptors,
they are superior electron pair donors. Raines and coworkers have shown that thioamide
interactions may have stabilizing effects via n-π* interactions (in which a thiocarbonyl
sulfur donates lone pair electron density into another carbonyl group) in certain turn
geometries.110 Despite the larger size of sulfur, the longer length of the thiocarbonyl
bond, and the potential for altered stabilizing and/or destabilizing interactions, it has been
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shown that a single thioamide substitution incurs only minor perturbation to peptide
secondary structure (discussed below).
The unique properties of the thioamide that are most relevant to our spectroscopic
studies are the red shift in the carbonyl π - π * absorption and the lower oxidation
potential of the thioamide.111,112 The change in the absorption maximum to ~ 270 nm
allows the thioamide to have spectral overlap resulting in FRET interactions with
fluorophores such as Cnf and Tyr. The ~ 2 eV change in oxidation potential allows the
thioamide to be competitive in fluorophore PET quenching processes with other easily
oxidized natural and unnatural amino acids.113
Chemical Synthesis of Thiopeptides. Thioamide-containing peptides can be
synthesized on solid phase using pre-activated thioamide precursors and standard Fmocchemistry procedures.114 Fmoc-protected thiocarboxybenzotriazoles can be generated
from the corresponding Fmoc-protected amino acid using 4-nitro-1,2-phenylenediamine
(nitro route) or N-Boc-phenylenediamine (Boc route) (Figure 2.2). In general, the nitro
route is preferable for several practical reasons. The presence of the electron-withdrawing
nitro group leads to deactivation of the p-amino group. As a result, the initial coupling of
the amino acid proceeds in a regioselective manner. Since no additional protecting group
is required, the overall scheme requires fewer steps. Additionally, the nitro route is
compatible with amino acids bearing acid-labile protecting groups. Although generally
lower-yielding, an important advantage of the Boc route is that the final benzotriazole
products are more stable and can potentially be stored for longer periods of time. To date,
our group has reported successful thioamide incorporation from benzotriazole precursors
for the following amino acids: Ala, Asp, Glu, Leu, Phe, and Val.115-118 We have also
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demonstrated that Arg, Ile, and Pro can be similarly installed into peptides (unpublished
results). Conceivably, a thioamide analog of any of the natural amino acids can be
incorporated into peptides using appropriate protecting group manipulations.

Figure 2.2 Synthesis of Thioamide Precursor Compounds.

Thioamide Effects on Protein Folding. Several independent studies have
examined the effect of thioamide substitution on the thermodynamic stability of α-helices
and β-sheets. In α-helices, thioamide substitution at the C-terminus (within the last four
residues) is expected to be tolerated, as the thiocarbonyl would not participate in
hydrogen bonding at these sites. Other positions within a tightly packed α-helix were
initially proposed to be unable to accommodate the increase in the (thio)amide-amide
hydrogen bond distance or the larger size of the sulfur atom.119 In order to examine the
effect of thioamide substitution within α-helical structures, Miwa et al. prepared
thioamide analogs of GCN4, a 35-residue helical peptide that dimerizes to form a
parallel, two-stranded coiled-coil.120 Circular dichroism (CD) measurements confirmed
that thioamide substitution (at either the C-terminus or in the middle of the helix) yielded
structures that were similar to those formed by the native peptide. The melting
temperatures (Tms) of the folded coiled-coils were derived by measuring the temperaturedependent change in the CD signal corresponding to helical content. A slight increase in
Tm was observed for the peptide containing a thioamide near the center of the helix,
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suggesting that the increase in hydrogen bond strength conferred by the thioamide NH
may enhance thermal stability in a position-dependent manner. In a separate study,
Fischer, Kiefhaber, and coworkers introduced single thioamide substitutions at a central
or an N-terminal position in an alanine-based model helical peptide.121 CD measurements
revealed that incorporation of an Ala′ residue at either location led to helix destabilization
similar in magnitude to that observed for a Gly substitution at each respective position
(roughly 1.7 kcal/mol). It should be noted that this study differs significantly from the
Miwa α-helix study in that the dimeric nature of GCN4 may also be influenced by
thioamide incorporation, whereas the artificial α-helices in this study are monomeric and
may provide a more direct assessment of the impact of thioamides on the α-helix itself.
Taken together, these results demonstrate that the effect of thioamide incorporation on αhelix stability may ultimately be dependent on the position in question.
To determine whether a thioamide linkage is compatible with β-sheet secondary
structure, Miwa et al. prepared a thioamide-containing β-hairpin peptide, comprised of
two antiparallel strands joined by a type II′ β-turn.122 To minimize perturbation of the
hairpin structure, the thioamide residue was inserted into the i + 2 position of the β-turn.
In this position, the thiocarbonyl points toward the exterior of the hairpin, while the
thioamide NH can still participate in an interstrand hydrogen bond. NMR and CD
experiments confirmed that the hairpin conformation and stability were similar to that of
the corresponding oxoamide peptide. More recently, Gai, Degrado, and coworkers used
thioamides to site-specifically examine the role of interstrand hydrogen bond formation
in the folding of a stable monomeric β-hairpin known as tryptophan zipper (Trpzip). 123 In
these studies, thioamide residues were placed in a manner such that the thiocarbonyl
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would be forced to participate in backbone-backbone hydrogen bonding throughout the
β-hairpin sequence. Analysis of CD thermal melting curves for the mutant peptides
revealed that the degree of β-hairpin destabilization depended on the position of the
interstrand hydrogen bond being perturbed, with the effect far less pronounced at the
terminal region of the hairpin. To further examine the mechanistic basis of thioamideinduced destabilization, the folding and unfolding rates of the mutant β-hairpins were
determined by measuring their relaxation rates in response to a laser-induced
temperature-jump using time-resolved IR spectroscopy. Thioamide incorporation at the
turn region slowed down the rate of folding, whereas incorporation at the terminal region
dramatically increased the rate of unfolding. Similar to observations in thioamidecontaining α-helices, the effect of thioamide substitution into β-sheets is likely to be
dependent on the position of incorporation and on whether the residue is involved in the
formation of a key hydrogen bond in the native sequence or a folding intermediate.
Although thioamide substitution has been investigated in model peptides, there
are few examples describing how thioamide incorporation into full-length proteins affects
their ability to fold or function. To date, only one protein is known to naturally contain a
thioamide linkage. Methyl-coenzyme M reductase, an enzyme that contains a thioglycine
residue near its active site, catalyzes the final methane-forming step in methanogenic
archaea.40, 41 It has been proposed that the embedded thiocarbonyl moiety may work as a
redox active one-electron relay system to facilitate the oxidation and reduction of
cofactor and substrate.124 The X-ray crystal structure of Methyl-coenzyme M reductase
has been determined, providing insight as to the geometry that thioamide residues adopt
in complex folded proteins. The Gly′ residue is not located in a canonical α-helix or β-
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sheet. The thiocarbonyl length is extremely long (1.8 Å) and the C-N bond length is very
short (1.3 Å), consistent with the predominance of resonance structure B as a
representation of the thioamide. As one might expect, the hydrogen bond to sulfur is
unusually long (3.5 Å) as compared to a typical backbone hydrogen bond in a protein (~
3.0 Å). However, no increase in thioamide NH hydrogen bond donor strength is apparent,
as the NH hydrogen bond is not unusually short (3.1 Å). Choudhary et al. note that the
thiocarbonyl group engages in a strong n-π* interaction with the side-chain carbonyl of a
nearby asparagine residue.125 However, since Methyl-coenzyme M reductase has
presumably evolved to take advantage of this specialized Gly′ residue, it is not clear that
this information has general implications for the introduction of thioamides into existing
secondary structures.
Fischer and coworkers have been able to demonstrate that a thioamide can be
chemically installed into a different enzyme without perturbing its inherent activity.126,127
Ribonuclease (RNase) S, originally generated by cleaving RNase A into two fragments
using subtilisin, is comprised of the separated S-peptide (residues 1 to 20) and the Sprotein (residues 21 to 124). In solution, the S-protein is inactive but folded, whereas the
S-peptide is disordered. Upon binding to the S-protein, residues 3-13 of the S-peptide
adopt an α-helical structure, yielding a catalytically active bimolecular complex.128 To
monitor backbone hydrogen bond formation in the transition state of the S-peptide/Sprotein association, single thioamide substitutions were introduced into different
positions between residues 1 and 15 of the S-peptide. All of the S-peptide mutants bound
to the S-protein to generate catalytically active complexes. However, isothermal titration
calorimetry (ITC) experiments revealed that the thermodynamic stability of each mutant
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RNase S complex was reduced to varying extents, ranging from 0.6 to 4.7 kcal/mol.
These results indicate that some thioamide substitutions can be tolerated in full-length
proteins without grossly perturbing their native state or function, but that one must use
caution in their placement.

Figure 2.3 The Impact of Thioamide Substitution on Protein Folding.
Left: Circular dichoism (CD) analysis of α-helical peptide sequences by Reiner et al. showed that
Ala′ substitution can be comparably destabilizing to glycine substitution. Middle: NMR analysis of
a α-turn sequence by Miwa and coworkers showed that Gly′ was compatible with turn formation
(p indicates D-proline). Right: The geometry of a hydrogen-bonded Gly′ residue can be seen in
the sole structurally-characterized example of a full-length protein containing a thioamide residue,
Methyl-coenzyme M reductase (PDB ID 1MRO).Figures adapted from references 116 (left), 124
(middle) and 125 (right).

Thioamide Quenching of Cnf. In 2010, our laboratory reported that thioamide
quenching of the unnatural amino acid p-cyanophenylalanine (Cnf or F*) can be used to
monitor protein folding.115 Cnf was chosen for these initial experiments because of its
large extinction coefficient (ε = 13,000 M-1 cm-1 at 240 nm) and substantial spectral
overlap with thioamides. The theoretical value of R0 was calculated to be 15.6 Å,
indicating that the thioamide/Cnf FRET pair can be used to measure distance changes in
the 8 to 32 Å range. In order to experimentally verify the distance-dependence of this
interaction, a series of peptides was synthesized that contained thioleucine (Leu´) at the
N-terminus and Cnf at the C-terminus, separated by an increasing number of proline
residues. Quenching efficiency was determined as

E Q  1  FThio / FOxo
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(Eq. 2.1)

where FThio is the fluorescence intensity of a given Leu´PronCnf peptide, and Foxo is the
fluorescence of the oxoamide control peptide LeuPro2Cnf. By plotting the quenching
efficiency as a function of distance (R) and fitting the data to a 1/R6 function, the halfmaximal change in fluorescence was determined to occur at a distance of 16.5 Å.
Although this result is in good agreement with the calculated prediction based on Förster
theory, it is also possible that Dexter energy transfer, a fluorescence quenching
mechanism that depends on direct overlap of donor and quencher molecular orbitals, may
contribute to Cnf quenching at short distances.10 Dexter transfer has a 1/eR distance
dependence, which also provides a good fit to the Pro series data. Therefore, it is likely
that both mechanisms contribute to thioamide quenching.

Figure 2.4 Fluorescence Emission as a Function of Chomophore Spacing.
The fluorescence emission of Leu′-Pron-Cnf (n = 2−10) at 293 nm is shown. The “∞” data point
indicates the fluorescence of Leu-Pro2-Cnf. The solid line indicates the distance dependence
predicted by Förster theory with R0 = 15.6 Å (∼5.1 prolines). The inset shows EQ as a function of
the computed Leu′−Cnf interchomophore distance for the proline series. The data were fit to
Förster (solid line) and Dexter (dashed line) distance dependences.

In order to demonstrate that thioamide quenching of Cnf can provide useful
information on conformational changes, a proof of principle experiment was performed
using a small, well-folded peptide prepared by chemical synthesis. HP35, a variant of the
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villin headpiece subdomain, is known to adopt a compact helical structure in which the
N- and C-termini are in close proximity (within 20 Å).129 Since global unfolding of HP35
leads to a significant increase in the distance between the termini, we chose to
incorporate Leu′ at the N-terminus and Cnf at the C-terminus for FRET experiments.
Additionally, because Cnf is excited at 240 nm and fluoresces with a maximum at 295
nm, Trp23 was mutated to Phe to ensure that Trp fluorescence (arising from direct
excitation or from Cnf/Trp FRET) would not convolute the spectral data. By obtaining
temperature-dependent CD measurements, we were able to show that the Tm of the
double-labeled HP35 variant (HP35-L′1F23F*35) was similar to that of the corresponding
oxoamide control protein (HP35-F23F*35), indicating that the thioamide replacement did
not exert a measureable effect on overall stability. We were then able to demonstrate that
the thermal denaturation of HP35 can be accurately monitored by observation of
Cnf/thioamide FRET. Quenching efficiency (EQ) was determined over a range of
temperatures (5 to 75 ºC) by comparing the fluorescence intensity of the thioamide
protein to the oxoamide control. Upon converting EQ to distance using Förster theory, we
determined that the separation between the termini of HP35 increased from 21 Å in the
folded form to a distance beyond that measurable by our probe pair (32 Å) in the
unfolded state.
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Figure 2.5 Villin HP35 unfolding monitored by Cnf/thioamide FRET.
Left: Villin HP35 structure modified with the Cnf nitrile on Phe35. Right: Fraction folded as
determined from temperature-dependent CD spectroscopy for HP35-Leu′1Cnf35 (●) and HP35Cnf35 (○) and temperature dependence of the Leu′1/Cnf35 separation determined by comparison
of EQ computed from the HP35-Leu′1Cnf35/HP35-Cnf35 fluorescence ratio with the proline series
distance dependence computed using either the Förster (◆) or Dexter (◇) equation. Figure
adapted from Goldberg et al.115

Thioamide Quenching of Intrinsic Protein Fluorescence. Although electrontransfer-induced quenching of Trp and Tyr fluorescence by many functional groups is
well documented, there are only a few reports of the effect of a thioamide on protein
fluorescence. The first observation of fluorophore quenching by thioamides was reported
by Wiczk et al. In this study, thioamide quenching of Trp in a short model peptide was
examined in neat propylene glycol.130 In non-polar solvent, thioamide absorbance is redshifted and Trp emission is blue-shifted, resulting in significant spectral overlap and an
enhanced likelihood of FRET. It was unclear from this study whether thioamide
quenching of Trp would occur under aqueous conditions. Additionally, Rownicka et al.
reported quenching of bovine serum albumin fluorescence by 2-n-propyl-6-thiouracil,
which contains a thioamide.131 Despite these initial reports, neither group carried out
further systematic studies on thioamide quenching of intrinsic protein fluorescence.
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The Cnf/thioamide pair is not generally compatible with Trp- and Tyr-containing
proteins because FRET between the residues can complicate data interpretation. Since
global replacement of these aromatic residues is undesirable, we chose to explore
thioamide quenching of Trp and Tyr fluorescence in order to understand the effects of
thioamide incorporation on the near-UV fluorescence of typical proteins.
§ 2.2 Results and Discussion
We began our investigation by considering a possible FRET mechanism for
thioamide quenching of Trp and Tyr. According to Förster theory, the efficiency of
energy transfer between a fluorophore and quencher depends on the spectral overlap of
donor emission and acceptor absorbance.9 Although the Tyr emission spectrum has
moderate overlap with the absorbance of a thioamide, the Trp emission spectrum has
almost no overlap (Figure 2.6). These observations are borne out in the theoretical
calculations of R0, the distance at which energy transfer is 50% efficient. Using the
previously reported quantum yields for Tyr (Φ = 0.14) and Trp (Φ = 0.13), and assuming
the transition moment dipoles to be randomly oriented during the course of energy
transfer (κ2 = 2/3), we calculated R0 to be 13.4 Å for the Tyr/thioamide FRET pair, and
4.0 Å for the Trp/thioamide pair in aqueous solutions. For small values of R0, such as
those that we calculated for Trp, Förster theory may not provide an adequate prediction
of quenching, since other short-range mechanisms will contribute significantly.
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Figure 2.6 Thioleucylalanine ester (Leu'Ala), Tyrosine (Tyr) and Tryptophan (Trp) Spectra.
Absorption spectrum of Leu'Ala (solid orange line) shown with relative absorption intensity
normalized to extinction coefficient (12,400 M-1cm-1 at 266 nm). The fluorescence spectra of Tyr
and Trp (dashed blue and dotted red lines, respectively) are arbitrarily normalized to emission
maxima. The shaded area indicates the spectral overlap that contributes to FRET between a
thioamide and Tyr.

To verify the distance dependence predicted by Förster theory, we synthesized
groups of peptides that contained either Trp or Tyr at the C-terminus and thioleucine
(Leu´) at the N-terminus, separated by an increasing number of proline residues.
Fluorescence spectra of dilute samples of each peptide were taken in phosphate buffer at
pH 7.00. In both cases, the fluorescence intensity showed a strong dependence on
distance, at length scales much greater than that predicted by Förster theory (Figure 2.7).
This is particularly noticeable for Trp, where a half-maximal change in fluorescence is
observed at 17 Å, far exceeding the predicted R0 of 4.0 Å. The distance dependence of
both Tyr and Trp are shown fit to a sigmoidal expression, which provides a reasonable
description of the distance dependence without assigning a mechanistic interpretation.
Fits of the data to other mechanism-based equations, including Forster, Dexter, and
electron transfer are provided below with accompanying discussion. The sigmoidal fit in
Figure 2.7 serves as a working, empirical “ruler” based on quenching efficiency to be
used while we investigate the mechanism of quenching further.
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Figure 2.7 Fluorescence Intensity as a Function of Chomophore Separation.
Left: The fluorescence emission at 305 nm of Leu'- Pron-Tyr (n = 2-10) is shown. Right:
Fluorescent emission at 355 nm of Leu'-Pron-Trp (n = 2-11). In both plots, the “∞” data point
indicates the fluorescence of Leu-Pro2-Tyr or Leu-Pro2-Trp. Sigmoidal fits to the data shown (3 or
more trials per peptide, bars represent standard error). Distances determined from molecular
dynamics simulations.

To test the utility of our spectroscopic ruler and verify that quenching takes place
in a molecular context other than the Pro series, we conducted protein-binding studies in
which the thioamide was incorporated into peptides that bind to the protein calmodulin
(CaM). We chose CaM because it expresses well in E. coli and it has been thoroughly
studied from a structural and biophysical standpoint. CaM has been shown to bind a
variety of helical peptides derived from its endogenous protein interaction partners.132
These peptides bind with high affinity in a central groove formed by the folding of the Nand C-terminal CaM lobes. In particular, we studied the binding of a peptide derived
from the intracellular domain of an olfactory cyclic nucleotide-gated ion channel
(pOCNC).133 This peptide binds with a low nM affinity, and its CaM-bound structure has
been determined previously by NMR.133 Therefore, we expected that 1:1 mixtures of 10
µM each CaM and pOCNC would be stably bound and that the NMR structures could be
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used to determine interatomic distances. These measurements would then be compared to
the corresponding distances derived from our FRET measurements.
Chicken CaM contains two tyrosine residues, Y100 and Y139, and, in the presence
of Ca2+, binds helical peptides with diverse sequences. We prepared derivatives of
pOCNC in which thiophenylalanine (Phe´) was incorporated at the N-terminus of the
peptide (pOCNC-F1´). As a control for any changes in fluorescence due to factors other
than thioamide quenching, we prepared an oxoamide version of the peptide (pOCNC)
with phenylalanine at the N-terminus. From NMR structural data, we estimated the
distance between the thiocarbonyl carbon and the center of the phenol ring to be 19 Å for
Y100 and 16 Å for Y139.133 Titrations of each peptide into CaM solutions are shown in
Figure 2.8. A 28% decrease in fluorescence is seen at saturating concentrations of
pOCNC-F1´, whereas essentially no change in fluorescence is seen with the oxoamide
control pOCNC. Since these peptides differ only in the O-to-S substitution in the F1/R2
amide bond, we assign the quenching to the Tyr/thioamide interaction. Both Trp and Tyr
fluorescence are sensitive to their local environment with respect to solvent accessibility,
pH, neighboring residues, and other chromophores.134-136 CaM undergoes a substantial
conformational rearrangement upon peptide binding, and we were concerned that these
factors might alter Tyr fluorescence independent of thioamide quenching.137,138
Therefore, the inclusion of an oxoamide control is essential to assign quenching
specifically to the Tyr/thioamide interaction. Corrected pOCNC-F1´ fluorescence values
can be fit to a 1:1 binding model to obtain a KD of less than 280 nM.
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Figure 2.8 CaM Binding pOCNC.
Left: CaM structure taken from PDB 1SY9. Image created in PyMOL. Y100 and Y139 are rendered
in grey; the thioamide bond is highlighted in yellow. Right: Titration of pOCNC (filled circles) and
pOCNC-F1' (open squares) into a solution of 10 μM CaM in 15 mM HEPES buffer, 140 mM KCl,
and 6 mM CaCl2, pH 6.70, monitored by fluorescence spectroscopy. Fluorescence data are
normalized to CaM in the absence of peptide and corrected for peptide fluorescence.

Prediction of the efficiency of quenching (EQ) from Förster theory is complicated
by the fact that the two donor Tyr have different extinction coefficients (ε) and quantum
yields (Φ), both of which contribute to FRET (i.e. quenching) efficiency.137,139‐141 Using
reported ε and F values for each Tyr, we calculated EQ values from Förster theory and an
empirical calibration based on Figure 2.7. Since Phe is not noticeably fluorescent at the
excitation wavelength of Tyr, we generated Y100F and Y139F mutants to verify the effect
of thioamide quenching on each Tyr residue independently. Table 2.1 summarizes the
observed quenching of each mutant in a stoichiometric ratio with pOCNC-F1´, as well as
theoretical predictions from Förster theory (EQ Förster) and our empirical spectroscopic
ruler (EQ Calculated) using distances from the NMR structure. There is reasonable
agreement between our empirical EQ and the observed EQ for the single Tyr mutants, but
the WT values deviate, perhaps because we are not weighting the fluorophore
contributions or orientation effects (κ2) properly.
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Table 2.1 Quenching of CaM Mutant Fluorescence by Thioamide Peptides.

CaM Mutant

EQ (%)

EQ (%)

EQ (%)

(Donor, DQ Distance)a

Experimentalb

Calculatedb,c

Försterb,c

WT
Y100F (Y139, 16 Å)
Y100W (W100, 19 Å)
Y139F (Y100, 19 Å)
Y139W (W139, 17 Å)

28 ± 1
50 ± 2
27 ± 3
22 ± 2
58 ± 2

42
56
30
34
40

10
14
0
8
0

a

Donor/quencher (DQ) distance measured in PyMol from aromatic ring
of Tyr or Trp to thiocarbonyl carbon. bCalculations described in the
Supplementary Information. c We estimate the error to be ± 15% for Tyr
predictions and ± 20% for Trp predictions.

To further examine quenching of Trp, we mutated either Y100 or Y139 to Trp.
Stimulation at 295 nm allowed us to selectively excite the Trp residue. The observed EQ
of the Trp mutants at stoichiometric concentrations of pOCNC-F1´ are reported in Table 1
along with predicted quenching efficiencies. Several observations are worth noting from
these data. First, given the predicted and observed distance dependencies, a FRET
mechanism is clearly not responsible for Trp quenching, and is at best partially
responsible for Tyr quenching. Second, the exponential distance-dependence one might
expect for though-bond electron transfer is seen both in the Pro series and the CaMbinding experiments, which shows that the rigidity of the Pro σ-bond framework is not
necessary for efficient transfer over 15-20 Å distances. Third, the observed quenching
efficiency in the CaM binding experiments is in moderate agreement with the quenching
level predicted from our polyproline rulers, indicating that they may be useful as
empirical standards. Further investigation in other systems (below), allowed us to gain a
greater understanding of local environment and orientation effects.
We demonstrated that thioamides quench Trp and Tyr fluorescence in a distancedependent fashion that can be used to monitor biological interactions, such as
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macromolecular binding events. It is well established that Trp and Tyr are also quenched
by many other functional groups. However, since we can compare our synthetic
thioamide proteins to all-oxoamide equivalents, we should be able to separate thioamidequenching from quenching by protein sidechains or backbone in interpreting our data.
The Trp data presented here as well as other data collected in our laboratory show that
thioamides are capable of quenching red-shifted fluorophores with no spectral overlap
through an electron transfer process. Given the substantial difference in the oxidation
potentials between oxoamides (3.25 eV) and thioamides (1.21 eV), it is not surprising
that thioamide-specific quenching can occur.142 We are investigating this phenomenon
further in the context of Tyr and Trp as well as other fluorophores. The methods for the
semi-synthesis of large thioamide-containing proteins described below may be used to
extend our findings to mapping interactions among two full-sized proteins.
§ 2.3 Native Chemical Ligation of Thioamide-Containing Peptides: Development
and Application to the Synthesis of Labeled α-Synuclein for Misfolding Studies
In order to expand the utility of the thioamide as a spectroscopic probe, our
laboratory has developed semi-synthesis techniques for its installation into full-length
proteins.116 Backbone thioamides cannot currently be installed into a protein by means of
ribosomal expression. Therefore, we incorporate thioamides into full-length proteins
using native chemical ligation (NCL), a fragment condensation reaction that typically
takes place between peptides bearing a C-terminal thioester and an N-terminal
cysteine.143 Ligation proceeds when the thiol of the N-terminal Cys attacks the Cterminal thioester to form an S-acyl intermediate. This intermediate undergoes an
irreversible S to N acyl shift to generate a native peptide bond containing Cys at the
ligation site. NCL reactions have been shown to be tolerant of protein functional groups
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as well as a variety of non-native functional groups. Thus, we expected thioamides to be
compatible with NCL conditions, although we had some concerns regarding Edman-type
side reactions or Cys desulfurization through attack of the nucleophilic thioamide
(Scheme 2.1). Another potential concern was desulfurization of the thioamide via
transient water attack at the thiocarbonyl carbon followed by expulsion of H2S from the
tetrahedral intermediate. However, initial investigations of NCL reactions between short
peptides demonstrated that thioamides can be placed at nearly any position in the
thioester or Cys peptide fragments.

Figure 2.9 Native Chemical Ligation Mechanism and Potential Thioamide Side Reactions.

Misfolding of the abundant neuronal protein α-Synuclein (αS) has been
implicated in the pathogenesis of several debilitating neurodegenerative disorders
including Parkinson’s disease (PD).53 However, the molecular details underlying the
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conversion of αS into neurotoxic species remain poorly understood. Accordingly, a more
complete picture of the structural changes of αS upon misfolding would greatly facilitate
our understanding of the spread of PD.58 Many fluorescence-based studies have
attempted to determine structures for aggregation intermediates, but they often employ
fluorophores that can perturb the structure, particularly when substituted at sites that do
not natively contain an aromatic amino acid.144 Our thioamide probe, which has been
shown to quench natural and unnatural amino acids, should offer much greater freedom,
particularly in the placement of the acceptor (i.e., the thioamide) in a donor/acceptor pair.
Here, we demonstrate that we can use semi-synthesis to generate thioamide-labeled αS
and that thioamide fluorescence quenching can be used to track conformational changes
during the course of its aggregation.
§ 2.4 Results and Discussion
Note: Semi-Synthesis of αS was performed by Solongo Batjargal and Yanxin Wang.116
In order to make labeled αS through semi-synthesis, we generated constructs for
producing a version of αS with an N-terminal His tag which could be removed by
proteolysis to reveal an N-terminal Cys for ligation. We chose to use commercially
available Factor Xa protease, which selectively cleaves an IEGR sequence and had been
used previously in expressed protein ligation.145 Since αS has no native Cys, we
introduced one by altering the expression construct to remove the first eight residues and
leave an N-terminal Cys (αS9–140C9) after proteolysis.
Solution-phase thioesterification of protected peptides can lead to epimerization
of the α-carbon of the C-terminal residue. We therefore examined an on-resin
thioesterification method for synthesizing the thioamide-containing fragment of αS for
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ligations. Our method uses a Cb-Pro-Go linker, where Cb is a t-Bu-protected Cys, and Go
is glycolic acid. Following acidic cleavage from the resin, the Cb t-Bu group is removed
by treatment with TCEP, initiating a cascade of reactions resulting in a peptide thioester
attached to the diketopiperazine (Dkp) product of Cb-Pro-Go rearrangement (Scheme 2.2).
The Dkp thioester can then either react directly with an N-terminal Cys or undergo
transesterification with a thiol additive.

Figure 2.10 On-Resin Thioester Generation by N-to-S Rearrangement.

The scheme for the semi-synthesis of Val3-labeled αS is shown in Figure 2.10.
The C-terminal fragment, HTag-αS9–140C9, was expressed in E. coli, purified by Ni-NTA
chromatography, and proteolyzed with Factor Xa to give αS9–140C9. The N-terminal
fragment was synthesized on solid phase using the CbPGo linker, with a thioamide
inserted at Val3 during SPPS (αS1–8V′3-CbPGo). Activation of the peptide by TCEP
yielded αS1–8V′3 Dkp thioester, which reacted with αS9–140C9 in situ to give full-length
αSV′3C9. Although ligations reached only 50% completion, ligated αSV′3C9 could be
purified by HPLC. The integrity of the thioamide bond after ligation was assessed by
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MALDI MS of the full-length protein and trypsinized products, as well as by UV
absorption spectroscopy.

Figure 2.11 Synthesis of Labeled αS by Ligation of a Thioamide Peptide to an Expressed
Protein Fragment.
Left: C-Terminal fragment of αS9-140 with an N-terminal His tag, an S9C mutation, and IEGR
cleavage sequence expressed and purified on Ni-NTA resin. After Factor Xa cleavage to
generate an N-terminal Cys, the protein fragment is ligated to synthetic αS1-8 with a thioamide at
position 3 (αS1-8V′3), generated in situ from precursor αS1-8V′3-CbPGo. Top Right: PAGE gel
analysis of ligation. Far Right: MALDI MS of full length aSV′3C9 (calcd m/z 14, 536) or trypsinized
αSV′3C9, giving aS1-6V′3 (calcd m/z 828.4). There is no peak corresponding to desulfurized
oxopeptide αS1-6 (calcd m/z 812.4).

In order to demonstrate the value of incorporating thioamide probes into a protein
such as αS, we carried out an aggregation experiment in which intramolecular
conformational changes were monitored in an αS construct. Here, we employ an αS
construct with a single Trp donor fluorophore (W94) and a single thioamide quencher
(V′3). The native αS sequence has no Trp residues, so selective excitation of an
introduced Trp can be achieved with 295 nm light. Comparison to an oxoamide control
(i.e., αSW94) allows us to isolate thioamide quenching effects from other environmental
effects on Trp fluorescence. Since through-space quenching does not occur over distances
longer than 30 Å, observation of Trp fluorescence quenching normalized to oxoamide
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controls shows that the Trp must be within 30 Å of the thioamide residue. However, in an
oligomer or fibril, quenching can arise through either inter- or intramolecular
interactions. In order to isolate intramolecular misfolding events, we carry out
aggregation experiments with our αSV′3C9W94 construct present in a 1:30 ratio with WT
αS. A ratio of less than one Trp/thioamide-labeled αS per 26 WT αS should ensure that,
on average, no two labeled αS are directly next to each other in aggregates. This derives
from a simple statistical packing model in which each monomer unit would be at the
center of a cube with 26 partners along the centers of faces and vertices, or at corners.
The construct used in aggregation studies was synthesized by ligation of the same
synthetic fragment (αS1–8V′3) with an expressed C-terminal fragment (αS9–140C9W94). For
an aggregation experiment, the presence of non-native Cys in the sequence could be
problematic as the formation of disulfide-bonded dimers would alter the aggregation
mechanism. Therefore, we incubated αS with β-mercaptoethanol (BME) to prevent
disulfide bond formation. No significant increase in aggregation rate was observed in the
Cys-containing mutants.
Aggregation experiments were carried out by shaking the 1:30 αSV′3C9W94/αS
mixtures at 37 °C in phosphate-buffered saline with BME. Although overall Trp
fluorescence increased over 4 days during protein aggregation, the relative fluorescence
of the thioamide (FThio/FOxo) decreased. (See section 2.6, Materials and Methods for
additional primary fluorescence data.) This indicates that positions 3 and 94 approach
each other to within 30 Å in the oligomeric and fibrillar states, but that they are more
separated in the monomeric state. Since we used a 1:30 αSV′3C9W94/αS ratio, we
interpret the quenching as arising primarily from intramolecular interactions within the
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labeled molecule. We normalize our data to an equivalent oxoamide protein (1:30
αSW94/αS) in order to account for other local effects on fluorescence, which are
necessarily complex in an aggregate. We monitored overall fibrillization by ThT
fluorescence, as well as the independent metrics of Congo Red (CR) staining and
sedimentation PAGE gel analysis (see below).
Comparing the ThT data to the Trp fluorescence data clearly indicates that we can
observe quenching in oligomers, which occur at early time points (<24 h), before
fibrillization and ThT fluorescence (Figure 2.12). It is unlikely that multiple labeled αS
molecules are present in oligomers of less than 30 monomer units. Therefore, quenching
of Trp fluorescence provides evidence of close intramolecular approach of residues 3 and
94 when bound in oligomers, consistent with some previous studies showing folding of
the N- and C-termini before fibrillization.101 Our experiments show that thioamide
fluorescence quenching should be useful in monitoring intermediates in the aggregation
process, which are silent in the conventional ThT protocol. Conducting many such
experiments in conjunction with positional scanning of the thioamide probe should
provide mechanistic insight into the aggregation process and the mode of toxicity of these
metastable intermediates.
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Figure 2.12 Monitoring Intramolecular Misfolding During αS Aggregation Using Thioamide
Quenching.
Left: Monomeric αSV′3C9W94 mixed in a 1:30 ratio with WT αS. Trp fluorescence quenching is
observed in oligomers and fibrils. ThT fluorescence is only observed for fibril-bound ThT. Top
Right: Schematic representation of αSV′3C9W94 construct showing Trp, thiovaline, and Cys.
Bottom Right: Normalized Trp (squares) and ThT (circles) fluorescence data for four aggregation
experiments with αSV′3C9W94 (Thio) and control experiments with αSW94 (Oxo).

§ 2.5 Conclusion
We have recently shown that thioamide quenching of Trp or Tyr could be used to
monitor interactions for native proteins.146 These experiments would be limited to
thiopeptides synthesized on solid phase without the ability to ligate thioamide-containing
peptide fragments. Thus, the methods developed here will be used to synthesize
thioamide-labeled proteins for use in the study of protein folding and protein–protein
interactions. Misfolded or aggregating proteins are particularly attractive as they are often
refractory to higher resolution structural techniques such as crystallography or NMR. We
envision generating a large number of labeled αS constructs and using thioamide
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fluorescence quenching to monitor conformational changes during aggregation and
misfolding. Our proof-of-principle experiment indicates that these studies are feasible
and should reveal information that cannot be accessed with common methods such as
ThT binding. Of course, our methods are potentially applicable to a great number of
protein dynamics questions, and we will continue to explore thioamide compatibility with
NCL reactions for the synthesis and study of these proteins.
§ 2.6 Materials and Methods
General Information. Boc-L-thionoleucine-1-(6-nitro)benzotriazolide and Boc-Lthionophenylalanine-1-(6-nitro)benzotriazolide were purchased from Bachem (Torrance,
CA). 2-chlorotrityl resin, Fmoc-Ala-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Leu-OH, FmocArg(Pbf)-OH, Fmoc-Pro-OH, Fmoc-Gly-OH, Fmoc-Val-OH, Fmoc-Phe-OH, FmocIle(OtBu)-OH, Fmoc-Tyr(OtBu) and Fmoc-Trp(Boc)-OH were purchased from
Novabiochem (San Diego, CA).

Piperidine and 2-(1H-benzotriazol-1-yl)-1,1,3,3-

tetramethyluronium hexafluorophosphate (HBTU) were purchased from American
Bioanalytical (Natick, MA).

Sigmacote®, N,N-diisopropylethylamine (DIPEA), hen

egg-white lysozyme, and phenyl-sepharose CL-4B resin were purchased from SigmaAldrich (St. Louis, MO). E. coli BL21(DE3) cells and a QuickChange® site-directed
mutagenesis kit were purchased from Stratagene (La Jolla, CA). DNA oligomers were
purchased from Integrated DNA Technologies, Inc (Coralville, IA). All other reagents
were purchased from Fisher Scientific (Pittsburgh, PA). Milli-Q filtered (18 MΩ) water
was used for all aqueous solutions (Millipore; Billerica, MA). All peptide synthesis
reaction vessels (RVs) were treated with Sigmacote® prior to use. DNA sequencing was
performed at the University of Pennsylvania DNA sequencing facility. Matrix-assisted
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laser desorption ionization (MALDI) mass spectra were collected with a Bruker Ultraflex
III MALDI-TOF-TOF mass spectrometer (Billerica, MA). UV absorbance spectra were
obtained with a Hewlett-Packard 8452A diode array spectrophotometer (currently
Agilent Technologies; Santa Clara, CA). Fluorescence spectra were collected with a
Varian Cary Eclipse fluorescence spectrophotometer fitted with a Peltier multicell holder
(currently Agilent Technologies; Santa Clara, CA). Circular dichoism experiments were
conducted with an Aviv 410 CD spectrometer (Aviv Biomedical; Lakewood, NJ).
Peptide Synthesis was performed by Jacob Goldberg and Alyssa Klein.
Peptide Synthesis and Purification. Leu-Pro2-Trp (LP2W) and Leu-Pro2-Tyr (LP2Y)
were each synthesized on a 12.5 μmol scale on 2-chlorotrityl resin. For each synthesis, 2chlorotrityl chloride resin (100-200 mesh; 0.6 mmol substitution/g; 12.5 μmol) was added
to a dry glass RV. The resin was swollen by two successive 15 min incubations with 5
mL dimethylformamide (DMF) and magnetic stirring. After swelling, DMF was removed
with vacuum suction and Fmoc-Trp(Boc)-OH or Fmoc-Tyr(OtBu)-OH was coupled to
the resin. The amino acid in DMF (5 equiv; 42 mM, 1.5 mL) and DIPEA (10 equiv; 22
μL) were added to the RV and the mixture was allowed to react for 30 min with magnetic
stirring. Spent solution was removed with vacuum suction and the resin beads were
washed thoroughly with DMF. Excess DMF was removed with vacuum suction and the
resin beads were deprotected by treatment with 20% piperidine in DMF (5 mL) for 20
min with magnetic stirring. The deprotection solution was drained from the RV and the
beads were rinsed extensively with DMF. Subsequent amino acid couplings and
deprotections proceeded as described above, with the exception that the remaining Fmocprotected amino acids were activated with HBTU (5 equiv) prior to addition to each
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reaction. The N-terminal Fmoc group was removed before the peptide was cleaved from
the resin. After the beads were washed extensively with DMF and dried with CH2Cl2,
peptides were cleaved by successive 60 min and 30 min incubations on a rotisserie with
2.5 mL of a fresh cleavage cocktail of trifluoroacetic acid (TFA), water, and
triisopropylsilane (TIPS) (10:9:1 v/v). After each treatment, the resulting solution was
expelled from the RV with nitrogen and reduced to a volume of less than 1 mL by rotary
evaporation. The combined residue was diluted with 6 mL of CH3CN/H2O (2:1 v/v).
The peptides were purified by reverse-phase HPLC on a Vydac 218TP C18 semiprep column (Grace/Vydac; Deerfield, IL) using a linear solvent gradient that ranged
from 98% to 60% aqueous phase over 19 min, then to 0% aqueous phase over 5 min, then
returning to 98% aqueous phase during a 10 min wash out period. Trp peptides eluted at
approximately 23 min with this method and Tyr peptides eluted at approximately 19 min.
MALDI-MS was used to confirm identities (Table 2.2). Purified peptides were dried in a
vacuum centrifuge.
Polyproline peptides Leu'-Pron-Trp (L'PnW), n = 2-11, and Leu'-Pron-Tyr (L'PnY),
n = 2-10 were each synthesized on a 10 μmol scale using a procedure analogous to that
described above. These peptides were synthesized from a common pot of resin (100
μmol). After coupling the appropriate number of proline residues, a 10 μmol portion of
resin was removed from the RV and transferred to a separate, clean RV for thioleucine
coupling. Since the thioleucine was introduced through the pre-activated Boc-Lthionoleucine-1-(6-nitro)benzotriazolide, HBTU was not added for these couplings. As
the synthesis progressed, reagents were scaled accordingly. Peptide cleavage,
purification, and characterization followed that described above. The CaM binding
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peptide pOCNC has the sequence FRRIARLVGVLREFAFR; in the thioamide derivative
pOCNC-F1', the N-terminal phenylalanine is replaced with thiophenylalanine. The
general sequence of these peptides is derived from the bOCNCp peptide fragment
described by Contessa et al. (Sequence: GGFRRIARLVGVLREWAYR). Each peptide
was synthesized on a 100 μmol scale using the same general procedures as those
described above. Briefly, a peptide consisting of residues R2-R17 was synthesized on a
200 μmol scale on 2-chlorotrityl resin with 5 equiv amino acid, 10 equiv DIPEA, and 5
equiv HBTU when needed. Before removal of the Fmoc group from R2, the resin beads
were divided into 2 equal portions and transferred to clean RVs for the final coupling of
either Fmoc-L-Phe-OH or Boc-L-thionophenylalanine-1-(6-nitro)benzotriazolide. After
removal of the N-terminal Fmoc group from pOCNC with 20% piperidine, the resin
beads were incubated on a rotisserie twice for 60 min with 10 mL portions of fresh
TFA/H2O/TIPS (38:1:1 v/v). The thioamide-containing peptide was cleaved from the
resin and deprotected with two successive 60 min incubations of the resin beads with 10
mL portions of fresh TFA/H2O/TIPS (18:1:1 v/v). After each incubation period, the
cleavage cocktail for each peptide was expelled from the RV with nitrogen and dried by
rotary evaporation. The residue was diluted to 10 mL with CH3CN/H2O (3:2 v/v) before
purification. Crude peptides were purified by reverse-phase HPLC with linear solvent
gradients that ramped from 98% to 70% aqueous phase over 6 min, then to 56% aqueous
phase over 14 min, then to 0% aqueous phase over 5 min, followed by a 10 min wash out
period, during which the solvent system returned to 98% aqueous phase. Using this
method, the peptides eluted at approximately 19.5 min (Figure 2.13). Peptides were
analyzed by MALDI-MS (Table 2.2).
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Figure 2.13 Analytical HPLC Chromatograms of Purified Peptides.
Top: pOCNC monitored at 215 nm. Bottom: pOCNC-F1' monitored at 277 nm. Absorbance is
normalized. Solvent gradients given in text.
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Table 2.2 Calculated and Observed Peptide Masses.

Peptide

Calculated m/z
[M+H]+

Observed m/z
[M+H]+

Calculated m/z
[M+Na]+

Observed m/z
[M+Na]+

LP2Y

489.27

489.15

511.25

511.12

L'P2Y

505.25

505.14

527.23

527.11

L'P3Y

602.30

602.12

624.28

624.08

L'P4Y

699.35

699.16

721.36

721.14

L'P5Y

796.41

796.28

818.39

818.20

L'P6Y

893.46

893.29

915.44

915.27

L'P7Y

990.51

990.21

1012.49

1012.18

L'P8Y

1087.57

1087.24

1109.55

1109.21

L'P9Y

1184.62

1184.60

1206.60

1206.57

L'P10Y

1281.67

1281.66

1303.65

1303.66

LP2W

512.29

512.02

534.27

534.01

L'P2W

528.26

528.28

550.25

550.26

L'P3W

625.32

625.10

647.30

647.07

L'P4W

722.37

722.14

744.35

744.12

L'P5W

819.42

819.33

841.40

841.30

L'P6W

916.48

916.41

938.46

938.39

L'P7W

1013.53

1013.28

1035.51

1035.27

L'P8W

1110.58

1110.27

1132.56

1132.25

L'P9W

1207.63

1207.58

1229.62

1229.51

L'P10W

1304.69

1304.57

1326.67

1326.57

L'P11W

1401.74

1401.69

1423.72

1423.67

pOCNC

2106.26

2106.78

2128.24

2128.75

pOCNC-F1'

2122.23

2122.31

2144.22

2144.28
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Förster Distance Calculation. The Förster distance is given in Å by equation 2.1,
R06 

9000(ln10) 2Q D J
128  5 n 4 N A

(Eq. 2.1)

where κ2 is a geometrical factor that relates the orientation of the donor and acceptor
transition moments, QD is the quantum yield of the donor, n is the index of refraction of
the solvent, NA is Avogadro’s number, and J is the spectral overlap integral defined in
units of M-1•cm-1•nm4. Combining constants and rearranging gives R0 as

R0  0.211{Q D 2 n4 J}1/ 6

(Eq. 2.2)

J is formally defined as
J
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(Eq. 2.3)

0

where εA(λ) is the molar extinction coefficient of the acceptor at each wavelength λ and
fD(λ) is the normalized donor emission spectrum given by

f D () 



FD ( )

 F  ()d

(Eq. 2.4)

D

0

where FDλ(λ) is the fluorescence of the donor at each wavelength λ. Fluorescence spectra
of LP2W and LP2Y in water were integrated with KaleidaGraph from 300 to 450 nm for
LP2W and 280 to 400 nm for LP2Y to calculate fD(λ). UV-Vis spectra of
thioleucylalanine ester in water were used to determine εA(λ). The literature value of ε273
= 12,400 M-1•cm-1 was used to prepare solutions of known concentration. J was
calculated to be 1.63 × 109 M-1•cm-1•nm4 for the Trp/thioamide pair and 2.21 × 1012 M1

•cm-1•nm4. Substituting these results into equation 2.2, as well as the quantum yields

(0.13 for Trp and 0.14 for Tyr), 1.33 for the index of refraction of water, and 2/3 for κ 2
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gives Förster distances of 4.0 Å for the Trp-thioamide pair and 13.4 Å for the Tyrthioamide pair.
Polyproline ruler experiments were performed by Jacob Goldberg.
Fluorescence Spectroscopy. Dry proline series peptides were brought up in a minimal
volume of pH 7.0 phosphate buffer (150 mM NaCl, 10 mM Na2HPO4, pH adjusted with
HCl). Tryptophan-containing peptides were diluted to concentrations of approximately 10
M, as determined by absorbance at 280 nm (ε280 = 13,270 M-1•cm-1 for thioamidecontaining peptides; ε280 = 5,600 M-1•cm-1 for all others). Tyrosine-containing peptides
were diluted to concentrations of approximately 20 M, as determined by absorbance at
274 nm (ε274 = 14,420 M-1•cm-1 for thioamide-containing peptides; ε274 = 1,420 M-1•cm-1
for all others). Corrected fluorescence spectra were collected at 25 °C in triplicate for
each peptide using quartz fluorometer cells with path lengths of 1.00 cm. For all Trp
experiments, the excitation wavelength was 295 nm and emission data was collected
from 300 - 500 nm as the average of three scans. For all Tyr experiments, the excitation
wavelength was 275 nm and emission data was collected from 280 – 400 nm. For all
experiments, the excitation and emission slit widths were 5 nm, the scan rate was 120
nm/min, the averaging time 0.5 s, and the data interval 1.0 nm. Examples of fluorescence
spectra and associated UV spectra are shown in Figure 2.14.
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Figure 2.14 UV Absorption and Fluorescence Emission Spectra for Pro Series Peptides.
Top Left: Tyr UV spectra collected between 200 and 320 nm and background corrected against
average absorption from 450 to 500 nm. Top Right: Tyr fluorescence emission spectra collected
between 285 and 400 nm with excitation at 275 nm. Bottom Left: Trp UV spectra collected
between 200 and 320 nm and background corrected against average absorption from 550 to 650
nm. Bottom Right: Trp fluorescence emission spectra collected between 305 and 480 nm with
excitation at 295 nm. Emission spectra colored according to corresponding absorption spectrum.

Proline Series Fluorescence. Fluorescence intensities at the wavelength of maximum
emission (λmax = 305 nm for Tyr and λmax = 355 nm for Trp) were averaged from three
separate trials for each proline peptide, except for L'P10W, which represents six trials.
These values were then normalized to the fluorescence intensity of Leu-Pro2-Trp or LeuPro2-Tyr, as appropriate, and plotted against the number of prolines separating the
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chromophores and that distance in angstroms (Figure 2.15). The resulting data sets were
fit to a sigmoidal function F(x):

F(x)  c1 

c 2  c1
 x c4
1  
c 3 

(Eq. 2.5)

Here, c1 through c4 are constants and the variable x is defined with respect to the choice
of the abscissa. In Figure 2.15, the data were fit to equation 2.5 with the independent
variable in terms of n, the number of prolines. Using this fit, the distance in prolines at
which 50% quenching is observed is 5.17 ± 0.59 prolines for Tyr (R2 = 0.98) and 4.58 ±
0.79 prolines for Trp (R2 = 0.98). Figure 2.16 shows the fits to the same equation with the
independent variable explicitly cast in angstroms. The distance in angstroms at which
50% quenching is observed is 16.2 ± 2.0 Å for Tyr (R2 = 0.98) and 15.1 ± 3.0 Å for Trp
(R2 = 0.97).

Figure 2.15 Fluorescence Intensity as a Function of Interchomophore Distance.
Explicit fits of Tyr (left) and Trp (right) fluorescence data were fit to equation 2.5 with the
abscissa in angstroms. Distance calculations described below.
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Quenching efficiency (EQ) as a function of distance in angstroms was calculated using the
formula:
E Q  1 (F/F0 )

(Eq. 2.6)

where F is the fluorescence at each data point and F0 is taken to be the upper asymptotic
limit, c1. The resulting data sets were plotted against distance in angstroms and fit to
equation 2.5. Both curves fit the data reasonably well, with goodness-of-fit values of R2 =
0.98 for Tyr and R2 = 0.97 for Trp. The distances corresponding to 50% quenching are
16.7 ± 2.2 Å for Tyr and 15.5 ± 3.0 Å, which agree with those values found fitting the
raw fluorescence data as described above.

Figure 2.16 Quenching Efficiency as a Function of Interchromophore Distance.

Normalized fluorescence data were also fit to FRET, Dexter, and electron transfer
models to evaluate their suitability for describing the observed quenching. For the FRET
model, the data were fit to equation 2.7 using KaleidaGraph.
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F  F0 16 
 R  
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(Eq. 2.7)

Here, F0, the fluorescence of the donor in the absence of the acceptor, and R0, the
Förster distance, are adjustable parameters, and R is the separation between the
chromophores in either the number of prolines or the distance in angstroms as calculated
from molecular dynamics simulations (described below). Plots of these fits are shown in
Figure 2.17 as solid traces. Although the curves generally follow the observed pattern of
quenching, the values for R0 that were found to do not agree with those calculated from
theory. For example, R0 was calculated to be 13.4 Å for the Tyr-thioamide pair and was
found to be 16.6 ± 0.6 Å experimentally, assuming a FRET model. For the case of a Trpthioamide FRET pair, we predicted R0 to be 4.0 Å, but found a value of 15.3 ± 0.6 Å
experimentally.
The data sets were also fit to a Dexter model (Eq. 2.8) using KaleidaGraph.







1
F  F0 1
 2R  

 1 k expL  
 Dex  


(Eq. 2.8)

Here F0, k, and LDex (taken to be the sum of the chromophore radii) are adjustable
parameters, and R is again the interchromophore separation in number of prolines or
distance in angstroms.10 Values of 7.64 ± 0.84 Å (R2 = 0.99) and 7.38 ± 1.02 Å (R2 =
0.98) were found for LDex for Tyr and Trp, respectively. These values are in relatively
close agreement with those predicted by quantum mechanical calculations: 7.16 Å for
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Tyr/thioamide and 7.44 Å for Trp/thioamide (see below for description of distance
determination).

Figure 2.17 Fluorescence Intensity Fit to FRET and Dexter Models.
Tyrosine (left) and tryptophan (right) fluorescence data from fit to a FRET model (solid trace) or a
Dexter model (dashed trace) with respect to chromophore separation in number of prolines (top)
or distance in angstroms (bottom).

Fluorescence intensities were then converted to EQ according to equation 2.6. The
quenching efficiencies were fit to each model using equation 2.9 for FRET and equation
2.10 for Dexter.
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EQ 

EQ 

1
 R 6
1  
R0 

1
 2R 
1 k exp

LDex 

(Eq. 2.9)

(Eq. 2.10)

In each case, the values for F0 obtained from the corresponding distance-inangstroms plots were used to compute quenching efficiency. Using this method, R0 was
found to be 16.2 ± 0.5 Å (R2 = 0.96) for the Tyr-thioamide pair and 15.1 ± 0.5 Å (R2 =
0.95) for the Trp-thioamide pair. Again, these values are larger than those predicted by
Förster theory. For the Dexter model, LDex was found to be 7.6 ± 0.7 Å (R2 = 0.98) for the
Tyr-thioamide pair and 7.5 ± 1.0 Å (R2 = 0.96) for the Trp-thioamide pair.
Finally, the data were also fit to a general distance-dependent quenching (DDQ)
model that has previously been used to describe electron transfer.







1
F  F0 1
2R  a  

 1 ka exp r  
 e  


(Eq. 2.11)

In this equation, a is the distance of closest approach of the chromophores, re is
the so-called characteristic distance, and ka is the rate of the reaction at the distance a. As
before, R is defined as the distance between the chromophores in prolines or angstroms.
We note that the form of this equation is similar to that used to describe Dexter transfer,
which also has a 1/eR distance dependence. Both data sets were fit to equation 2.11 . The
data were then converted to quenching efficiencies using equation 2.6 and fit to equation
2.12 with KaleidaGraph (Figure 2.18).
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(Eq. 2.12)

Using this equation, re was found to be 3.79 ± 2.51 Å for Tyr and 3.75 ± 3.59 Å for Trp
in the polyproline ruler system.

Figure 2.18 Proline Series Quenching Efficiency Described by FRET and Dexter Models.
Thioamide quenching Tyr (left) and Trp (right) fluorescence efficiencies calculated with equation
2.6 and fit to 1/R6 distance dependence as described by FRET (Top) or 1/eR distance
dependence as described by Dexter transfer (Bottom). Error bars indicate standard error.
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Figure 2.19 Proline Series Fluorescence Fit to a DDQ Model.
Tyr (left) and Trp (right) fluorescence data from Figure 2.15 fit to equation 2.11 with the
chromophore separation in either number of prolines (Top) or distance in angstroms as
determined by molecular dynamics simulations (bottom), described below. Error bars represent
standard error.
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Figure 2.20 Proline Series Quenching Efficiency Described by a DDQ Model.
Thioamide quenching Tyr (left) and Trp (right) fluorescence efficiencies calculated with equation
2.6 and fit to 1/eR distance dependence as described by the DDQ model (Equation 2.11). Error
bars indicate standard error.

Molecular Dynamics Calculations: Polyprolines. Starting geometries for 22 proline
series peptides (with N-terminal Leu, C-terminal Tyr or Trp and n intervening prolines,
with n = 2-12) were generated using polyproline type II helix  and  angles of - 78° and
149°, respectively. All peptide bonds were initially trans (i.e.  = 180°). N- and Ctermini were left as charged amines and carboxylates, respectively. These were inserted
into a TIP3P water box with 10 Å periodic boundaries and no ions. Simulations were
performed using the NAMD 2.7b2 package and the CHARMM27 all-atom force field.147
Covalent bonds involving hydrogen were held rigid using the SHAKE algorithm,
allowing a 2 fs time step. A cutoff distance of 12 Å was maintained in calculating
nonbonded interactions. Bonded and nonbonded forces were evaluated at every time step,
and full electrostatic forces were evaluated at every other time step through application of
the particlemesh Ewald (PME) method.148 The simulation was initiated at 100 K,
equilibrated for 25 ps, and warmed to 300 K at a rate of 0.025 K/fs. After warmup, 5 x
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106 step trajectories (10 ns) were run in the constant temperature and pressure (NPT)
ensemble at 300 K.
Computational Studies were performed by E. James Petersson.
Chomophore Geometries: Polyprolines. For each 10 ns trajectory, a Tcl script was run
in VMD (http://www.ks.uiuc.edu/) to cull distance and orientation information for the
leucyl carbonyl and aromatic ring at every tenth timestep over the last 9 ns of the
trajectory. The script identified the midpoint between CE1 and CE2 (CEmp) of Tyr or the
midpoint between CD2 and CE2 (CDEmp) of Trp. Likewise, the script identified the
Leu1 C as the midpoint of the amide. (Figure 2.21) These midpoints serve as convenient
anchors that are less sensitive to conformational fluctuations than a single atom position.
The interchromophore distance (R) was determined as the CEmp-C distance for LeuPron-Tyr peptides and the CDEmp-Pron-C distance for Trp peptides). These distances are
shown in Figure S10, plotted as a function of the number of Pro for the Tyr and Trp
series peptides. Data for analogous calculations done on Leu-Pron-Phe were reported
previously and are also shown in Figure 2.22.115

Figure 2.21 Interchomophore Distances.
Left: Timestep 1 from Leu-Pro2-Tyr simulation shown with atoms used in determining distance (R)
illustrated. Right: Timestep 278 from Leu-Pro2-Trp simulation shown with atoms used in
determining distance (R) illustrated. Images rendered using PyMOL.
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The relationship between chromophore spacing and the number of prolines is
relatively linear in all cases, thus a simple linear fit to the data was used to generate the
distances in Å used on the abscissa of Figure 2.22. These equations are listed in Figure
2.21.

Figure 2.22 Interchromophore Distances from MD Simulations.
Average distances from last 9 ns of 10 ns simulations of polyproline peptides. Bars indicate
RMSD. Equations indicate linear fits to data.
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Table 2.3 Interchomophore Distances Determined from MD Simulationsa



Pro2
Average
RMSD

Tyr
8.1
1.8

Pro3
Average
RMSD

11.0
2.4

11.0
1.7

Pro4
Average
RMSD

12.9
1.2

13.8
1.7

Pro5
Average
RMSD

15.3
1.6

16.0
1.4

Pro6
Average
RMSD

19.1
2.1

19.0
1.8

Pro7
Average
RMSD

21.2
2.0

23.1
2.1

Pro8
Average
RMSD

24.0
1.9

24.8
1.3

Pro9
Average
RMSD

27.2
2.0

27.5
1.9

Pro10
Average
RMSD

31.5
2.6

29.4
1.9

Pro11
Average
RMSD

32.4
2.0

34.2
1.9

Pro12
Average
RMSD

37.0
2.1

35.3
2.6

a

Trp
8.3
1.7

Distances (in Å) calculated as described in text.
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Quantum Mechanical Calculations. Phenol and indole structures were optimized at the
B3LYP level of theory with a 6-311G+ basis set using GAUSSIAN 03 (Gaussian, Inc.;
Wallingford, CT). For Dexter fitting, the phenol (Tyr) diameter (dTyr = 7.38 Å) was
computed as the sum of the O12 to C6 distance (4.16 Å) plus the van der Waals radii of
oxygen (1.52 Å) and carbon (1.70 Å). The van der Waals radius (RTyr = 3.69 Å) was
computed as one half of this value. The indole (Trp) diameter (dTrp = 7.94 Å) was
computed as the sum of the N1 to C8 distance (4.54 Å) plus twice the van der Waals
radius of carbon (1.70 Å). The van der Waals radius (RTrp = 3.97 Å) was computed as one
half of this value. The thioamide van der Waals radius (RSCN = 3.47 Å) has been reported
previously.

Figure 2.23 Chomophore Lengths.
B3LYP/6-311G+ minimized geometries for phenol (left), indole (center), and thioformamide
(right). Interatomic distances used in calculating chomophore radii are indicated. Figure rendered
using Gaussview 4.1.

Cloning of Calmodulin Expression Constructs. A plasmid containing the wild-type
chicken calmodulin (CaM) gene was provided by Joshua Wand from the University of
Pennsylvania School of Medicine. An insert containing the CaM gene (458 base pairs
from start to stop codon) was cloned into a pET15b vector (Novagen, Gibbstown, NJ)
between the NcoI and XhoI cut sites. Quikchange® site-directed mutagenesis was used to
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generate the following CaM mutants: Y100F, Y139F, Y100W, and Y139W. The mutant
plasmids were verified by DNA sequencing analysis with a T7 promoter primer.
A. CaM Gene
5'-atggctgatcaactgacagaagagcagattgcagaattcaaagaagctttttcactattt
gacaaggatggtgatggtactataactacaaaggagttggggactgtgatgagatcacttggt
cagaaccccacagaagcagaattacaggacatgatcaatgaagtagacgctgatggcaatggc
acaattgacttcccagagtttctgacaatgatggcaagaaaaatgaaagatacagatagcgaa
gaagaaattagagaagcgttccgtgtgtttgacaaggatggtaatggttacattagtgctgca
gaacttcgtcatgtgatgacaaatcttggggagaagctaacagatgaagaagttgatgaaatg
attagggaagcagacattgatggtgatggtcaagtaaactatgaagagtttgtacagatgatg
acagcgaagtga-3'

B. Chicken CaM Amino Acid Sequence
MADQLTEEQIAEFKEAFSLFDKDGDGTITTKELGTVMRSLGQNPTEAELQDMINEVDADGNGTIDFPEFLT
MMARKMKDTDSEEEIREAFRVFDKDGNGYISAAELRHVMTNLGEKLTDEEVDEMIREADIDGDGQVNYEEF
VQMMTAK

C. DNA Oligomers used for Quikchange® Mutagenesis
Y100F_For

5'-gacaaggatggtaatggtttcattagtgctgcagaactt-3'

Y100F_Rev

5'-aagttctgcagcactaatgaaaccattaccatccttgtc-3'

Y139F_For

5'-agacattgatggtgatggtcaagtaaactttgaagagtttgtaca-3'

Y139F_Rev

5'-tgtacaaactcttcaaagtttacttgaccatcaccatcaatgtct-3'

Y100W_For

5'-tgacaaggatggtaatggttggattagtgctgcagaacttcg-3'

Y100W_Rev

5'-cgaagttctgcagcactaatccaaccattaccatccttgtca-3'

Y139W_For

5'-tgatggtgatggtcaagtaaactgggaagagtttgtacagatgatgac-3'

Y139W_Rev

5'-gtcatcatctgtacaaactcttcccagtttacttgaccatcaccatca-3'

DNA Sequence of Chicken CaM Gene from Start to stop codon. B: Amino acid sequence of
chicken CaM. Y100 and Y139 residues highlighted in red. C: Forward and reverse DNA oligomers
used for site-directed mutagenesis.

Protein Expression and Purification. The plasmid containing the chicken CaM gene
was used to transform Escherichia coli BL21(DE3) cells. Transformed cells were
selected on the basis of ampicillin resistance. Single colonies were used to inoculate 50
mL of M9 minimal media supplemented with ampicillin (100 g/mL). To an autoclaved
solution containing 42.3 mM Na2HPO4, 22.0 mM KH2PO4, and 8.5 mM NaCl, the
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following autoclaved solutions were added per liter of M9 salts: 10 mL of 10% NH4Cl, 1
mL of 2 M MgSO4, 1 mL of 15 mg/mL FeCl2 (in 1.0 M HCl), 1 mL of 15 mg/mL ZnCl2
(in acidified H2O), and 2 mL of 10% BactoTM Yeast Extract. The primary 50 mL culture
was incubated at 37 C with shaking at 250 rpm overnight. The cells were harvested at
5000 g for 15 min and the resulting pellet was re-suspended in 1 L of M9 minimal media
supplemented with ampicillin. The 1 L culture was incubated at 37 C with shaking at
250 rpm until the absorbance at 600 nm reached 0.9 AU. Protein expression was induced
with isopropyl D-galactoside (IPTG), and the culture was incubated at 25 C for an
additional 12 h. The cells were again harvested at 5000 g for 15 minutes and the resulting
pellet was suspended in 15 mL of MOPS resuspension buffer: 50 mM 3-(Nmorpholino)propanesulfonic

acid

(MOPS),

100

mM

KCl,

1

mM

ethylenediaminetetraacetic acid (EDTA), 1 mM dithiothreitol, pH 7.5. Cell lysis was
achieved by incubating the resuspended cells with lysozyme (150 g/mL) for 1 h at room
temperature followed by brief sonication. Following sonication, the cell lysate was
allowed to cool on ice for 5 min. CaCl2 was added to the sonicated lysate to a final
concentration of 5 mM prior to centrifugation for 20 minutes at 30,000 g, 4 C. CaM was
purified from the cleared cell lysate using a phenyl-sepharose CL-4B column with EDTA
as eluant. Using a total resin bed volume of 20 mL, the column was first equilibrated with
4 column volumes of Buffer A (50 mM Tris base, 1 mM CaCl2, pH 7.5). After the cleared
cell lysate was loaded and allowed to pass through the resin, the column was washed with
4 column volumes of Buffer A, 4 column volumes of high-salt Buffer B (50 mM Tris
base, 0.5 M NaCl, 0.1 mM CaCl2, pH 7.5), and an additional 2 column volume washes of
Buffer A to restore low-salt conditions. CaM was eluted with Buffer C (10 mM Tris base,
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10 mM EDTA, pH 7.5) and collected in 4 mL fractions until absorbance at 280 nm was
no longer detected. A second column purification was performed on the first batch of
eluted fractions (re-saturated with CaCl2 to a concentration of 20 mM) to obtain CaM
with high levels of purity. Column fractions were dialyzed against 10 mM ammonium
bicarbonate (pH 8.0) and stored as a lyophilized powder at -20 C. SDS-PAGE analysis
was performed to analyze dialyzed CaM elution fractions.

Figure 2.24 SDS-PAGE gel of purified CaM mutants.
Approximately 10 M samples denatured at 95 °C in the presence of SDS.

Calmodulin Circular Dichroism Measurements. Mutant stability was evaluated using
temperature-dependent circular dichroism (CD) spectroscopy. Since calcium-containing
CaM (holo CaM) is thermostable (Tm > 90 °C), we specifically examined the thermal
unfolding of the apo protein, for which the reported Tm is 55 °C.149 To compare the apo
and holo forms, purified protein was dialyzed against 2 mM EDTA in 50 mM 4-(2hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) pH 6.70 or 10 mM CaCl2 in 50
mM HEPES pH 6.70. CD data were obtained from approximately 20 M protein samples
diluted in the appropriate buffer monitoring at 222 nm, between 5 and 95 oC, using the
variable temperature module provided with the Aviv 410 CD spectrometer. Data were
collected with a 1 °C/min slope, 30 s averaging time, 2 min temperature equilibration, 5 s
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response, and 1 nm band width. The resulting ellipticity (D) measurements were
transformed to molar residue ellipticity values () using

   D /(cnR )

(Eq. 2.13)

where c is concentration (M), ℓ is the path length (cm), and nR is the number of residues.
To determine fraction folded (ff) for the apo protein, linear baselines were fit to the low
temperature (F = mFT + bF) or high temperature (U = mUT + bU) data. The full data
range was then fit to equation 2.14 where K = K = e-(H – TS)/RT, H and S are adjustable
parameters and R = 8.3145 J•mol-1•K-1. Plots are shown for each mutant in Figure 2.25.

  F (T)ff (T)  u (T)(1 ff (T)) ff  K/(1 K)

(Eq. 2.14)

Since the holo protein did not melt, only the molar residue ellipticity as a function of
temperature is shown for each mutant (Figure 2.25).

Figure 2.25 Temperature-Dependent Circular Dichroism Spectroscopy of Wildtype CaM
and Mutants.
Left: Fraction folded as a function of temperature as determined by molar residue ellipticity ( ) at
222 nm measured for 20 µM solutions of each protein in the absence of Ca2+. Right: Molar
residue ellipticity (D) at 222 nm measured for 20 µM solutions of each protein in the presence of
Ca2+.
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Peptide Binding Experiments. All peptide binding experiments were conducted in 15
mM HEPES buffer, 140 mM KCl, and 6 mM CaCl2, pH 6.70. Dry peptides and
lyophilized protein were brought up in a minimal amount of buffer to make fresh
concentrated stock solutions for each experiment. The absorbance at 280 nm of each
protein solution was used to determine its concentration (ε280,WT = 3000 M-1•cm-1;
ε280,Y100F = 1500 M-1•cm-1; ε280,Y139F = 1500 M-1•cm-1; ε280,Y100W = 7400 M-1•cm-1; and
ε280,Y139W = 5400 M-1•cm-1). For each mutant, solutions were prepared that contained
approximately 10 M protein and a variable amount of peptide, ranging from 0 to
approximately 20 M and representing at least seven distinct concentrations. Each
sample was prepared in triplicate using one of two methods. For at least one trial of each
mutant, concentrated stocks of protein and peptide were combined with buffer to prepare
solutions at each peptide-concentration step. The fluorescence of each solution was
measured as described below. For the second trial of each mutant, a sample of protein
was diluted to approximately 10 M in buffer. The fluorescence of this solution was
measured as described below and then a concentrated peptide solution of either pOCNC
or pOCNC-F1' was added to obtain a sample that was approximately 20 M in peptide.
The fluorescence of this solution was then recorded and the solution was diluted with 10
M protein to prepare samples of varying peptide concentration, while maintaining
constant protein concentrations. The fluorescence of each sample was measured between
dilutions. No variation was observed in the fluorescence of samples prepared by either
method. Fluorescence spectra of pOCNC and pOCNC-F1' were acquired in the absence of
protein at each concentration with excitation wavelengths of 275 nm and 295 nm.
Essentially no fluorescence was observed exciting the peptides at 295 nm. To confirm
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that the observed quenching was coming from a peptide binding event, we incubated 10
M CaM in buffer in the presence and absence of 20 M thioacetamide and measured the
fluorescence by exciting at 275 nm and 295 nm; no change in fluorescence was observed.
Corrected fluorescence measurements as the average of three scans were taken of
each sample at 25 °C using quartz fluorometer cells with path lengths of 1.00 cm. For
WT, Y100F, and Y139F experiments, the excitation wavelength was 275 nm and emission
data were collected from 280 -400 nm. For Y100W and Y139W experiments, the excitation
wavelength was 295 nm and emission data were collected from 300 - 500 nm. For all
experiments, the excitation and emission slit widths were 5 nm, the scan rate was 120
nm/min, the averaging time 0.5 s, and the data interval 1.0 nm. Representative
fluorescence spectra are shown in Figure 2.26.
Since pOCNC and pOCNC-F1' are slightly fluorescent when excited 275 nm
(Figure 2.26), all binding experiment data was background corrected for contributions
from peptide fluorescence. The raw signal of the peptide in buffer was subtracted from
the raw signal of the protein•peptide complex at each concentration step. These
background-corrected values were normalized to the fluorescence of the protein in the
absence of peptide (i.e. to the 0 M sample). The quenching efficiencies listed in Table
2.1 were estimated from the normalized fluorescence at 1:1 binding stoichiometry.
Predictions of the quenching efficiency for each protein were calculated using our
empirical ruler and using Förster theory. The average distance between the thiocarbonyl
carbon atom of pOCNC-F1' and either the ε1 and ε2 carbons of Tyr or the δ2 and ε2
carbons of Trp were calculated using PyMol from the NMR structure PDB 1SY9. Using
this metric the distance between the thioamide and tyrosine was found to be 19.3 Å for
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Y100 and 15.9 Å for Y139. For Trp, the distance was found to be 19.0 Å for W100 and 17.0
Å for W139. Equation (2.6) was used directly to calculate quenching efficiencies at these
distances for each of the mutants (Y100F, Y139F, Y100W, and Y139W). For the WT protein,
we weighted the contribution from each Tyr using the fluorescence sensitivity, which we
defined to be the product of the extinction coefficient and the quantum yield (ΦY100 =
0.105; ΦY139 = 0.061) at 275 nm. For Förster calculations, we used equation 2.1 and the
values of J that we had previously determined from the spectral overlap of
thioleucylalanine ester with Trp or Tyr to determine a value of R0 for each fluorophore. In
these calculations, we took κ2 to be 2/3, approximated n to be 1.33, and substituted the
appropriate quantum yield for each donor (ΦW100 = 0.15; ΦW139 = 0.29). We used these
values of R0 in equation 2.1 with the distances inferred from the NMR structure to
compute the theoretical quenching efficiency for a FRET mechanism for each mutant.
Again, we weighted the quenching efficiency contributions for each Tyr in the wildtype
enzyme with their fluorescence sensitivity factors as described above. The backgroundcorrected, normalized fluorescence data for the titration of pOCNC-F1' was fit to equation
2.15 using KaleidaGraph.

y  1 R

 1


 [P]0  [ P ]0 [L]0  
 Ka


2

 1


 [P]0  [P ]0 [L]0   4[P]02 [L]0
 Ka

2[P]0

(Eq. 2.15)

Here we define [L]0 and [P]0 to be the total concentration of peptide and protein,
respectively. Ka is the equilibrium constant for the peptide binding to the protein to form
a 1:1 protein-peptide complex and R is an instrumental response parameter. Ka and R are
adjustable parameters in the fit.

99

Figure 2.26 Representative Fluorescence Spectra of CaM Mutants.
Top Left: Fluorescence of pOCNC (circles) and pOCNC-F1' (squares) as a function of peptide
concentration in buffer (ex. 275 nm; em. 305 nm). Top Right: Emission spectra of 10 M WT CaM
in the presence (dashed trace) and absence (solid trace) of 13 M pOCNC-F1' (ex. 275 nm).
Center: Emission spectra of 8.5 M Phe mutants with (dashed) and without (solid) 13 M
pOCNC-F1' (ex. 275 nm). Bottom Left: Emission spectra of 9.4 M Y100W CaM with (dashed) and
without (solid) 13 M pOCNC-F1' (ex. 295 nm). Bottom Right: Emission spectra of 13 M Y139W
CaM with (dashed) or without (solid) of 13 M pOCNC-F1' (ex. 295 nm).

100

Semi-Synthesis of αSV′3C9W94 was performed by Solongo Batjargal and Yanxin Wang.116
Expression and Purification of WT αS and αSW94. The plasmid containing the αS
gene was used to transform Escherichia coli BL21(DE3) cells. Transformed cells were
selected on the basis of ampicillin resistance. Single colonies were used to inoculate 5
mL of LB media supplemented with ampicillin (100 μg/mL). The primary 5 mL culture
was incubated at 37 °C with shaking at 250 rpm for 5 hours. 500 mL of LB media
supplemented with ampicillin was inoculated with 1 mL of the primary culture. The 500
mL culture was incubated at 37 °C with shaking at 250 rpm for 20 hours. The cells were
harvested at 5000 g for 15 min and the resulting pellet was resuspended in a high-salt
buffer (750 mM NaCl, 10 mM Tris, pH 7.6, 1 mM EDTA, 1 mM PMSF) and sonicated.
Following sonication, the cell lysate was boiled for 30 minutes prior to centrifugation for
20 minutes at 30,000xg, 4 °C. The cleared lysate was dialyzed overnight against
purification buffer (50 mM Tris, 150 mM NaCl, pH 8.0) prior to loading on a Superdex
200 column (25 cm) connected to a BioCad Sprint (FPLC) system. FPLC fractions were
dialyzed against phosphate buffered saline (pH 7.0) at 4 °C and stored at -80 °C until
further use. SDS-PAGE analysis was performed to analyze the purity of αS elution
fractions.
Aggregation Assays. Aggregation experiments were performed according to literature
precedent. 350 L samples for aggregation assays were prepared (97 M WT αS with 3
M αSW94 or 3 M αSV′3C9W94) in phosphate buffered saline (pH 7.0) containing 1 mM
-mercaptoethanol. Aggregation was seeded by the addition of approximately 10%
(wt/wt) pre-formed WT αS fibrils. The samples were incubated at 37 C for 4 to 6 days
with continuous shaking at 1100 rpm. 40 L aliquots were periodically removed to
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monitor changes in tryptophan fluorescence and ThT or Congo Red binding. Protocols
and examples of primary fluorescence or absorbance data are given below.
Fluorescence Spectroscopy. Fluorescence experiments were performed following
literature precedent. 40 L aliquots were periodically removed from aggregation
experiments to monitor changes in tryptophan fluorescence and ThT binding. The 40 L
aliquots were diluted to 120 L with phosphate buffered saline prior to loading the
sample into quartz cuvettes. To selectively monitor changes in Trp fluorescence in the
presence of tyrosine, the excitation wavelength was 295 nm and emission data was
collected from 315 to 385 nm. ThT binding was determined by directly adding 1 mL of
ThT solution (20 M in phosphate buffered saline) to the cuvette after monitoring Trp
fluorescence. The samples were incubated within the cuvettes for two minutes prior to
collecting ThT fluorescence data. The excitation wavelength was 446 nm and emission
data was collected from 460 to 600 nm. For all experiments, the temperature was 37 °C,
the excitation and emission slit widths were 5 nm, the scan rate was 120 nm/min with an
averaging time of 0.5 s, and the data interval 1.0 nm. Examples of primary spectra are
shown in Figure 2.27 and averaged data for Trp and ThT fluorescence from four
aggregation trials are shown in Table 2.4.
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Figure 2.27 Examples of Fluorescence Data from αS Aggregation Experiments.
Left: Trp fluorescence, excited at 295 nm. Right: ThT fluorescence, excited at 436 nm. In both
cases, red, green, and blue indicate data at 0, 8, and 72 h respectively. Solid lines: 1:30
αSW94/WT mix. Broken lines 1:30 αSV′3C9W94/WT mix.
Table 2.4 Normalized Fluorescence Data from Aggregation Experiments
Time
(h)
0

Oxo
FTrp
SE

Oxo
FTrp

Thio
FTrp

1

Thio
FTrp
SE

Eq

1

Eq
SE
1

Oxo
FThT

Oxo
FThT
SE
1

Thio
FThT

Thio
FThT
SE

1

4

1.155

0.052

1.141

0.015

0.988

0.046

1.117

0.045

1.040

0.096

8

1.115

0.012

1.079

0.020

0.968

0.021

1.034

0.106

1.040

0.131

16

1.255

0.079

1.182

0.059

0.942

0.076

1.564

0.169

1.263

0.155

32

1.379

0.081

1.214

0.077

0.881

0.076

2.372

0.357

1.485

0.221

72

2.134

0.188

1.809

0.090

0.848

0.086

3.323

1.034

2.871

1.005

96

2.201

0.201

1.851

0.192

0.841

0.116

2.480

0.576

2.260

0.837

FTrp at 350 nm and FThT at 490 nm collected as described above for 1:30 αSW94/WT mix (Oxo) or 1:30
αSV3C9W 94/WT (Thio). SE = Standard error

Congo Red Absorbance Assay for Aggregation Experiments. CR assays were
performed following literature precedent. After 96 hours of aggregation, a 20 L aliquot
from the aggregation assay was removed and added to 110 L of 20 M CR in phosphate
buffered saline (pH 7.0). A blank sample was prepared by adding 20 L of buffer to the
CR solution. All samples were incubated at room temperature for 30 minutes prior to
collecting absorbance data.
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PAGE Gel Analysis of Aggregation Experiments. Immediately following the assembly
of the aggregation reaction, a 10 L aliquot from each sample was removed for PAGE
gel analysis and stored at - 80 °C. After 96 hours of aggregation, an additional 10 L
aliquot was removed from each sample. Each aliquot was diluted to 30 L with MilliQ
water and centrifuged for 45 min at 13,200 rpm to determine the loss of soluble protein
post-aggregation. 15 L of the resultant supernatant was removed from the centrifuged
samples and run on an 18% SDS-PAGE gel. The gel was stained with Coomassie blue
and scanned.

Figure 2.28 Congo Red and PAGE Gel Analysis of Aggregation Experiments.
Left: CR absorption assay shows a red shift and increase in absorbance, indicating fibrillization of
αSV′3C9W94/αS mixtures or αSW94/αS mixtures after 4 days. Right: Gel band intensity of soluble
fraction before aggregation (Pre) and after 4 days of aggregation (Post) shows a loss of soluble
monomer due to fibrillization.
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Chapter 3 : Incorporation of Minimally-Perturbing Unnatural Probe
Pairs into Full-Length α-Synuclein for Folding Studies
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Adapted with permission from (Rebecca F. Wissner, Solongo Batjargal, Colin M. Faden,
and E. James Petersson. J. Am. Chem. Soc. 2013, 135, 6529–6540). Copyright (2013)
American Chemical Society and from (Rebecca F. Wissner, Anne M. Wagner, John B.
Warner, E. James Petersson. Synlett. 2013, 24, 2454-2458.). Copyright (2013) Georg
Thieme Verlag KG Stuttgart.
§ 3.1 Labeling Proteins with Fluorophore/Thioamide Förster Resonant Energy
Transfer Pairs by Combining Unnatural Amino Acid Mutagenesis with Native
Chemical Ligation
Thioamide Quenching of Cnf in Proteins. Thioamides can quench fluorophores
that

have

spectral

emission

overlap

with

thioamide

absorption,

such

as

cyanophenylalanine (Cnf) and tyrosine (Tyr), through a Förster resonance energy transfer
FRET mechanism.115,150 Other fluorophores are quenched by thioamides through a
photoinduced electron transfer (PET) mechanism, like tryptophan, coumarin, and
acridone.113,151 Here we will focus on thioamide FRET partners, for which more reliable
distance information can be obtained by applying Förster theory. To use thioamide FRET
quenching to study protein conformation, we generate constructs in which we label the
protein with a Cnf donor fluorophore and a thioamide analog of one of the natural amino
acids. We denote these analogs using either the three or one letter amino acid code with a
prime symbol indicating the thiocarbonyl (thioleucine is shown in Figure 3.1). Distance
constraints are assigned by computing quenching efficiency (EQ = 1 – FThio/FOxo) from the
fluorescence of equimolar concentrations of Cnf/thioamide-labeled protein (FThio) and a
Cnf-labeled control (FOxo). After appropriate corrections to the Förster radius (R0) for
each Cnf location, the Cnf/thioamide separation (RFRET) is determined according to
Förster theory. (Figure 3.1 and discussion below) These distance measurements are used
to monitor conformational changes in the protein.
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Figure 3.1 Cyanophenylalanine/Thioamide FRET Interactions.
Top Left: Cyanophenylalanine (Cnf, F*) and leucyl thioamide (Leu', L'). Top Right: Normalized
absorption (dotted black line) and fluorescence emission (dashed black line) spectrum of Cnf and
absorption spectrum of Leu'Ala (yellow line). The shaded area indicates the spectral overlap that
contributes to FRET. Bottom: Distance (RFRET) calculations are made using Förster theory as
described in text.

All of our initial studies used small peptides and proteins in which the thioamide
was incorporated by solid phase peptide synthesis (SPPS). In order to use
fluorophore/thioamide pairs to monitor structural changes in full-sized proteins, we
needed to identify methods for incorporating these two modifications with high
efficiency. Happily, we have found that thioamides are compatible with native chemical
ligation (NCL) reactions.116 NCL is a valuable method for synthesizing proteins by
fragment condensation of a C-terminal thioester peptide and an N-terminal Cys peptide in
buffered aqueous media.152,153 We found that thioamides could be placed at nearly any
position in the thioester or Cys peptide fragments. Furthermore, we found that thioamides
could be used in NCL reactions in which the N-terminal Cys fragment was expressed as a
protein construct in E. coli (expressed protein ligations). In general, we wish to minimize
the need for manual synthesis by maximizing the role of biosynthesis in preparing labeled
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proteins. These protein ligations can limit the portion that must be prepared by SPPS to a
few amino acids around the thioamide. SPPS is deemed necessary for the incorporation
of backbone thioamide modifications, but sidechain fluorophores like Cnf can be
incorporated during ribosomal biosynthesis.
To easily incorporate Cnf, we have employed unnatural amino acid (Uaa)
mutagenesis methods pioneered by Schultz and coworkers.22,23 These methods allow one
to insert a Uaa at a specific site in the protein by using a so-called orthogonal aminoacyl
tRNA synthetase (aaRS) that is selective for the Uaa. The UaaRS charges a tRNA that
recognizes the UAG stop codon. The UAG stop codon is mutated into the protein coding
sequence at the site of interest. Plasmids coding for the UaaRS, tRNA, and protein of
interest are transformed into E. coli. After growth in the presence of the Uaa, protein
containing the unnatural amino acid is purified for use in biochemical experiments or
subsequent NCL reactions.

Figure 3.2 Combining Unnatural Amino Acid Mutagenesis and Native Chemical Ligation.
Thioamide-bearing peptides are synthesized on solid phase starting from activated benzotriazole
precursors and standard Fmoc-protected amino acids. For N-terminal thioamides, a thioester is
installed as a masked group or formed by post-synthetic activation. To generate the Cnf-labeled
protein fragment, E. coli cells are transformed with two DNA plasmids; one encoding the protein
with a UAG stop codon at the site of interest, and one encoding an aminoacyl tRNA synthetase
that is selective for an unnatural amino acid (UaaRS) with a tRNA that recognizes the UAG stop
codon. Protein is expressed under standard conditions and the N-terminal Cys generated by
proteolysis. Ligation of the two fragments gives the full length protein, labeled with both Cnf and
the thioamide.
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Here, we made use of Uaa mutagenesis to incorporate donor fluorophores for
thioamide FRET experiments examining both protein/protein interactions and
intramolecular measurements of protein folding. In intermolecular experiments, no
manipulation of the Uaa-containing protein is required following purification. The
protein is simply mixed with a thioamide-labeled peptide or protein and quenching
observed. We use this strategy to examine a series of pairwise interactions in which Cnf
is incorporated in the calcium sensor protein calmodulin (CaM) and the thioamide is
incorporated in a CaM-binding peptide. The combinatorial nature of these experiments
allows one to rapidly generate a matrix of m x n FRET measurements from m Cnf-labeled
proteins and n thioamide-labeled peptides. To carry out intramolecular experiments, we
combined Uaa mutagenesis with NCL. Cnf was incorporated by Uaa mutagenesis into
protein constructs in which the termini could be used in ligation to thiopeptides.
Strategies for ligating to both the C- and N-termini are described. The resulting doublelabeled proteins can then be used in intramolecular folding experiments. Again,
combinatorial assembly can be used to make m x n double-labeled proteins from m Nterminal fragments and n C-terminal fragments. We applied our double-labeling strategy
to study conformational changes in α-synuclein (αS), an amyloidogenic protein found to
aggregate in Parkinson’s Disease (PD).51,53,154
Our methods should be applicable to a wide variety of proteins: essentially any
proteins that express well in E. coli and are amenable to refolding after ligation.
Moreover, since this combination of Uaa mutagenesis and NCL to label proteins on the
backbone and sidechain is unprecedented (examples of sidechain ligation using Uaa
mutagenesis exist),31,155 the considerations here should be useful to those who wish to
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combine these two methods for other reasons, such as incorporating olefin or D-amino
acid modifications in combination with unnatural sidechains.125,156-158
§ 3.2 Results and Discussion
Note: CaM peptide binding assays were performed with Colin Fadzen. Synthesis of
αSFF*39C123A'124 was performed by Solongo Batjargal.
To begin combining Uaa mutagenesis with thioamides, we returned to CaM as
our model system. Since Cnf is excited at 240 nm and fluoresces with a maximum at 295
nm, we began by mutating the two endogenous Tyr residues in CaM to Phe, generating a
construct hereafter referred to as CaMF. This “all Phe background” ensures that Tyr
fluorescence does not confound our ability to interpret Cnf data. Both the extinction
coefficient and quantum yield of Phe (240 = 65 cm-1•M-1,  = 0.022) are substantially
smaller than the values for Cnf (240 = 10,333 cm-1•M-1,  = 0.110), so in these proteins
all fluorescence emission at 295 nm should derive from Cnf.
To incorporate Cnf, we used a plasmid containing a UaaRS/tRNA pair previously
selected for Cnf incorporation by Mehl and coworkers.159 This was paired with a plasmid
encoding CaM under isopropyl β-D-1-thiogalactopyranoside isopropyl (β-IPTG) control.
We expressed CaMF in M9 media supplemented with Cnf and purified the full-length
protein by two rounds of phenyl sepharose chromatography. Four positions were chosen
for incorporation of Cnf: F13, F17, F93, and Y100. Four pOCNC peptides were synthesized:
an all Phe oxopeptide (pOCNC), and three thiopeptides – pOCNC-F1, pOCNC-L11, and
pOCNC-F16. Before performing fluorescence titration experiments, native PAGE gel
analysis was used to ensure that each CaMF/pOCNC combination formed stable
complexes. This allowed us to eliminate CaMFF*17 from further binding experiments.
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Figure 3.3 FRET in CaM/Peptide Complexes.
Top: Binding of thioamide-labeled peptides (green) to Cnf-labeled CaM (blue) in the presence of
Ca2+. Bottom Left: An image showing Cnf (pink) at position 100 in calmodulin (CaMFF*100) and
thiophenylalanine (yellow sulfur atom) at position 1 in the pOCNC peptide (pOCNC-F'1). Ca2+ ions
are shown as purple spheres. Adapted from PDB ID 1SYD using PyMol. The 18.9 Å separation
shown represents an average of the separation of the center of the thioamide from the center of
the α-carbons of the Cnf ring. Bottom Right: Fluorescence emission spectra of solutions of 10 µM
CaMFF*100 in the presence of increasing concentrations of pOCNC-F'1. Inset: Relative
fluorescence of complexes of CaMFF*100/pOCNC-F'1 (FThio) to an oxoamide control
CaMFF*100/pOCNC (FOxo).

For each of the other Cnf mutants, we performed the same set of experiments,
which are described using CaMFF*100 as an example. Fluorescence wavelength scans
were acquired for mixtures of 10 µM CaMFF*100 with between 0 and 15 µM pOCNC or
pOCNC-F1. For each concentration, the fluorescence emission from the pOCNC-F1
complex (FThio) was normalized to the fluorescence emission from the pOCNC complex
(FOxo). For F*100 a concentration-dependent decrease was observed for FThio, while no
change was seen FOxo. Plotting FThio/FOxo (or 1 – EQ) as a function of concentration shows
that binding reaches saturation at 1:1 CaMFF*100/pOCNC-F1 (Figure 3.3) The quenching
(FRET) efficiency can then be used to calculate a separation according to RFRET =
R0(1/EQ - 1)1/6. We observed 25% quenching at saturating concentrations of pOCNC-F1,
which translates into a 20 Å separation using Förster theory. This is in excellent
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agreement with the 19 Å average separation computed from the 20 lowest energy
structures deposited from the NMR structure determination by Contessa et al.133 These
calculations were performed using  = 0.110 and an orientation factor (2) of 2/3.
We completed comparable experiments for each pair of Cnf mutant and
thiopeptide. The separation in the seven pairs spanned a distance range from 8 to 31 Å,
covering the range that is accessible with the Cnf/thioamide FRET pair. In the case of
CaMFF*100/pOCNC-F1, no change in fluorescence was observed in the “oxoamide
control” experiment. For other mutants, some changes in fluorescence were observed for
pOCNC. Regardless, these effects can be deconvoluted by calculating EQ relative to the
oxoamide control as we do. Such oxoamide control experiments are essential as many
factors can influence fluorescence. 135,160,161 Therefore, we always compare any thioamide
quenching measurement to the most relevant control, in this case the CaM/pOCNC
oxopeptide complex.

Figure 3.4 CaM/pOCNC Label Sites.
Cnf shown at thee positions in CaM with three possible pOCNC thiopeptides. Images based on
one of the 20 low energy structures in PDB ID 1SYD, modified using PyMol.

The oxopeptide complex is also valuable in determining the appropriate value of
 to be used in FRET distance calculations. The changes in fluorescence intensity upon

pOCNC binding represent a change in Cnf quantum yield as it moves into a new
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environment. For example, the emission of CaMFF*93 starts out at 3.8% of the emission
of an equimolar concentration of CaMFF*100, but it increases 3.2-fold upon pOCNC
binding. Therefore, the relevant quantum yield for the CaMFF*93/pOCNC complex is
0.014. We use this value in our calculation of RFRET for all thiopeptide complexes with
CaMFF*93. Similar corrections to the quantum yield were performed for CaMFF*13.
Correction of the quantum yield of CaMFF*100 was not necessary, presumably because
Cnf is solvent-exposed at this position.
The distances calculated from our FRET measurements are collected in Table 3.1.
All measurements are within 3 Å of the average value observed in the NMR structure
except for F*100/F16. Moreover, our measurements are always correct in predicting the
relative order of thioamide proximity for a given Cnf mutant. While it may be surprising
that we achieve reasonable agreement between theory and experiment using a value of
2/3 for 2, deriving 2 values from the 20 lowest energy NMR structures has only a small
effect on this agreement (see discussion below). The RFRET values obtained using 2 = 2/3
are more representative of the application of thioamide FRET in a structure determination
experiment (i.e. one in which the target structure is unknown and 2 would be difficult to
fit accurately).
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Table 3.1 Distances in CaM/pOCNC Complexes

CaM/pOCNC Mutants
a
()
All Phe control
F*13/F1 (0.003)
F*13/L11 (0.003)
F*17
F*93/F1 (0.014)
F*93/L11 (0.014)
F*100/F1 (0.110)
F*100/L11 (0.110)
F*100/F16 (0.110)

% EQ
b
Obsvd

RFRET
c
(Å)

RNMR
d
(Å)

0
11 ± 1
37 ± 2
e
NB
79 ± 2
43 ± 4
25 ± 3
17 ± 2
f
10 ± 3

––
13
11
––
12
13
20
21
23

––
14
14
––
9
12
19
24
31

 determined by comparison to fluorescence emission of 10 µM Cnf,  = 0.110. bEQ determined
for 1:1 CaM/pOCNC complex. cRFRET calculated from EQ as described in text. dRNMR is an average
value calculated from the twenty lowest energy structures in PDB ID 1SYD. eNB indicates no
binding by native PAGE gel analysis. fMixture of R17 D- and L- epimers of pOCNC-F'16 peptide.
Both bind with high affinity by native PAGE gel analysis.
a

These CaM experiments involved intermolecular quenching, but our method, like
FRET in general, is equally applicable to intramolecular conformational changes.
However, obtaining Cnf/thioamide double-labeled proteins represents a biosynthetic
challenge, as one ideally wishes to have complete freedom in placing the chromophores
within the protein sequence. While this is easily accomplished in small peptides made by
SPPS, and conceivably could be done by NCL, we wished to use a combination of NCL
and Uaa mutagenesis to minimize unnecessary peptide synthesis. Therefore, we assessed
the compatibility of these two methods. We chose αS as a model system because we had
previously shown that thioamides could be incorporated into αS, and we wished to
compare PET quenching of Trp in αS to FRET quenching of Cnf at similar locations.116
First, we examined thioamide incorporation at the αS N-terminus. For protein
expression, we used the UaaRS/tRNA plasmid pDULE2-Cnf and a plasmid encoding αS
with an N-terminal truncation that could be revealed after proteolysis of a His10
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purification sequence using Factor Xa (Figure 3.5, a).162 The proteolyzed protein contains
an N-terminal Cys for use in NCL with the synthetic thioester. The Factor Xa method
provides a general method for generating NCL constructs containing unnatural amino
acids, but in the specific context of αS, prolonged incubation with Factor Xa can lead to
protein loss via aggregation. Therefore, we have also used constructs directly encoding
αS with an N-terminal truncation plus Met in a fashion similar to that described by
Hejjaoui et al (Figure 3.5, b).163 The N-terminal Met residue is removed in vivo by Met
aminopeptidase to reveal the requisite Cys.164 Protein harvested from E. coli contains an
N-terminal thiazolidine ring formed by the condensation of Cys with either pyruvate or
acetaldehyde. This is treated with methoxylamine hydrochloride to reveal free Cys for
NCL reactions. Regardless of the method used in producing the expressed fragment, once
purified, usage in subsequent NCL reactions is identical.
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Figure 3.5 Semi-synthesis of Double-Labeled Proteins with N-terminal Thioamides.
Expressed C-terminal protein fragment: A) Using a plasmid encoding an N-terminal HisTag with a
Factor Xa site; B) Using a plasmid encoding the truncated protein where N-terminal Met is
removed by Met aminopeptidase. MeONH2•HCl used to cleave the thiazolidine which forms with
intracellular aldehydes. (R = Me or CH2CO2H) Synthetic N-terminal thiopeptide thioester: C)
Synthesis on Cl-Trt resin and activation to form thioester with PyBOP, followed by deprotection
with TFA; D) Synthesis on Rink amide resin with CbPGo masked thioester. The expressed protein
fragment and synthetic thiopeptide are combined in the presence of thiophenol and the ligated,
full-length protein isolated.

Synthesis of a thioamide-containing thioester peptide using Fmoc chemistry could
be accomplished by one of two methods. The thiopeptide can be synthesized on Cl-Trt
resin, cleaved under mild conditions (10% AcOH) to retain the sidechain protecting
groups, and then activated using PyBOP to form the thioester (Figure 3.5, c).165,166 This
method can lead to epimerization of the α-carbon of the C-terminal amino acid, but this
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can be avoided by using short (< 30 min) reaction times during PyBOP activation.167 A
more significant inherent limitation is the insolubility of protected peptides > 15 amino
acids in most solvents.165 This limits use of the PyBOP method to short peptides.
The other method makes use of a thioester that is masked during synthesis as a
disulfide. Several variations of masked thioester exist (Figure 3.5, d). In our previous
work, we used a thee residue CbPGo sequence where Cb is a t-Bu-protected Cys and Go is
glycolic acid.116,168,169 Deprotection of the Cys thiol initiates a cascade reaction
generating a diketopiperazine thioester that is competent in NCL reactions. Synthesis of
peptides with the CbPGo linker is inefficient because of ester linkage instability.
Therefore we reserve its use for longer peptides where it is necessary.
All αS protein constructs tested contain Tyr to Phe mutations at positions 39, 125,
133, and 136 to generate an “all Phe” background construct, αSF. As was the case for
CaMF, these mutations allow us to more easily interpret Cnf fluorescence data.
Combinations of methods a or b with c or d were used to synthesize double-labeled αS.
While all combinations were viable, for αSFF4C9F*94, our highest yields were obtained
with a combination of methods 3.5b and 3.5c. Protein expression yields were typically 3
mg/L of culture after methoxylamine treatment. Ligations were typically carried out on
the 0.1 µmol scale at pH 7.2 with 1% thiophenol. After 24 hours, 60 - 70% yields of
ligated product were typically seen, and the products purified by C4 reverse phase HPLC.
PAGE gel, spectroscopic, and MALDI MS analyses of the ligation confirm production of
homogeneous, double-labeled αS. Data for other reactions are shown in Materials and
Methods.
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Figure 3.6 Characterization of αSFF'4C9F*94 Ligation Product.
Top Left: PAGE gel showing: αSF9-140C9F*94 before (1) and after (2) MeONH2•HCl treatment,
ligation of αSF9-140C9F*94 to αSF1-8F'4-SR thioester (3), purified αSF-F'4C9F*94 (4), αSFC9F*94 (5),
and αSWT (6). See HPLC chomatogram in Materials and Methods for separation of ligated
product. Top Right: MALDI MS analysis of full-length αSFF'4C9F*94. Bottom Left: UV/Vis
absorption spectrum of αSFF'4C9F*94 showing thioamide absorption at 266 nm. Inset: MALDI MS
analysis of trypsinized 1-6 fragment, confirming the presence of the thioamide at F'4; Calcd m/z
(M+H): 828.35, Obsvd: 828.65. The asterisk indicates the absence of peaks corresponding an
oxoamide at Phe4 in the 1-6 fragment; Calcd m/z (M+H): 812.38. Bottom Right: Fluorescence
emission spectra of αSFF'4C9F*94 showing Cnf emission at 295 nm. Inset: MALDI MS analysis of
trypsinized 81-96 fragment, confirming the presence of the Cnf at position 94; Calcd m/z (M+H):
1503.78, Obsvd: 1504.30. The asterisk indicates the absence of peaks corresponding Tyr at
position 94 in the 81-96 fragment; Calcd m/z (M+H): 1494.78.

The methods shown in Figure 3.5 permit protein double-labeling with thioamides
located at the N-terminus. To insert thioamides at the C-terminus, we made use of intein
fusion constructs popularized by Muir and others.153 These self-splicing domains have
been engineered to stall at a thioester intermediate and can be intercepted by treatment
with a small molecule thiol to give a thioester suitable for NCL. We have found that the
expression of intein fusion constructs is compatible with Uaa mutagenesis. In fact, yields
of intein fusions of αS Cnf mutants (e.g. αSF1-122F*94-Int) are higher (20 mg/L culture)
than comparable expressions of the full-length protein using either T7 or PRK vectors
previously used to express αS Cnf mutants (3 - 5 mg/L). The synthetic thiopeptide with
N-terminal Cys (αSF123-140C123A124) was prepared by standard SPPS.
118

Figure 3.7 Semi-synthesis of Double-Labeled Proteins with C-terminal Thioamides.
An expressed N-terminal protein fragment is generated using a plasmid encoding a truncated
version of the protein with a C-terminal intein. Thiolysis of the stalled intein generates a thioester
suitable for NCL. The synthetic thiopeptide with an N-terminal Cys is made by standard SPPS.
The expressed protein fragment and synthetic thiopeptide are combined in the presence of
thiophenol and ligated, full-length protein isolated.

The thioester αSF1-122F*39-SR was prepared from αSF1-122F*39-Int using the thiol
mercaptoethane sulfonate (MESNA). This was combined with αSF123-140C123A124 in a
buffer containing thiophenol. Although some C-terminal Asn cyclization (~ 25% based
on crude MALDI MS estimates, see Supporting Information) of the intein thioester
occurred in competition with the desired MESNA thiolysis, this was not a major problem
since the resulting cyclic succinimide was not competent for ligation. Ligations were
typically carried out on the 0.3 µmol scale. After 16 hours, 50% yields were obtained,
and the products purified by FPLC using an ion-exchange column. Once again PAGE
gels, spectroscopy, and MALDI MS were used to analyze the ligation reaction. These
data are shown in Figure 3.8. The data confirm that we have again produced
homogeneous, full-length, double-labeled αS.
Using these two methods, we should be able to label a variety of proteins with
thioamides at the N- or C-terminus, with complete freedom in placement of the donor
fluorophore. Since we have previously shown that thioamides are compatible with the
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MeONH2•HCl conditions used to deprotect N-terminal thiazolidines, the methods used
here should also be compatible with internal thioamide-labeling through three component
ligations. In addition, we note that the use of C-terminal inteins may be generally useful
to those employing Uaa mutagenesis. One major limitation of the method is that the
inherent competition with release factors at the UAG stop codon can lead to protein
truncation.170 Purifying the full-length protein containing the Uaa can be difficult for sites
near the C-terminus, where the truncated form is only slightly shorter. The His-tagged
intein provides a convenient handle that will only be present in the untruncated protein.
Since the intein can be cleaved by thiolysis or hydrolysis in a traceless manner, the Uaalabeled fragment or protein can be obtained in pure form in an efficient manner.

Figure 3.8 Characterization of αSFF*39C123A'124 Ligation Product.
Top Left: PAGE gel showing: αSF1-122F*39-Int before (1) and after thiolysis of the intein to generate
αSF1-122F*39-SR thioester (2), ligation of αSF123-140C123A'124 to αSF1-122F*39-SR thioester (3), purified
αSFF*39C123A'124 (4), αSFF*39C123 (5), and αSF (6). Top Right: MALDI MS analysis of full-length
αSFF*39C123A'124. Bottom Left: UV/Vis absorption spectrum of αSFF*39C123A'124 showing thioamide
absorption at 266 nm. Inset: MALDI MS analysis of trypsinized 103-140 fragment, confirming the
presence of the thioamide at A'124; Calcd m/z (M+H): 4228.69, Obsvd: 4228.47. The asterisk
indicates the absence of peaks corresponding an oxoamide at Ala124 in the 103-140 fragment;
Calcd m/z (M+H): 4212.72. Bottom Right: Fluorescence emission spectrum of αSFF*39C123A'124
showing Cnf emission at 295 nm. Inset: MALDI MS analysis of trypsinized 35-43 fragment,
confirming the presence of Cnf at position 39; Calcd m/z (M+H): 960.52, Obsvd: 960.77. The
asterisk indicates the absence of peaks corresponding Tyr at position 39 in the 35-43 fragment;
Calcd m/z (M+H): 951.51.
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In order to demonstrate the value of double-labeling a protein such as S, we
carried out experiments in which intramolecular conformational changes were monitored.
S aggregates by first forming soluble oligomers which eventually convert into larger,

insoluble fibrils.53,60,85,154 Both the oligomers and fibrils have been shown to be cytotoxic,
and recent evidence has shown that extracellular S can enter neurons and catalyze
misfolding of S within healthy neurons.171-174 Therefore, there is substantial current
interest in understanding the structural dynamics of the meta-stable S monomers and the
rearrangements that occur on formation of oligomers and subsequent fibrillization.
Several researchers have recently shown the value of being able to construct semisynthetic S to study the effects of post-translational modification on its folding, our
modification should provide a uniquely non-perturbing method for tracking its
dynamics.91,116,163,175,176
We envision thioamide quenching as a method for site-selectively monitoring
conformational changes during S refolding. While a number of researchers have studied
αS conformation using other techniques such as NMR, IR, and EPR, we find
fluorescence to be particularly useful because the sensitivity of the technique permits one
to use low concentrations of double-labeled S which should not undergo aggregation on
the timescale of our experiments.60,85,174,177-181 This strategy allows us to monitor longrange (25 - 30 Å) interactions that are difficult to observe with other techniques.
Moreover, FRET is easily applied to interactions involving residues in dynamic regions
of proteins, such as the termini of S.
We have previously shown that conformational dynamics during aggregation can
be monitored by intramolecular quenching of Trp by a thioamide.116 Here, we
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demonstrated that we can monitor conformational changes in monomeric S, using urea
or trimethylamine oxide (TMAO) to denature or compact S, respectively. Performing
oxoamide control experiments allowed us to correct for any changes in fluorescence not
due to the thioamide, and correct the Cnf quantum yield in order to properly interpret the
observed quenching in terms of interchromophore distance.

Figure 3.9 αS Refolding Assay.
Monomeric double-labeled αS (e.g. αSFF'4C9F*94) is diluted to 1 µM in either Tris buffer with 1 mM
BME, or the same buffer with urea or TMAO added. Cnf fluorescence is measured at 295 nm
(FThio). Identical experiments are carried out with donor-only labeled αS (e.g. αSFC9F*94) to
determine FOxo. EQ = 1 – FThio/FOxo.

The NCL procedures that we use to synthesize our thioamide-labeled proteins
introduce a Cys into the αS sequence at position 9 or 123. However, we have previously
shown that the presence of non-native Cys in the sequence does not cause aberrant
aggregation when incubated with β-mercaptoethanol (BME) to prevent disulfide
formation.116 While Cys can have an effect on Cnf emission, since we include Cys
mutations in our oxoamide control experiments, we can account for these changes as
well.182,183
We carried out refolding experiments with the constructs described above,
αSFF4C9F*94 and αSFF*39C123A124, as well as αSFF4C9F*39. In the “native” state, when
our constructs were incubated in buffer alone, we observed varying levels of quenching
relative to the equivalent oxoprotein control. (Figure 3.10) For F*94/F4 and F*94/A124 we
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observe no quenching. For F*39/F4, we observe some quenching, which we interpret as
resulting from local compaction of the N-terminus.

All of these observations are

consistent with previous FRET experiments performed on αS. The observed N-terminal
compaction is similar to the roughly 30 Å separation observed by Rhoades and coworkers
using Alexa Fluor 488 and Alexa Fluor 594 dyes in single molecule FRET experiments.70
Ferreon et al. observed FRET efficiencies consistent with separations of ~ 70 Å in single
molecule FRET experiments with αS labeled at positions 7 and 84 with the same dye
pair.184,185 This is well outside the useful range of the Cnf/thioamide FRET pair, so it is
not surprising that we see no quenching for F*94/F4. Our results for F*39/F4 are
consistent with experiments carried out by Lee, Gray, and coworkers using Trp and
nitrotyrosine as a FRET pair.68,186 Our F*39/A124 data are consistent with reports by Nath
et al. showing a ~ 45 Å interaction between probes at positions 33 and 130, which is
beyond the range of the Cnf/thioamide pair.70
When 6 M urea was used as an additive, an increase in FThio/FOxo was observed
for F*39/F4, consistent with greater unfolding of the protein. For the other two mutants,
no change in FThio/FOxo was observed, indicating that these regions were indeed less
compacted. Control experiments using Cnf itself indicate that although an inherent
change in Cnf quantum yield plays a role in the observed change in fluorescence, there is
nonetheless an observable expansion of αS once one corrects for inherent effects on Cnf
fluorescence. In contrast, an increase in quenching (i.e. FRET) was observed as a
function of TMAO concentration for all three mutants. The changes in EQ as a function of
TMAO concentration can be seen in Figure 3.10. This indicates increased compaction of
both N- and C- termini, as well as folding of the N-terminal region on itself.

123

Figure 3.10 Refolding of αS in TMAO.
Top: Quenching efficiency of αSFF'4C9F*94 (red), αSFF*39C123A'124 (green), or αSFF'4C9F*39 (blue)
determined in phosphate buffer at 25 °C at varying concentrations of TMAO. Quenching
efficiency determined by comparison to the equivalent oxoprotein: αSFC9F*94, αSFF*39C123, or
αSFC9F*39, respectively. Bottom: Interchromophore distances computed using Förster theory as
described in Supporting Information.

To assign distance constraints based on these measurements, we converted the
measured EQ values to distances using Förster theory. As with CaM, we computed a
specific R0 value for each construct using the quantum yields of Cnf for the oxoamide
control proteins αSFC9F*39 (R0 = 15.6 Å in 0 M TMAO), αSFC9F*94 (R0 = 13.6 in Å in 0
M TMAO), or αSFF*39C123 (R0 = 13.5 Å in 0 M TMAO). Förster radii for each mutant in
other TMAO concentrations are given in Supporting Information. We use these rather
than simply using R0 values calculated from free Cnf because the variation among the
different mutants demonstrates that the protein context influences quantum yield. The
RFRET values that result from our calculations indicate that Cnf and the thioamide come
into very close proximity in TMAO. While these results are consistent with the single
molecule studies of Deniz and coworkers, it is surprising that our RFRET values are so
small.185 This may be the result of a dominant contribution from very close contact.
Ferreon et al. observe subpopulations with near unity FRET efficiencies, but the Alexa
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Fluor FRET pair that they use has high FRET efficiency for any separation less than 30
Å.184,187 Our probes have a shorter effective range (8 – 31 Å) than theirs, and therefore
provide a more precise report on the close contact induced by TMAO. We will continue
to study this phenomenon, not only with thioamides, but also with other short range
FRET pairs such as Cnf and Trp.48,188 Finally, it may be more appropriate to use polymer
models rather than simple Förster theory to interpret our FRET data. These models have
clear value when interpreting single molecule FRET data, which may have broad and
asymmetric FRET efficiency distributions. Although the value is less clear for ensemble
measurements, we will explore the interpretation of our FRET data using models such as
those used by Lee, Gray, Rhoades, and Plaxco.68,70,71,186,189
The application of our recently developed Cnf/thioamide FRET probe pair to
studies of the folding of full-sized proteins requires the ability to synthesize those labeled
proteins in an efficient manner. Although we could, in theory, construct Cnf- and
thioamide-labeled proteins purely through ligation, we have developed a far more
expedient approach by melding the methods of unnatural amino acid mutagenesis and
protein ligation. Intermolecular studies simply require that Cnf be incorporated into
proteins expressed in E. coli through established unnatural amino acid mutagenesis
techniques. Intramolecular studies require more complex semi-synthesis to obtain doubly
labeled proteins, wherein a Cnf-labeled protein fragment can be expressed in E. coli and
then ligated to a synthetic thiopeptide. This combination of methods minimizes SPPS of
natural amino acid segments. The same methods can be used to synthesize proteins
labeled with other donor fluorophores such as coumarin, or any fluorophore conjugated
to a bioorthogonal handle, such as p-azidophenylalanine.190,191 In fact, we have identified
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a synthetase for the incorporation of the fluorescent amino acid acridonylalanine (Acd),
which we have previously shown to be quenched by thioamides.113,192 We are currently
working to optimize yields of Acd/thioamide labeled proteins using methods analogous
to those described here.
The doubly labeled proteins produced using these methods can be applied to
monitor protein folding and dynamics. For example, here we have studied the structure of
a CaM/peptide complex and determined the average separation of residues in the
disordered protein αS in various buffer conditions. The benchmarking results using CaM
help to validate our method and provide a foundation for the application of thioamide
FRET to other systems. These experiments show clearly that meaningful interpretations
of the interchromopore distances require determining changes in the donor quantum
yield. This is easily accomplished using the oxoamide control experiments that we
always include in order to determine quenching efficiency. Moreover, the dependence of
quenching efficiency on Cnf quantum yield supports a FRET mechanism for quenching
as opposed to Dexter or PET mechanisms, which were difficult to discount based on
previous data.10,115 The confirmation of a FRET mechanism for Cnf/thioamide
interactions allows one to confidently interpret thioamide quenching using Förster’s
equations for future applications. Nonetheless, it is worth noting that there was an
imperfect match of observed distances (RFRET) and predicted distances (RNMR) that was
not resolved by considering the orientation parameter 2. This may be because simply
using the 20 structures developed in solving the NMR structure does not fully account for
intermediate geometries between these valleys on the potential energy surface.
Calculating RFRET by sampling 2 over extended molecular dynamics trajectories may
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give improved agreement with the FRET data. Additionally, fluorescence lifetime
measurements (which are concentration-independent) would remove the influence of
small deviations in concentration on our determination of EQ. We will explore both of
these aspects in subsequent work.
The αS experiments show how one might use our method in an intramolecular
sense. The addition of TMAO results in compaction of monomeric αS, consistent with
previous independent observations by Deniz as well as small angle X-ray scattering
experiments by Fink.80,185 The short effective range of our probes allows us to obtain
more precise information about close contact of regions of the protein than similar
experiments with larger fluorophores. Moreover, the small size of our chomophores
leaves less uncertainty in their location relative to the protein structure. Thus, the
thioamide probes provide new short-range information on TMAO-induced conformations
of αS, complementing data obtained in single molecule experiments. We continue to
apply fluorophore/thioamide pairs to the study of folding transitions in αS monomers as
well as to monitoring conformational changes during aggregation.
Of course, our labeling strategy is not restricted to CaM or αS. Any protein which
can be expressed at high levels in E. coli and reversibly unfolded should be amenable to
double-labeling using a combination of Uaa mutagenesis and NCL. This strategy should
be particularly appealing when one of the modifications cannot be incorporated
ribosomally (i.e. backbone modifications such as olefin isosteres). For larger dyes that are
attached post-translationally, Uaa mutagenesis at two sites, or used in combination with
Cys modification is probably more efficient.28,32,38,193 However, even in those cases, it can
be difficult to separate labeled from unlabeled protein, whereas the ligated products of
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our reactions differ substantially in size and can easily be separated by HPLC or FPLC.
The major current limitations of our labeling methods are that Uaa mutagenesis
expression yields can be low (3 - 5 mg/L), and if these are coupled to inconsistent NCL
yields, it can be difficult to obtain sufficient quantities of protein for biophysical
experiments. We will continue methodological studies to improve both aspects to make
these methods as accessible as possible to the general biochemical community.
§ 3.3 Efficient, Traceless Semi-Synthesis of α-Synuclein Labeled with a
Fluorophore/Thioamide FRET Pair
Despite the agreement of our Cnf/thioamide data with other studies of αS in
TMAO, we were somewhat concerned about the presence of the non-native Cys residues
in our labeled αS constructs.185 Cys mutants of αS display enhanced aggregation kinetics
and altered fibril morphology as a result of intermolecular disulfide bond formation.194,195
Although we performed the previous FRET studies with our Cys-containing doublelabeled constructs in the presence of a reducing agent, it is nonetheless possible that some
amount of disulfide formation occurred during our experiments.
While many laboratories carry out protein synthesis with subsequent radical
desulfurization of Cys to form Ala, this strategy is not viable for us as desulfurization of
the thioamide would also occur.196 Methods developed in our laboratory enable us to
generate double-labeled αS for misfolding studies that does not contain cysteine at the
ligation site. It has been shown that NCL can be performed with an N-terminal
homocysteine (Hcs) in place of Cys.197-200 Hcs can then be selectively methylated to yield
methionine at the ligation site. Hcs-mediated ligation was previously restricted to short
C-terminal peptides in which Hcs could be installed using SPPS. We have recently
established that we can use E. coli aminoacyl transferase (AaT) to deliver disulfide128

protected Hcs (S-(thiomethyl)homocysteine, Hcm) to the N-terminus of a large expressed
protein fragment.201 In E. coli cells, AaT transfers Phe, Leu, or Met from an aminoacyl
tRNA to the N-terminus of a protein.202,203 By using a modified methionine aminoacyl
tRNA synthetase enzyme (Met*RS), we can generate Hcm-tRNA in situ, which serves as
a viable substrate for AaT.204 Once Hcm is transferred to the N-terminus of a protein, it is
easily deprotected by a reducing agent to form Hcs for ligation. By combining unnatural
amino acid mutagenesis with EPL at homocysteine (which is later converted to
methionine), we can incorporate our minimal FRET pair into αS in a traceless manner
that minimizes unnecessary synthesis of peptide fragments composed of natural amino
acids. A retrosynthetic analysis of our target protein, Ac-αSFAsp'2Cnf39, is shown in
Figure 3.11.

Figure 3.11 Retrosynthetic Analysis of Ac-SFAsp'2Cnf39.

§ 3.4 Results and Discussion
Previously, we have shown that fluorenylmethoxycarbonyl (Fmoc)-protected
thiocarboxybenzotriazoles can be used with conventional Fmoc-protected amino acids to
synthesize thioamide-containing peptides.205,206 The procedure for the preparation of
Fmoc-Asp(Ot-Bu)-nitrobenzotriazole is illustrated in Scheme 3.1.114 Coupling of 4nitro-1,2-phenylenediamine to Fmoc-Asp(Ot-Bu)-OH was achieved using isobutyl
chloroformate to generate the coupled product in 89% yield. The amide was then added
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to a solution of P4S10 and anhydrous Na2CO3 at 0 ºC. Selective thionation of the Asp
backbone carbonyl was completed within 1 h to afford the thioamide in 79% yield.
Intramolecular diazonium cyclization of the thioamide gave the activated benzotriazole
in 67% yield. The benzotriazole can be isolated from the final reaction by precipitation
with ice-cold water in sufficient purity for peptide coupling reactions. Since the activated
benzotriazoles are subject to degradation though hydrolysis and intramolecular
nucleophilic attack by the carbonyl oxygens, it is best to minimize handling of compound
the benzotriazole prior to peptide coupling.

Figure 3.12 Synthesis of Aspartyl Thioamide Precursor

The N-terminal thioamide-containing fragment of αS was synthesized using
standard Fmoc-based SPPS procedures with the exception of direct acylation of Val3 by
the pre-activated thioaspartate precursor compound (i.e., no activating agents were
added). The thiopeptide was synthesized on 2-chlorotrityl resin, cleaved under mild
conditions (10% AcOH) to retain the Asp side-chain protecting group, and then activated
using benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) to
form the mercaptopropionate thioester (Figure 3.13). Epimerization of the α-carbon of the
C-terminal phenylalanine residue was eliminated by reducing the PyBOP activation time
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to 25 minutes. Following acidic deprotection of Asp(Ot-Bu)2, the thioester peptide was
isolated by HPLC (2.5 mol, 2.5% isolated yield) and its identity was confirmed by
MALDI MS analysis.

Figure 3.13 Synthesis of Thioamide-Containing Thioester Peptide for Native Chemical
Ligation

The expressed C-terminal Cnf-containing αS fragment for NCL was generated as
depicted in Figure 3.14. AaT selectively modifies the α-amine of proteins bearing a lysine
or arginine as the N-terminal residue. Prior to this work, we demonstrated that Met5Lys6
could be used as a point of disconnection in the synthesis of αS. To minimize
perturbation of native αS dynamics resulting from Cnf incorporation, we chose to replace
the similarly sized Tyr or Phe at position 39. A plasmid containing the C-terminal protein
fragment (αSF6-140) with a TAG codon installed at position 39 was prepared. An Nterminal His11 tag and a Factor Xa proteolysis site precede the αS gene. E. coli cells were
transformed with two plasmids, one containing the Cnf-selective mutant synthetase
(CnfRS) with tRNA and the other containing HisTag-αSF6-140TAG39. Following an initial
growth period, protein expression was induced by adding Cnf and isopropyl β-D-1thiogalactopyranoside (IPTG) to the culture medium. The expressed protein, HisTag-αSF6140Cnf39,

was purified by Ni-affinity chromatography and subsequently cleaved by Factor

Xa to yield αSF6-140Cnf39. Following purification by ion-exchange chromatography, the
truncated protein was incubated with AaT, Met*RS, E. coli total tRNA, Hcm, and ATP
for 2 h resulting in complete formation of αSF5-140Hcm5Cnf39. αSF5-140Hcm5Cnf39 was
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subjected to an additional round of ion-exchange chromatography prior to use in the NCL
reaction. Typically, about 1 mol of pure αSF5-140Hcm5Cnf39 is obtained from a 1 L
protein expression.
The ligation reaction was initiated by incubation of αSF5-140Hcm5Cnf39 with 1.5
equivalents of Ac-MetAspValPhe-SR in degassed ligation buffer (6 M guanidinium
hydrochloride, 0.2 M sodium phosphate, 20 mM tris(2-carboxyethyl)phosphine, 2%
thiophenol, at pH 7.5). Disulfide deprotection of the Hcm residue was observed by
MALDI MS within five min. The ligation reaction was allowed to proceed for 24 h prior
to buffer exchange into methylation reaction buffer (20 mM Tris, pH 8.6). AcαSFAsp2Hcs5Cnf39 was converted to Ac-αSFAsp2Cnf39, with native Met5, by a short
treatment (10 min) with 3000 equivalents of MeI. Allowing the reaction to proceed for
longer periods of time led to S-alkylation of the thioamide (data not shown). AcαSFAsp2Cnf39 was isolated from the NCL reaction by HPLC and characterized by
MALDI MS, as well as UV-Vis and fluorescence spectroscopy (Figure 3.14). The yield
over the two-step ligation and methylation sequence was 41%. MALDI MS analysis of
trypsin-digested Ac-αSFAsp2Cnf39 confirmed selective alkylation of Hcs to form Met in
the purified product.
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Figure 3.14 Ac-SFAsp2Cnf39 Synthesis.
Left: Functionalization of SF6-140Cnf39 by a) cleavage of His11 tag at Factor Xa site, b) attachment
of Hcm by AaT-catalyzed modification, c) ligation of an N-terminal thioester peptide (3.5), and d)
conversion of Hcs to Met by methylation to form Ac-SFAsp2Cnf39 . Top Right: MALDI MS
analysis of full length -SFAsp2Cnf39 . Calcd m/z (M+H)+ 14480.1, found 14479.6. Middle Right:
Trypsinized fragment corresponding to residues 1-6 of Ac-SFAsp2Cnf39 confirms methylation.
Calcd m/z (M+H)+ 828.34, found 828.46. The asterisk indicates the expected mass of the 1-6
fragment with unmethylated Hcs at position 5. Calcd m/z (M+H)+ 814.39. Bottom Right:
Trypsinized fragment corresponding to residues 33-43 of Ac-SFAsp2Cnf39 confirms Cnf
incorporation. Calcd m/z (M+H)+ 1189.66, found 1189.85. The asterisk indicates the expected
mass of the 33-43 fragment with Tyr at position 39. Calcd m/z (M+H)+ 1180.65.

Using a similar double-labeled construct containing cysteine at the ligation site
(Ac-αSFPhe4Cys9Cnf39), we observed thioamide quenching of Cnf after compaction of
the protein in high concentrations of TMAO.206 Since the Ser-to-Cys mutation in this
protein constituted a small deviation from the native S protein sequence, we sought to
investigate this phenomenon using our newly synthesized Ac-αSFAsp'2Cnf39 construct.
To correct for any changes in Cnf fluorescence that are not due to the presence of the
thioamide, an oxoamide control protein (αSFCnf39) was also prepared for fluorescence
experiments. In buffer without TMAO, thioamide quenching of Cnf in Ac-αSFAsp2Cnf39
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(i.e., FRET) was minimal. In accordance with our previous observations, thioamide
quenching of Cnf increased as a function of TMAO concentration (Figure 3.15, left axis).
To assign distance constraints based on these measurements, the measured quenching
efficiency (EQ) values were converted to distances using Förster theory. In 2 M and 4 M
TMAO, RFRET was calculated as 16.4 Å and 13.7 Å, respectively (Figure 3.15, right axis).
Taken together with our previous results, these data indicate that the N-terminal region of
αS undergoes significant compaction in high TMAO concentrations. Furthermore, our
new results conclusively demonstrate that the observed quenching is not due to Cysmediated dimerization of αS.

Figure 3.15 Ac-SFAsp2Cnf39 Refolding Assay.
Left: Monomeric double-labeled S (Ac-SFAsp2Cnf39) is mixed with TMAO to induce
compaction and an increase in quenching efficiency (EQ). Right: EQ (blue dashed line) of AcSFAsp2Cnf39 determined at varying concentrations of TMAO. Interchomophore distance (RFRET,
green solid line) computed using Förster theory as described below.

By combining unnatural amino acid mutagenesis with EPL at Met, we installed
our minimal Cnf/thioamide FRET probe pair into αS without introducing a mutation at
the ligation site. We demonstrated that selective alkylation of Hcs can be performed in
the presence of a thioamide, rendering our new ligation strategy compatible with the
minimal probe pairs that we have developed. The αS refolding studies presented here
demonstrate how this methodology can be used to study protein folding dynamics,
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though these techniques are by no means limited to αS. Over 20,000 proteins in the PDB
contain MetArg or MetLys motifs that can be used as points of disconnection in their
retrosynthetic analyses.201 We are currently working to expand these methods even
further by combining EPL at Met with multiple ligation strategies. This methodology will
allow us to install thioamide-containing synthetic fragments in the middle of a large
protein target in a traceless and efficient manner.
§ 3.5 Combining Uaa Mutagenesis with Expressed Protein Ligation to Incorporate
Acd/Thioamide Pairs into Full-Length Proteins.
Recently, our laboratory has developed methods for the efficient synthesis and in
vivo incorporation of acridon-2-yl alanine (Acd), a blue-wavelength fluorescent amino
acid.47 Acd is a useful fluorophore because of its small size (222 Å3), near unity quantum
yield in water (F = 0.95), unusually long lifetime (t ~ 15 ns) and high photostability (<
5% degradation after 3 hs irradiation).113,207,208 To incorporate Acd ribosomally, we
screened a library of synthetase mutants for the ability to incorporate Acd in response to a
TAG

codon

(Figure

3.16).

An

MjTyrRS

previously

selected

for

4-(2′-

bromoisobutyramido)phenylalanine (Brb) was identified as capable of utilizing Acd for
protein incorporation.209 With a synthetase mutant identified, we were able to show that
Acd can be incorporated into several other proteins by expressing them in E. coli,
including α-synuclein, triose phosphate isomerase, and calmodulin.
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Figure 3.16 Ribosomal Incorporation of Acd.
E. coli cells are transformed with two DNA plasmids: one encoding an mRNA for the protein of
interest with a UAG stop codon at the site of interest, and one encoding an aminoacyl tRNA
synthetase that is selective for an unnatural amino acid (UaaRS) with a cognate tRNA that
recognizes the UAG stop codon (tRNACUA). The UaaRS charges tRNACUA with the unnatural
amino acid and the aminoacyl tRNACUA delivers the Uaa to the site of interest in the protein during
ribosomal biosynthesis. Inset: UaaRSs were screened for successful incorporation of acridon-2ylalanine (1, Acd, δ) from a pool previously selected for incorporation of 4-(2′bromoisobutyrlamido)phenylalanine (2, Brb, ζ) and p-benzoylphenylalanine (3, Bzf, β).

Previously, we have shown that Acd can be efficiently quenched by a thioamide
though a PET mechanism.113 This makes the Acd/thioamide pair an extremely small,
non-perturbing set of labels since Acd is only 47% larger than Trp and the thiomide is
essentially isosteric with an amide. As an initial proof of principle, we have shown that
thioamide/Acd PET quenching can be used to monitor the thermally-induced unfolding
of a small well-folded polypeptide known as HP35.
Prior to this work, we combined unnatural amino acid mutagenesis with expressed
protein ligation at Hcs to install a FRET pair, Cnf and a thioamide, into full-length αS
(described in more detail in Section 3.5).117 Thioamide FRET partners, such as Cnf,
provide reliable distance information. However, Cnf cannot be selectively excited in the
presence of Tyr. Therefore, our studies were limited to mutants of αS in which each
native Tyr residue was replaced by Phe. Here, we have shown that we can combine Acd
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incorporation with expressed protein ligation at Hcs to incorporate the thioamide/Acd
pair into full-length αS in a traceless manner.

Figure 3.17 Combining Uaa Mutagenesis with NCL at Hcs to Generate Full-Length aS
Containing a Thioamide/Acd Pair.

§3.6 Results and Discussion
The expressed C-terminal Acd-containing αS fragment for NCL was generated as
shown in Figure 3.17. Previously, we have shown that we can use Met5Lys6 as the point
of disconnection.210 To diminish perturbation of native αS dynamics resulting from Acd
incorporation, we chose to replace the aromatic residue phenylalanine (F94). Our
laboratory and others have shown that mutation of F94 to a bulkier aromatic amino acid,
tryptophan, does not abrogate amyloid formation.116 A plasmid containing αS6-140 with a
TAG codon installed at position 94 was prepared (αS6-140TAG94). In this construct, the αS
gene is preceded by an N-terminal His11 tag and a Factor Xa proteolysis site. E. coli cells
were dually transformed with a plasmid containing a UaaRS/tRNA pair selected for Acd
incorporation as well as the plasmid containing His11-αS6-140TAG94. Following the initial
growth period, protein expression was induced by adding acridonyl-2-alanine and IPTG
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to the culture medium. His11-αS6-140Acd94 was purified by Ni-affinity chromatography
and subsequently cleaved by Factor Xa to yield αS6-140Acd94 bearing the requisite Nterminal lysine for the AaT ligation reaction. Following purification by ion-exchange
chromatography, αS6-140Acd94 was incubated with AaT, Met*RS, tRNA, Hcm, and ATP
for 2 h resulting in complete formation of αS5-140Hcm5Acd94. αS5-140Hcm5Acd94 was
subjected to an additional round of ion-exchange chromatography prior to carrying out
the native chemical ligation reaction. Despite performing several rounds of ion-exchange
chromatography, a significant amount of Tyr-containing protein was observed by
MALDI-MS.

Figure 3.18 Ac-SD2Acd94 Synthesis.
Left: Functionalization of S6-140Acd94 by a) cleavage of His11 tag at Factor Xa site, b) attachment
of Hcm by AaT-catalyzed modification, c) ligation of an N-terminal thioester peptide, and d)
conversion of Hcs to Met by methylation to form Ac-SFD2Cnf39. MALDI-MS analysis of αS6+
140Hcm5Acd94. Calcd m/z (M + H) 14121, found 14122 (corresponding to αS5-140Hcm5Acd94) and
14102 (corresponding to αS5-140Hcm5Tyr94).
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Native chemical ligation was performed by incubating αS5-140Hcm5Acd94 (in the
presence of the Tyr-containing protein contaminant) with 2 equivalents of AcMD'VF-SR
in degassed ligation buffer. Complete disulfide deprotection of Hcm was observed by
MALDI MS within five minutes (data not shown). The ligation reaction was allowed to
proceed for 6 h, at which point unligated starting materials were not observed within the
limits of detection by MALDI MS. As expected, two ligation products were formed, due
to misincorporation of Tyr by the Acd synthetase. Fortuitously, these products were
separable by HPLC, and Ac-αSD'2Hcs5Acd94 was cleanly isolated and confirmed by
MALDI MS analysis. Finally, purified αSD'2Hcs5Acd94 was converted to αSD'2Acd94 by
a short treatment (10 min) with 3,000 equivalents of aqueous MeI.
Although we were able to demonstrate that expressed protein ligation at Hcs
could be combined with Acd incorporation to yield full-length αS containing a
thioamide/Acd pair, we encountered several unexpected experimental challenges during
this process. First, the yields of protein expression were extremely low (.5 mg – 1 mg/L).
Additionally, we observed significant incorporation of Tyr during protein expression.
Since we did not observe Tyr incorporation during the expression of other proteins, we
suspect at this stage that this issue may be vector and/or plasmid sequence dependent.
Upon repeating these initial studies, we observed an additional experimental issue
that required immediate attention. By MALDI-MS, we found evidence of
misincorporation

of

N-phenyl-p-aminophenylalanine

(Npf)

resulting

from

decarboxylation during the global deprotection/cyclization step of Acd synthesis. This
was true even when Npf was present as only a trace (<1% by HPLC) impurity in the Acd
batch.47 Since this byproduct, which is difficult to remove by silica chomatography, is
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more likely to be obtained using sulfuric acid, a two-step protocol was adopted with
saponification using LiOH followed by polyphosphoric acid (PPA) cyclization (Figure
3.19). Protein expressed using Acd batches from this PPA route consistently yielded pure
protein containing no Npf at the site of interest.

Figure 3.19 Synthesis of Acridon-2-ylalanine.
In the final step, global deprotection using H2SO4 yields Acd as well as trace amounts of the Npf
contaminant. Performing basic hydrolysis of OMe followed by PPA-mediated Boc
deprotection/Friedel crafts cyclization yields pure Acd for genetic incorporation.

Recently, the Mehl laboratory has performed negative selections to identify a
mutant Acd synthetase that can effectively discriminate against Npf and Tyr
misincorporation. With this improved Acd synthetase in hand, we should be able to
dramatically improve the yields of Acd-containing truncated αS mutants for EPL.
§ 3.7 Conclusions
The application of our minimally perturbing thioamide/Cnf FRET pair to studies
of full-sized proteins requires the ability to synthesize the labeled constructs in an
efficient manner. Here, we have shown that can combine methods of unnatural amino
acid mutagenesis with protein ligation to produce homogeneous doubly-labeled αS for
FRET studies. We were able to show that Cnf and thioamides can be installed at either
terminus of αS. Additionally, we demonstrated that we can monitor conformational
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changes in monomeric αS using urea or TMAO to denature or compact the protein,
respectively. Although thioamide/Cnf FRET is useful for studying the monomeric
conformation of αS, Cnf cannot be selectively excited in the presence of αS oligomers.
We have therefore shown that we can use our traceless double-labeling strategy to
incorporate the red-shifted thioamide/Acd PET pair into full-length αS for misfolding
studies. Importantly, these methods are not limited to studies of αS; virtually any protein
that is compatible with NCL can be doubly-labeled with thioamide/fluorophore pairs in a
similar fashion.
§ 3.8 Materials and Methods
General Information. Fmoc-L-4-cyanophenylalanine (Fmoc-Cnf-OH) was purchased
from Peptech (Burlington, MA). Boc-L-thionophenylalanine-1-(6-nitro)benzotriazolide,
Fmoc-Gln(Trt)-OH, Fmoc-Asn(Trt)-OHwere purchased from Bachem (Torrance, CA) or
EMD Chemicals (Philadelphia, PA). Benzotriazol-1-yl-oxy-tris-pyrrolidino-phosphonium
hexafluorophosphate (PyBOP), Fmoc-Ala-OH, Fmoc-Leu-OH, Fmoc-Glu(OtBu)-OH,
Fmoc-Lys(Boc)-OH, Fmoc-Trp(Boc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Pro-OH, FmocTh(tBu)-OH, Fmoc-Met-OH, Fmoc-Gly-OH, Fmoc-Val-OH, Fmoc-Phe-OH, FmocAsp(OtBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Cys(Trt)-OH A QuickChange® site-directed
mutagenesis kit was purchased from Stratagene (La Jolla, CA). DNA oligomers were
purchased from Integrated DNA Technologies, Inc (Coralville, IA). DNA sequencing
was performed at the University of Pennsylvania DNA sequencing facility. Protein
purification was conducted on a BioCad Sprint fast protein liquid chromatography
(FPLC) system (GMI Inc.; Ramsey, MN; originally from Perseptive Biosystems). HPLC
purification was carried out on a Varian Prostar system (currently Agilent Technologies;
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Santa Clara, CA). Intein plasmid pTXB1 and all restriction enzymes were purchased
from New England Biolabs (Ipswich, MA). 2-chlorotrityl chloride resin, and Rink amide
resin were purchased from Novabiochem (San Diego, CA). Piperidine and 2-(1Hbenzotriazol-1-yl)-1,1,3,3-tetramethyluronium

hexafluorophosphate

(HBTU)

were

purchased from American Bioanalytical (Natick, MA). Sigmacote, N,N-diisopropyl
ethylamine

(DIPEA),

thiophenol,

trifluoroacetic

acid

(TFA),

tris(2-

carboxyethyl)phosphine hydrochloride (TCEP), were purchased from Sigma-Aldrich (St.
Louis, MO). Ni-NTA resin was from Qiagen (Valencia, CA). E. coli BL21(DE3) cells
were purchased from Stratagene (La Jolla, CA). Sequencing-grade trypsin was purchased
from Promega (Madison, WI). Restriction Grade Factor Xa protease was purchased from
Novagen (San Diego, CA). All other reagents were purchased from Fisher Scientific
(Pittsburgh, PA). Milli-Q filtered (18 MΩ) water was used for all solutions (Millipore;
Billerica, MA). Matrix-assisted laser desorption ionization (MALDI) mass spectra were
collected with a Bruker Ultraflex III MALDI-TOF-TOF mass spectrometer (Billerica,
MA). UV/Vis absorbance spectra were obtained with a Hewlett-Packard 8452A diode
array spectrophotometer (Agilent Technologies, Santa Clara, CA). Fluorescence spectra
were collected with a Varian Cary Eclipse fluorescence spectrophotometer fitted with a
Peltier multicell holder (currently Agilent Technologies).
The following specifications are specific to work performed described in section 3.3
Protein purification was conducted on an ÄKTA fast protein liquid chromatography
(FPLC) system (GE Healthcare Life Sciences; Piscataway Township, NJ, USA).
Fluorescence spectra were collected using a Photon Technology International (PTI)
Quantamaster 40 fluorescence spectrometer (Birmingham, NJ, USA). Proton (1H) and
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carbon (13C) NMR spectra were collected with a Bruker DRX 500 MHz spectrometer
(Billerica, MA, USA). DEPT- 135 peaks are indicated parenthetically after 13C chemical
shifts. High resolution ESI mass spectrometry (HRMS) was conducted with a Waters
LCT Premier XE LC/MS (Milford, MA, USA).
CaM Peptide Synthesis and Purification. CaM binding peptides were synthesized on
Rink amide resin. Peptides were purified by reverse-phase HPLC using a binary system
of aqueous (Buffer A: water + 0.1% TFA) and organic (Buffer B: CH3CN + 0.1% TFA)
phases. Solvent gradients, column descriptions, and retention times are listed in Tables
3.11 and 3.12. Purified peptides were lyophilized or dried in a vacuum centrifuge.
Table 3.2 Summary of Purified Peptides.
Gradient
Retention Time
Column
†
Description
(min)
(Size: Brand)
S1
19.6
Semi-prep: Vydac 218 TP C18
S1
20.6
Semi-prep: Vydac 218 TP C18

Peptide
FRRIARLVGVLREFAFR (pOCNC)
F'RRIARLVGVLREFAFR (pOCNC-F1)
FRRIARLVGVL'REFAFR (pOCNC-L11)
‡

FRRIARLVGVLREFAF'R (pOCNC-F16)

S1

22.1

S2

13.3, 14.2

Semi-prep: Vydac 218 TP C18
Prep: Waters C18

†

Described in Table 3.12 ‡Separable epimers were observed during HPLC purification.

Table 3.3 Solvent Gradients Used for Peptide Purification and Analysis.
Gradient

Time
(min)

Buffer A
(%)

Gradient

Time
(min)

Buffer A
(%)

S1

0:00

98

S2

0:00

98

5:00

98

5:00

98

8:00

71

9:00

69

29:00

59

25:00

67

33:00

0

27:00

0

38:00

0

30:00

0

43:00

98

35:00

98
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Table 3.4 Calculated and Observed Peptide and Protein Masses.
Calculated
+
m/z [M+H]

Observed
+
m/z [M+H]

Calculated
+
m/z [M+Na]

Observed
+
m/z [M+Na]

F'RRIARLVGVLREFAFR (pOCNC-F1)

2106.26
2122.23

2106.75
2122.43

2128.24
2128.24

---

FRRIARLVGVL'REFAFR (pOCNC-L11)

2122.23

2122.16

2128.24

--

2122.23

2122.62

2128.24

--

F

16700.3

16699.8

16722.3

--

F

16700.3

16699.9

16722.3

--

16700.3

16700.6

16722.3

--

Peptide
FRRIARLVGVLREFAFR (pOCNC)

‡

FRRIARLVGVLREFAF'R (pOCNC-F16)
CaM F*13F100F139 (CaM F*13)
CaM F*93F100F139 (CaM F*93)
F
CaM F*100F139 (CaM F*100)

®

DNA Oligomers used for CaM Quikchange Mutagenesis
a. Mutation F13 to TAG
Forward: 5' – ACTGACAGAAGAGCAGATTGCAGAATAGAAAGAAGCTTTTTCACTATTTGAC – 3'
Reverse: 5' – GTCAAATAGTGAAAAAGCTTCTTTCTATTCTGCAATCTGCTCTTCTGTCAGT – 3'
b. Mutation F17 to TAG
Forward: 5' – GATTGCAGAATTCAAAGAAGCTTAGTCACTATTTGACAAGGATGGT – 3'
Reverse: 5' – ACCATCCTTGTCAAATAGTGACTAAGCTTCTTTGAATTCTGCAATC – 3'
c. Mutation F93 to TAG
Forward: 5' – AATTAGAGAAGCGTTCCGTGTGTAGGACAAGGATGG – 3'
Reverse: 5' – CCATCCTTGTCCTACACACGGAACGCTTCTCTAATT – 3'
d. Mutation Y100 to F
Forward: 5' – GACAAGGATGGTAATGGTTTCATTAGTGCTGCAGAACTT – 3'
Reverse: 5' – AAGTTCTGCAGCACTAATGAAACCATTACCATCCTTGTC – 3'
d. Mutation Y100 to TAG
Forward: 5' – GACAAGGATGGTAATGGTTAGATTAGTGCTGCAGAACTTCG – 3'
Reverse: 5' – CGAAGTTCTGCAGCACTAATCTAACCATTACCATCCTTGTC – 3'
e. Mutation Y139 to F
Forward: 5' – AGACATTGATGGTGATGGTCAAGTAAACTTTGAAGAGTTTGTACA – 3'
Reverse: 5' – TGTACAAACTCTTCAAAGTTTACTTGACCATCACCATCAATGTCT – 3'

Figure 3.20 DNA Oligomers for CaM Quikchange® Mutagenesis.

Cloning of Calmodulin Expression Constructs. A plasmid containing the wild-type
chicken calmodulin (CaM) gene was provided by Joshua Wand from the University of
Pennsylvania School of Medicine. An insert containing the CaM gene was cloned into a
pET15b vector (Novagen, Gibbstown, NJ) between the NcoI and XhoI cut sites.
Quikchange® mutagenesis was used to generate the following mutant plasmids: pET15b144

CaM-TAG13F100F139, pET15b-CaM-TAG17F100F139, pET15b-CaM-TAG93F100F139, and
pET15b-CaM-TAG100F139.
CaM Expression and Purification. Each plasmid containing a CaM mutant (pCaMTAG13, pCaM-TAG17, pCaM-TAG93, or pCaM-TAG100, see Supporting information for
plasmid construction) was transformed into pDULE2-Cnf-containing E. coli BL21(DE3)
cells. These cells were cultured and made competent through the Hanahan method.211
First, the pDULE2-Cnf plasmid was transformed into BL21(DE3) cells. Then, a colony
was picked based on streptomycin (Strep) resistance to grow cultures of competent cells.
Once pCaM was transformed into these cells, selection was based on both ampicillin
(Amp) and Strep resistance. Single colonies were used to inoculate 5 mL of LB media
containing Amp (100 μg/mL) and Strep (100 μg/mL). This primary 5 mL culture was
incubated at 37 °C with shaking at 250 RPM overnight, and then added to 1 L of M9
minimal media containing Amp and Strep at the same concentrations. M9 minimal media
was prepared by adding the following autoclaved solutions to 1 L of autoclaved water
containing 6 g Na2HPO4, 3 g KH2PO4, 0.5 g NaCl and 1 g NH4Cl: 1 mL of 2 M MgSO4,
1 mL of 15 mg/mL FeCl2 (in 1.0 M HCl), 1 mL of 15 mg/mL ZnCl2 (in acidified H2O), 2
mL of 10% Bacto™ Yeast Extract, 20 mL of 10% glycerol (v/v) and 1 L of 1 M CaCl2.
The 1 L secondary culture was incubated at 37 °C with shaking at 250 RPM until the
OD600 reached 0.7 - 0.9 AU. Protein expression was induced with isopropyl Dgalactoside (IPTG) and 95 mg (0.5 mM) Cnf, and the culture was incubated at 37 °C for
an additional 12 h. The cells were recovered from media at 6000 x g for 10 minutes. The
resulting pellet was suspended in 15 mL of CaM resuspension buffer (50 mM 3-(Nmorpholino)

propanesulfonic

acid

(MOPS),
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100

mM

KCl,

1

mM

ethylenediaminetetraacetic acid (EDTA), pH 7.5). Cell were lysed by sonication,
alternating between one minute of sonication. CaCl2 was added to the sonicated lysate to
a final concentration of 20 mM prior to centrifugation for 10 minutes at 6,000 x g, 4 °C.
Following centrifugation, the supernatant was collected for purification. CaM was
purified from the cleared cell lysate using a phenyl-sepharose (PS) CL-4B column with
EDTA as the eluent. A column with a total resin bed volume of approximately 8 mL was
first equilibrated with four 10 mL washes of PS Buffer A (50 mM Tris base, 1 mM
CaCl2). Then the cleared cell lysate was added to the column and collected as it ran
though to save any protein that did not bind to the column. Next, the column was washed
four times with 10 mL PS Buffer A. The column was then washed with four 10 mL
portions of high-salt PS Buffer B (50 mM Tris base, 0.5 M NaCl, 0.1 mM CaCl2).
Finally, an additional 10 mL wash of PS Buffer A was performed to restore the column to
a low-salt condition. CaM was eluted with 18 mL of PS Buffer C (10 mM Tris base, 10
mM EDTA, pH 7.5. This elution solution was then re-saturated with CaCl2 to a
concentration of 20 mM. This elution solution was repurified on a second PS column
using the same procedure to reduce truncation product. For the second PS column, rather
than adding 18 mL of PS Buffer C directly to the column, 1 mL elutions were collected
and analyzed by SDS-PAGE gel. Collection stopped when the protein was no longer
visible by gel. The elution fractions were dialyzed against CaM Buffer (140 mM KCl, 15
mM HEPES, 6 mM CaCl2, pH 6.7) and stored at -20 °C. Proteins were analyzed by SPS
PAGE gel and MALDI MS for purity.
Native PAGE Gel Analysis of CaM Mutants. CaM peptide binding can be detected by
native (non-denaturing) PAGE gel analysis.212 In order to determine whether mutant CaM
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was capable of binding peptide, 25 L samples were prepared containing 10 M of each
CaM mutant, with or without a stoichiometric equivalent of pOCNC-F1. Prepared
samples were then incubated for one hour at 4 C and loaded into a non-denaturing gel
with 2.5 L of 60% glycerol and 2.5 L of .01% bromophenol blue to assist loading. The
gel was stained with Coomassie blue and scanned.

Figure 3.22 Native PAGE analysis of CaM mutants.
Left: PAGE analysis demonstrates upward shift of the CaM protein band upon addition of
pOCNC-F1. No shift is observed upon addition of pOCNC-F1 to CaMFF*17, indicating this CaM
mutant does not bind pOCNC-F1.

Calmodulin Circular Dichoism Measurements. Mutant stability was evaluated though
both wavelength-dependent and temperature-dependent circular dichoism (CD)
spectroscopy. The wavelength-dependent signature for both the calcium-containing CaM
(holo CaM) and calcium-free CaM (apo CaM) was examined. Since holo CaM is
thermostable, only the thermal unfolding of apo CaM was determined. The apo form of
the protein was prepared by dialyzing the protein into 2 mM EDTA in 50 mM HEPES,
pH 6.70. The holo form of the protein was prepared by dialyzing into 6 mM CaCl2, 15
mM HEPES, 140 mM KCl, pH 6.70. Prepared samples containing 20 µM CaM were
monitored at 222 nm between 5 and 95 C using the variable temperature module for
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temperature-dependent scans and between 200 and 300 nm at room temperature for
wavelength-dependent scans. Data were collected with a 1 °C/min slope, 30 s averaging
time, 2 min temperature equilibration, 5 s response, and 1 nm band width. The data were
processed as previously described.

Figure 3.21 Temperature and Wavelength-Dependent Circular Dichoism Measurements of
CaM Mutants.
Left: Temperature-dependent trace shown for apo CaM mutants. Middle: Wavelength-dependent
trace (25 °C) shown for apo CaM mutants. Right: Wavelength-dependent trace (25 °C) shown for
holo CaM mutants. Coloring scheme for all thee plots CaMFF*13 (red), CaMFF*93 (green),
CaMFF*100 (blue).

Fluorescence Spectroscopy. Corrected fluorescence spectra were collected in triplicate
using quartz fluorometer cells with path lengths of 1.00 cm. For all Cnf experiments, the
excitation wavelength was 240 nm and emission data was collected from 275 - 400 nm as
the average of thee scans. The excitation and emission slit widths were 5 nm, the scan
rate was 120 nm/min, the averaging time 0.5 s, and the data interval 1.0 nm.
CaM/pOCNC Binding Assays. After synthesis, HPLC purification, and lyophilization,
the various pOCNC peptides were redissolved in CaM buffer (140 mM KCl, 10 mM
HEPES, 6 mM CaCl2, pH 6.7). The concentrations of the peptides were determined by
UV/Vis spectroscopy, using an extinction coefficient of 10, 270 M-1cm-1 at 273 nm for
the thioamide-containing peptides and 600 M-1cm-1 at 257 nm for the oxoamidecontaining peptide. The concentration of the CaM proteins was determined though the
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bicinchioninic acid (BCA) assay. For each peptide/protein combination, six solutions
were prepared that contained 10 μM CaM protein and 0 to 15 μM pOCNC peptide. In
addition, a solution of 10 μM peptide in the absence of protein was made to confirm that
no background fluorescence resulted from the peptide. The solutions were prepared three
times in order to obtain data in triplicate. EQ was computed from the raw fluorescence
data for CaM with thioamide-labeled pOCNC (FThio) or pOCNC (FOxo).

Figure 3.22 Fluorescence scans of pOCNC binding with CaM mutants.
Left: CaMFF*13, Middle: CaMFF*93, Right: CaMFF*100.

Figure 3.23 Fluorescence scans of thioamide pOCNC mutants binding with CaMFF*100.
Left: pOCNC-F1, Middle: pOCNC-L11, Right: pOCNC-F16.
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Figure 3.24 Fluorescence scans of pOCNC mutants binding with CaMFF*93.
Left: pOCNC-F1, Right: pOCNC-L11.

Figure 3.25 Fluorescence Scans of pOCNC Thioamide Tutants Binding with CaMFF*13.
Left: pOCNC-F1, Right: pOCNC-L11.

Titration Analysis of Binding Studies with CaM Mutants. Normalized titration curves
were obtained by plotting the ratio of the fluorescence of thioamide pOCNC complexes
to the corresponding oxoamide pOCNC complexes (both measured at 295 nm) as a
function of CaM/pOCNC ratio.
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Figure 3.26 Binding of Thioamide-Containing-pOCNC with CaMFF*100.
In each set, Left: Pymol figure illustrating the distance between the chromophores. Right: titration
data for the binding experiment. Top: pOCNC-F1, Middle: pOCNC-L11, Bottom: pOCNC-F16.
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Figure 3.27 Binding of Thioamide-Containing-pOCNC with CaMFF*93.
In each set, Left: Pymol Figure illustrating the distance between the chromophores. Right: titration
data for the binding experiment. Top: pOCNC-F1, Bottom: pOCNC-L11.

152

Figure 3.28 Binding of Thioamide-Containing-pOCNC with CaMFF*13.
In each set, Left: Pymol Figure illustrating the distance between the chromophores. Right: titration
data for the binding experiment. Top: pOCNC-F1, Bottom: pOCNC-L11.

Förster Distance Calculation. The Förster distance is given in Å by equation 3.1
R06 

9000(ln10) 2Q D J
128  5 n 4 N A

(Eq. 3.1)

where κ2 is a geometrical factor that relates the orientation of the donor and acceptor
transition moments, QD is the quantum yield of the donor, n is the index of refraction of
the solvent, NA is Avogadro’s number, and J is the spectral overlap integral defined in
units of M-1•cm-1•nm4. Combining constants and rearranging gives R0 as

R0  0.211{Q D 2 n4 J}1/ 6
J is formally defined as
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(Eq. 3.2)

J





f D (  ) A (  ) 4 d

(Eq. 3.3)

0

where εA(λ) is the molar extinction coefficient of the acceptor at each wavelength λ and
fD(λ) is the normalized donor emission spectrum given by

f D ( ) 



FD ( )

(Eq. 3.4)

 F  (  ) d
D

0

where FDλ(λ) is the fluorescence of the donor at each wavelength λ. J was calculated to
be 7.0×1012 ± 2×1011 M-1•cm-1•nm4 as previously described.115 Substituting this result
into equation 3.2 , as well as 0.11 for the quantum yield of Cnf, 1.33 for the index of
refraction of water, and 2/3 for 2 gives R0 = 15.6 Å for Cnf/thioamide FRET pairs with
Cnf at position 100 in CaM.213 For Cnf/thioamide FRET pairs with Cnf at position 13 in
CaM, we use 0.003 as a quantum yield for Cnf, and calculate R0 = 8.6 Å. For
Cnf/thioamide FRET pairs with Cnf at position 93 in CaM, we use 0.014 as a quantum
yield for Cnf, and calculate R0 = 11.1 Å. Quantum yields for each mutant were
determined by comparing the fluorescence output of the mutant relative to the
fluorescence of CaMFF*100 under oxopeptide (pOCNC) bound conditions using identical
concentrations and fluorometer settings. Comparison of CaMFF*100 fluorescence to free
Cnf showed that no substantial quenching occurred in this mutant in the absence of
thiopeptide (data not shown). These values of R0 were then used in determining
experimental chomophore separations (RFRET) for each set of Cnf/thioamide probe
locations according to equation (3.5)

RFRET  R 0(

1
 1)1 / 6
EQ

where EQ is defined by equation (3.6)
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(Eq. 3.5)

E Q  1  FThio / FOxo

(Eq. 3.6)

The resulting RFRET values are shown in Table 3.1.
Chromophore Geometries were determined by E. James Petersson and Colin Fadzen.
Chromophore Geometries from CaM/pOCNC NMR Structure. For each pair of Cnf
donor and thioamide acceptor locations, the corresponding residues were identified in the
1SYD PDB file, and a Tcl script was run in VMD (http://www.ks.uiuc.edu/) to cull
distance and orientation information for the Cnf ring (using the corresponding positions
in the natural Phe or Tyr in 1SYD) and the thioamide Xxx carbonyl (using the
corresponding positions in the given amide backbone unit in 1SYD). The following
positions were determined in accordance with the vectors identified in previous quantum
mechanical calculations: the midpoint between CE1 and CE2 (CEmp) of Cnf as a proxy
for the center of the Cnf transition dipole; the midpoint between Xxx C and N of the next
amino acid (CNmp) as a proxy for the midpoint of the thioamide dipole.115 The
interchomophore distance (RNMR) was determined as the distance between these two
midpoints. The culled data were also used to calculate theoretical FRET efficiencies for
each set of probe locations. The donor-acceptor dihedral angle (DA) was determined as
the Xxx O, CNmp, CEmp, Phe CE2 dihedral angle. The donor angle (D) was
determined as the Xxx O, CNmp, CEmp angle; and acceptor angle (A) was determined
as the CNmp, CEmp, CE2 angle. These parameters are illustrated in Figure 3.30.
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Figure 3.29 FRET Orientational Parameters.

Structure 1 from PDB 1SYD shown with atoms used in determining 2 and relevant
distances and angles illustrated. CNmp and CEmp indicated by black spheres. Shown
with nitrile and thioamide modifications for clarity, although geometry calculations are
identical for unmodified 1SYD file.
The orientational parameter from Förster theory, 2, was calculated as:
(Eq. 3.7)
where DA, D, and A are defined as above. Geometry-specific R0 values were calculated
for each of the twenty structures in PDB 1SYD using equations 3.2 and 3.3 where the
donor quantum yield (QD) is taken as 0.11, the spectral overlap integral (J) is calculated
as above, and the index of refraction (n) is taken as 1.33.213 For each timestep, this value
of R0 was used to calculate a geometry-specific FRET quenching efficiency (EQ) using
the corresponding donor-acceptor separation, RNMR (the CNmp/CEmp distance). EQ was
calculated using equation (3.6). Values averaged over all 20 structures in PDB 1SYD for
RNMR, 2, R0, and EQ are collected in Table 3.5 These RNMR values are listed in Table 3.1.
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Table 3.5 Orientation Parameters and Theoretical EFRET from CaM/pOCNC NMR Structuresa

a

CaM_F13/pOCNC_F1 ( = 0.003)

RNMR

2


R0

EQ

Average
RMSD

14.1
0.3

1.01
0.63

8.0
1.5

0.07
0.04

CaM_F13/pOCNC_L11 ( = 0.003)

RNMR



R0

EQ

Average
RMSD

14.1
0.4

0.92
0.47

8.1
1.3

0.07
0.03

CaM_F93/pOCNC_F1 (0.014)

RNMR



R0

EQ

Average
RMSD

8.9
0.3

1.12
0.58

11.1
1.4

0.73
0.14

CaM_F93/pOCNC_L11 (0.014)

RNMR

2

R0

EQ

Average
RMSD

12.2
0.5

1.19
0.68

10.8
1.8

0.39
0.15

CaM_F100/pOCNC_F1 (0.110)

RNMR

2

R0

EQ

Average
RMSD

18.9
0.3

1.30
0.57

16.2
2.1

0.32
0.11

CaM_F100/pOCNC_L11 (0.110)

RNMR

2

R0

EQ

Average
RMSD

24.4
0.4

1.02
0.58

15.2
2.2

0.09
0.04

CaM_F100/pOCNC_F16 (0.110)

RNMR

2

R0

EQ

Average
RMSD

31.3
0.7

1.05
0.68

14.6
2.8

0.02
0.01

2

2

Parameters calculated as described in text. All distances in Å.

Epimer Analysis of pOCNC-F16. Upon purification of pOCNC-F16, two distinct peaks
were observed with different retention times. We attribute this to epimerization resulting
from a reversible cyclization reaction similar to the Edman degradation reaction. Both
peaks contained the correct mass of pOCNC-F16 by MALDI MS. The fluorescence
titration assay was performed with a combination of both epimers of the peptide. To
confirm that both epimers bound CaMFF*100, a native PAGE gel was run with and
without each epimer of pOCNC-F16 as described previously.
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Figure 3.30 Native PAGE and HPLC analysis of pOCNC-F16.
Left: Gel analysis shows shift upon addition of each epimer of pOCNC-F16 to CaMFF*100,
indicating binding. Right: HPLC purification trace at 277 nm. Peaks 1 and 2 correspond to the
peptide epimers.

αS Peptide Synthesis and Purification. αS peptide fragments were synthesized on
chlorotrityl resin. Peptides were purified by HPLC using a binary system of Buffer A and
Buffer B. Thioesterification was performed as described in the main text. Solvent
gradients, column descriptions, and retention times are listed in Tables 3.6 and 3.7.
Purified peptides were lyophilized or dried in a vacuum centrifuge. Purified proteins were
exchanged into Tris buffer (20 mM Tris, 100 mM NaCl, pH 7.4).
Table 3.6 Summary of HPLC Purified Peptides and Proteins.
Peptide
Ac-MDVF'MKGL-S(CH2)2CO2Me
b
Ac-MDV'FMKGL-C PGo
αS123-140C123A'124

Gradient
†
Description
S3
S4

Retention Time
(min)
24.1
31.9

Column
(Size: Brand)
Semi-prep: YMCBasic C8
Semi-prep: Vydac 218 TP C18

S5

20.5

Prep: Waters C18

F

S6

31.5

Semi-prep: Vydac 218 TP C4

F

S6

28.9

Semi-prep: Vydac 218 TP C4

S7

28.9

Semi-prep: Vydac 218 TP C4

S6

29.5

Semi-prep: Vydac 218 TP C4

Ac-αS F'4C9F*39
Ac-αS F'4C9F*94
F

αS F*39C123A'124
F

Ac-αS V'3C9F*39
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Table 3.7 Calculated and Observed Peptide and Protein Masses.
Calculated
+
m/z [M+H]

Observed m/z
+
[M+H]

Calculated m/z
+
[M+Na]

Observed m/z
+
[M+Na]

1101.38

1101.43

1123.36

---

Ac-MDV'FMKGL-C PGo

1343.56

1343.91

1366.54

1365.89

αS123-140C123A'124

Peptide
Ac-MDVF'MKGL-S(CH2)2CO2Me
b

2078.86

2078.73

2100.66

2100.69

F

9

14438.1

14437.6

14461.1

---

F

9

14438.1

14439.6

14461.1

---

14386.1

---

14409.1

14411.3

αS C F*39
αS C F*94
F

αS F*39C123
F
αS Δ1-8

13516.0

13517.2

13534.0

---

F

C9F*39

14494.7

14495.7

14517.7

---

F

14494.7

14495.9

14517.7

---

F

Ac-αS V'3C9F*39

14494.7

14495.4

14517.7

---

αS1-122F*39SR

12475.2

12475.5

12497.2

---

14412.2

14412.5

14434.2

---

Ac-αS F'4C9F*39
Ac-αS F'4C9F*94

F

αS F*39C123A'124
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Table 3.8 Solvent Gradients Used for Peptide Purification and Analysis.
Gradient

Time
(min)

Buffer A
(%)

Gradient

Time
(min)

Buffer A
(%)

S3

0:00

98

S4

0:00

98

S5

S7

5:00

98

5:00

98

10:00

85

10:00

75

30:00

65

25:00

40

35:00

0

30:00

0

40:00

0

35:00

0

45:00

98

40:00

98

0:00

95

0:00

95

5:00

95

5:00

95

10:00

77

10:00

70

27:00

60

30:00

40

30:00

0

34:00

0

35:00

0

38:00

0

40:00

98

43:00

95

0:00

95

5:00

95

10:00

70

30:00

50

34:00

0

38:00

0

43:00

95

S6

Construction of Recombinant pET16b αS Expression Plasmids. The generation of
pET16b-His11IEGR-αSΔ1-8C9 has been described previously. All tyrosine residues (Y39,
Y125, Y133, and Y136) were mutated to phenylalanine by multiple rounds of QuikChange®
mutagenesis to generate pET16b-His11IEGR-αSFΔ1-8C9. The amber stop codon (TAG)
was subsequently mutated into the pET16b-His11IEGR-αSFΔ1-8C9 construct at nucleotides
corresponding to position 39 or 94 to generate pET16b-His11IEGR-αSFΔ1-8C9TAG39 and
pET16b-His11IEGR-αSFΔ1-8C9TAG94.
Construction of Recombinant pRK127 αS Expression Plasmids. A plasmid
containing the human wild-type αS gene cloned between NdeI and HindIII in the
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expression vector pRK172 was provided by Dr. Virginia Lee (Perelman School of
Medicine, University of Pennsylvania). All tyrosine residues were mutated to
phenylalanine by multiple rounds of Quikchange® mutagenesis to generate pRK172-SF.
The amber stop codon (TAG) was subsequently mutated into the pRK172-SF construct
at nucleotides corresponding to amino acid position 39 or 94 to generate pRK172SFTAG39 and pRK172-SFTAG94. In order to create N-terminal cysteine constructs for

native chemical ligation, a primer was designed to delete nucleotides corresponding to
amino acids 2-8 while simultaneously mutating Ser9 to Cys. This primer was applied to
pRK172-SFTAG39 and pRK172-SFTAG94 to generate pRK172-SFΔ2-8C9TAG39 and
pRK172-SFΔ2-8C9TAG94 (Figure 3.32). Ser9 was mutated to Cys in all full-length
oxoamide control constructs to yield pRK172-SFC9TAG39 and pRK172-SFC9TAG94.

Figure 3.31 Construction of pRK172-aSFΔ2-8C9TAG mutants.
A primer was designed to delete nucleotides corresponding to amino acid residues 2-8
(underlined) and mutate S9 to C (bolded) with a single round of Quikchange® mutagenesis.

Construction of Recombinant pTXB1-αS1-122F*39-HTag Expression Plasmid. A
plasmid containing a wild type αS gene was digested by NdeI and XhoI, gel-purified, and
ligated into NdeI/XhoI site of the pTXB1 vector which contained mini-intein GyrA from
the Mycobacterium xenopi followed by a chitin binding domain (CBD). An XhoI site
(CTCGAG) was introduced at D121/N122 of αS using QuikChange® mutagenesis .
Digestion with XhoI and ligation of the two sticky ends yielded a pTXB1-αS1-122D121LN122E-SapI site plasmid. Finally, QuikChange® mutagenesis was used to mutate L121D
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and N122E while simultaneously deleting the SapI site for generating pTXB1-αS1-122
plasmid.

Figure 3.32 Construction of αS1-122 Intein Expression Plasmid with C-terminal Chitin
Binding Domain.

To replace CBD with a polyhistidine tag at the C-terminus of the intein, two
HindIII sites were introduced at the N- and C- termini of CBD using QuikChange®
mutagenesis. The main portion of the CBD was removed by digestion with HindIII and
ligation of the two sticky ends. Then, six His were inserted between the HindIII and stop
codon. The plasmid sequence was confirmed by sequencing using T7-promotor as well as
T7-terminator primers. Lastly, the amber stop codon (TAG) was introduced at position 39
using QuikChange® mutagenesis to generate αSF1-122TAG39-Int construct.
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Figure 3.33 Construction of αS1-122 Intein Expression Plasmid with C-terminal His6 Tag.
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DNA Oligomers Used for αS QuikChange ® Mutagenesis
a. Mutation Y39F
Forward: 5' – GGAAAGACAAAAGAGGGTGTTCTCTTTGTAGGCTCCAAA – 3'
Reverse: 5' – TTTGGAGCCTACAAAGAGAACACCCTCTTTTGTCTTTCC – 3'
b. Mutation Y125F
Forward: 5' – GGATCCTGACAATGAGGCTTTTGAAATGCCTTCTGA – 3'
Reverse: 5' – TCAGAAGGCATTTCAAAAGCCTCATTGTCAGGATCC – 3'
c. Double Mutation Y133F_Y136F
Forward: 5' – CCTTCTGAGGAAGGGTTTCAAGACTTCGAACCTGAAGCC – 3'
Reverse: 5' – GGCTTCAGGTTCGAAGTCTTGAAACCCTTCCTCAGAAGG – 3'
d. Mutation Y39TAG
Forward: 5' – AAAAGAGGGTGTTCTCTAGGTAGGCTCCAAAACCAA – 3'
Reverse: 5' – CTTGGTTTTGGAGCCTACCTAGAGAACACCCTCTTTT – 3'
e. Mutation F94TAG
Forward: 5' – GCATTGCAGCAGCCACTGGCTAGGTCAAAAAGGACCAGTTGGG – 3'
Reverse: 5' – CCCAACTGGTCCTTTTTGACCTAGCCAGTGGCTGCTGCAATGC – 3'
e. Deletion 2-8 and Mutation S9C
Forward: 5' – AGAAGGAGATATACATATGTGCAAGGCCAAGGAGGG – 3'
Reverse: 5' – CTCCCTCCTTGGCCTTGCACATATGTATATCTCCTTCT – 3'
f. XhoI site introduction at D121/N122
Forward: 5' – GGAAGATATGCCTGTGGATCCTCTCGAGGAGGCTTATGAAATGCCTTCTG – 3'
Reverse: 5' – CAGAAGGCATTTCATAAGCCTCCTCGAGAGGATCCACAGGCATATCTTCC – 3'
g. Mutation L121D/E122N and deletion of SapI site
Forward: 5' – GGAAGATATGCCTGTGGATCCTGACAATTGCATCACGGGAGATGCA– 3'
Reverse: 5' – TGCATCTCCCGTGATGCAATTGTCAGGATCCACAGGCATATCTTCC – 3'
st

h. Insertion of HindIII – 1 site
Forward: 5' – TACTGGCCTCACCGGTCTGAAGCTTGGCCTCACGACAAATCC – 3'
Reverse: 5' – GGATTTGTCGTGAGGCCAAGCTTCAGACCGGTGAGGCCAGTA – 3'
nd

i. Insertion of HindIII – 2 site
Forward: 5' – CGTTCCTGCCTTGTGGCAGAAGCTTTGACTGCAGGAAGGGGATCC – 3'
Reverse: 5' –GGATCCCCTTCCTGCAGTCAAAGCTTCTGCCACAAGGCAGGAACGT – 3'
j. Introduction of His Tag
Forward: 5' – CTCACCGGTCTGAAGCTTCATCATCATCATCATCATTAATGACTGCAGGAAGGG – 3'
Reverse: 5' –CCCTTCCTGCAGTCATTAATGATGATGATGATGATGAAGCTTCAGACCGGTGAG – 3'

Figure 3.34 DNA Oligomers Used for S Mutagenesis.

Generation of pDule2-Cnf-BL21(DE3) E. Coli Cells for Unnatural Amino Acid
Mutagenesis. A plasmid encoding for an orthogonal tRNACUA and pCnf-tRNA
synthetase for the incorporation of pCnf through amber stop codon suppression
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(pDULE2-Cnf) was provided by Dr. Ryan Mehl (University of Oregon). E. coli
BL21(DE3) cells were transformed with this plasmid and plated onto LB agar plates
containing streptomycin. Following transformation, competent cells for protein
expression were brewed in accordance with the Hanahan method. Cells stocks were
stored at - 80 ºC in single-use aliquots.
Overexpression and Purification of Full-length αS Cnf Mutants. αSFC9F*39,
αSFC9F*94, and αSFF*39C123 were transformed into competent E. coli BL21(DE3) cells
harboring the orthogonal tRNACUA and pCnf-tRNA synthetase pair. Transformed cells
were selected on the basis of ampicillin (Amp) and streptomycin (Strep) resistance.
Single colonies were used to inoculate 5 mL of LB media supplemented with Amp (100
ug/mL) and Strep (100 ug/mL). The primary 5 mL culture was incubated at 37 ºC with
shaking at 250 rpm for 5 hours. The primary culture was used to inoculate 1 L of a
variant of M9 minimal media. To an autoclaved 1L solution containing 6 g Na2HPO4, 3 g
KH2PO4, .5 g NaCl and 1 g NH4Cl, the following autoclaved solutions were added: 1 mL
of 2 M MgSO4, 1 mL of 15 mg/mL FeCl2 (in 1.0 M HCl), 1 mL of 15 mg/mL ZnCl2 (in
acidified H2O), 2 mL of 10% Bacto™ Yeast Extract 6.5 mL 40% glucose (w/v), and 1 L
of 1 M CaCl2. When the OD600 of the secondary culture reached 0.8, Cnf was added (100
mg, 0.5 mM final concentration), and the culture was incubated overnight at 37 ºC with
shaking at 250 rpm. The cells were harvested at 5000 x g for 15 min and the resulting
pellet was resuspended in 20 mM Tris, pH 8. Following sonication, the cell lysate was
boiled for 20 minutes prior to centrifugation for 20 minutes at 30,000 x g, 4 ºC. The
cleared lysate was dialyzed against 20 mM Tris pH 8.0, loaded onto a Superdex 200
column (25 cm) connected to a BioCad Sprint (FPLC) system and eluted with 20 mM
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Tris, pH 8. FPLC fractions post size-exclusion chromatography were analyzed by SDS
PAGE. The fractions containing αS were then loaded onto a HighTrap Q HP column and
eluted over a 100 minute sodium chloride gradient (0 to 0.5M NaCl in 20 mM Tris, pH
8). FPLC fractions post ion-exchange chromatography were dialyzed against 20 mM
Tris, 100 mM NaCl, pH 7.4 and analyzed by SDS PAGE, MALDI, and fluorescence
spectroscopy.
Mass Spectrometry and Fluorescence Spectrum of αSFC9F*39

Figure 3.35 MALDI MS of αSFC9F*39.
MALDI MS of αSFC9F*39 (top left), trypsin digestion (top right), and primary fluorescence (bottom)
of full-length αSFC9F*39 .Calcd m/z of αSFC9F*39:14438.1 Calcd m/z of trypsin fragment 35-43:
961.1
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Mass Spectrometry and Fluorescence Spectrum of αSFC9F*94

Figure 3.36 MALDI MS of αSFC9F*94.
MALDI MS of αSFC9F*94.(top left), trypsin digestion (top right), and primary fluorescence (bottom)
of full-length αSFC9F*94. Calcd m/z of αSFC9F*94: 14438.1 Calcd m/z of trypsin fragment 81-96:
1503.8.

Mass Spectrometry and Fluorescence Spectrum of αSFF*39C123

Figure 3.37 MALDI MS of αSFF*39C123.
MALDI MS of αSFF*39C123. (top left), trypsin digestion (top right), and primary fluorescence
(bottom) of full-length αSFF*39C123. Calcd m/z of αSFF*39C123: 14409.1 Calcd m/z of trypsin
fragment 35-43: 961.1

C-Terminal Fragment Expression (Factor Xa). The plasmid pET16b_HTag-αSFΔ18C9F*39

(see Supporting Information for plasmid construction) was transformed into E.

coli BL21(DE3) cells containing pDULE2-Cnf (see above) and colonies were selected on
the basis of Amp and Strep resistance. Following growth of a primary culture in LB
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media, 1L of M9 minimal media containing glycerol as a carbon source (0.25% v/v) was
inoculated and allowed to grow at 37 ºC with shaking at 250 RPM. When the OD600
reached 0.8, Cnf was added (150 mg), and the culture was allowed to incubate overnight
at 37 ºC. The boiled and cleared lysate was prepared as described and incubated with 2
mL Ni-NTA resin for 1 hour at room temperature.116 The resin was washed with 20 mL
of 50 mM Tris, 150 mM NaCl, pH 8. The protein was eluted in eight 1.5 mL portions of
50 mM Tris, 150 mM NaCl, 250 mM imidazole, pH 8. Elution fractions were analyzed
by SDS-PAGE gel, combined, and dialyzed against Factor Xa cleavage buffer (50 mM
Tris, 150 mM NaCl, 5 mM CaCl2, pH 8.0) overnight. Following dialysis, His-tag
cleavage was achieved by overnight incubation with Factor Xa protease (10 units per 1
mg of HTag-αSFΔ1-8C9F*39). Factor Xa was inactivated by boiling the reaction for 20
minutes and the precipitated enzyme was removed by centrifugation for 20 minutes at
30,000 x g, 4 ºC. The supernatant was then subjected to incubation with 1 mL of Ni-NTA
resin for 1 h at room temperature to capture any remaining HTag-αS9−140FC9F*39. The
flow-through containing αSFΔ1-8C9F*39 was collected, analyzed by SDS-PAGE gel and
MALDI MS, dialyzed overnight against water, and stored at - 80 ºC.
Mass Spectrometry of αSFΔ1-8C9F*39 Generated by Factor Xa Cleavage. Factor Xamediated cleavage of the N-terminal histidine tag followed by an IEGR recognition site
was performed as described in the main text. Removal of the His tag was confirmed by
MALDI MS.
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Figure 3.38 MALDI analysis of αSFΔ1-8C9F*39 post Factor Xa cleavage.
Expected mass of αSFΔ1-8C9F*39 post cleavage: 13516.0

C-Terminal Fragment Expression (Met Aminopeptidase). The plasmids pRK_αSFΔ28C9F*39

and pRK_αSFΔ2-8C9F*94 (see Supporting Information for plasmid construction)

were transformed into competent E. coli BL21(DE3) cells with pDULE2-Cnf (see
above). Transformed cells were selected on the basis of Amp and Strep resistance. Single
colonies were used to inoculate 5 mL of LB media supplemented with Amp (100 ug/mL)
and Strep (100 ug/mL). The primary 5 mL culture was incubated at 37 ºC with shaking at
250 RPM for 5 hours and then used to inoculate 1 L of LB media. When the OD600 of the
secondary culture reached 0.8, the cells were isolated by centrifugation at 5000 x g for 15
minutes and gently re-suspended in 1 L of M9 minimal media containing Cnf (100 mg).
M9 minimal media was prepared as described above. The cells were harvested at 5000 x
g for 15 min and the resulting pellet was resuspended in 20 mM Tris pH 8. Following
sonication, the cell lysate was boiled for 20 min prior to centrifugation for 20 min at
30,000 x g, 4 ºC. The cleared lysate was loaded onto a Superdex 200 column (25 cm)
connected to a BioCad Sprint (FPLC) system and eluted with 20 mM Tris, pH 8. FPLC
fractions from size-exclusion chromatography were analyzed by SDS PAGE. The
fractions containing αS were then loaded onto a HighTrap™ Q HP column and eluted
over a 100 min NaCl gradient (0 to 0.5 M NaCl in 20 mM Tris, pH 8). FPLC fractions
from ion-exchange chromatography were dialyzed against 20 mM Tris, 100 mM NaCl,
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pH 7.4 and analyzed by SDS PAGE gel, MALDI MS, UV/Vis, and fluorescence
spectroscopy. Following dialysis, guanidinium hydrochloride and methoxylamine
hydrochloride were added to a final concentration of 6 M and 400 mM, respectively. The
pH was adjusted to 4.0 with NaOH and the solution was stirred overnight at 4 ºC.
Removal of N-terminal cysteine adducts was monitored by MALDI MS. Following
deprotection, the solution was dialyzed against water and dried in a vacuum centrifuge.
Mass Spectrometry of αSFΔ1-8C9F*39 Generated by Met Aminopeptidase Cleavage.
Deprotection of N-terminal cysteine adducts formed during protein expression was
performed as described in the main text. Prior to deprotection, adducts corresponding to a
mass increase of +26, +49, and +70 Da are observed. The reaction progress can be
monitored by MALDI MS.

Figure 3.39 MALDI Analysis of Methoxyamine Deprotection.
MALDI analysis pre (left) and post (right) overnight incubation with MeONH2•HCl in 6M Gdn•HCl,
pH 4.0, at 4 ºC. Calcd m/z of αSFΔ1-8C9F*39: 13516.0

Thioester Synthesis (PyBOP). Peptide synthesis and selective cleavage from Cl-Trt
resin was performed as previously described. Cleaved N-terminal peptide was dissolved
in THF, and 2-mercaptopropionate (3 equiv) was added to the solution. After stirring for
5 min, DIPEA (6 equiv) and a solution of PyBOP pre-dissolved in warm THF (3 equiv)
were added to the reaction mixture. The solution was allowed to stir for 30 min at room
temperature, at which point the solvent was removed by rotary evaporation. Sidechain
protecting groups were removed by incubating the peptide for 10 min with a cleavage
cocktail containing TFA, TIPS, thioanisole, and 1,2-ethanedithiol (47:1:1:1). Following
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concentration of the cleavage solution by rotary evaporation, the peptide was precipitated
with ether and isolated by centrifugation. The peptide thioester was purified by HPLC
and dried in a vacuum centrifuge.
Thioester

Synthesis

(CbPGo).

Ac-MDV3FMKGLCbPGo (αS1-8V'3-CbPGo,)

was

synthesized essentially as previously described, with the following modifications.
Bromoacetic acid (0.0695 g, 500 μmol, 5 equiv) was pre-activated with diisopropyl
carbodiimide (78 μL, 500 μmol, 5.0 equiv) for 30 min in dry DMF (6 mL). Also, the
peptide (αS1-8V'3-CbPGo) was cleaved from the resin with the treatment of
CH2Cl2/TFA/thioanisole (38:1:1 v/v, 5 mL) on a rotisserie for 1 h. The resulting solution
was concentrated by rotatory evaporation, precipitated in cold diethyl ether (20 mL),
centrifuged, and decanted ether. The precipitated peptide was dissolved in
acetonitrile/water (50:50 v/v) for HPLC purification.
Ligation to Form αSFF4C9F*39, αSFV3C9F*39, and αSFF4C9F*94. The expressed Cterminal protein fragment (1 equiv, 0.1 µmol) was dissolved in 100 µL of freshly
prepared ligation buffer (6 M Gdn·HCl, 200 mM Na2HPO4, 20 mM TCEP, 1% v/v
thiophenol, pH 7.2 for PyBOP-based thioesters or pH 8.0 for CbPGo thioesters). The
dissolved protein fragment was transferred to a microcentrifuge tube containing 1.2 equiv
of the dried N-terminal peptide thioester, purged with argon, and allowed to incubate
overnight at 37 ºC with shaking at 1000 RPM. The ligation solution was diluted to 3 mL
and dialyzed against water prior to HPLC purification (see Supporting Information).
Following HPLC purification, the product fractions were combined, concentrated, and
exchanged into 20 mM Tris, 100 mM NaCl, pH 7.4 using an Amicon (Millipore) Ultra
0.5 mL 3 kDa spin column.
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HPLC Analysis of Ac-αSFF4C9F*39 and Ac-αSFF4C9F*94 Ligations. Conditions for
native chemical ligation reactions using mercaptopropionate thioester peptide formed by
PyBOP activation were described in the main text. HPLC analyses of the ligation
reactions were performed after 20 h.

Figure 3.40 HPLC Analysis of Ligation of Ac-αSFF4C9F*39.
Peaks a, b, c, and d correspond to hydrolyzed Ac-αS1-8F4 thioester, αSFΔ1-8C9F*39, ligation
product Ac-αSFF4C9F*39, and intact Ac-αS1-8F4 thioester. Peaks earlier than a correspond to
hydrolyzed peptide side products.
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Figure 3.41 HPLC analysis of ligation of Ac-αSFF4C9F*94.
Peaks a, b, c, and d correspond to hydrolyzed Ac-αS1-8F4 thioester, αSFΔ1-8C9F*94, ligation
product Ac-αSFF4C9F*94, and intact Ac-αS1-8F4 thioester. Peaks earlier than a correspond to
hydrolyzed peptide side products.

Conditions for native chemical ligation reactions using peptide thioester formed
by in situ deprotection and rearrangement of the CbPGo linker are described in section
3.2. HPLC analyses of the ligation reactions were performed after 20 h. Due to low yields
of peptide synthesis, ligation reactions were not fully optimized.

Figure 3.42 HPLC Analysis of Ligation of Ac-αSFV3C9F*39.
Peaks a, b, and c, correspond to hydrolyzed Ac-αS1-8V3 thioester, αSFΔ1-8C9F*39, and ligation
product Ac-αSFV3C9F*39. Peaks earlier than b correspond to hydrolyzed peptide side products.
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Mass Spectrometry of Ac-αSFF4C9F*39.

Figure 3.43 MALDI MS analysis of Ac-αSFF4C9F*39.
MALDI MS analysis of Ac-αSFF4C9F*39 (bottom) and trypsin fragments containing thioamide (top
left) or Cnf (top right). Calcd m/z of thioamide-containing trypsin fragment 1-8: 828.4. Calcd m/z of
Cnf-containing trypsin fragment: 961.1 Calcd m/z of of Ac-αSFF4C9F*39: 14494.7

UV Absorbance and Primary Fluorescence Spectra of Ac-αSFF4C9F*39.

Figure 3.44 UV Asborbance and Fluorescence Spectrumof Ac-αSFF4C9F*39.
UV absorbance (left) and fluorescence spectrum (right) of Ac-αSFF4C9F*39. 1 µM samples were
prepared in Tris buffer (20 mM Tris, 100 mM NaCl, 1 mM BME, pH 7.5).
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Mass Spectrometry of Ac-αSFV3C9F*39.

Figure 3.45 MALDI MS analysis of Ac-αSFV3C9F*39.
Calcd m/z of Ac-αSFV3C9F*39:14494.7.

Expression and purification of αSF1-122F*39-Int. A plasmid encoding αS1-122F*39-IntHTag was transformed into E. coli BL21(DE3) cells containing the pDULE2-Cnf gene
(prepared and made competent using the Hanahan method). A starter culture of 4 mL LB
media was inoculated with a single colony and was grown at 37 °C in the presence of
Amp (100 mg/L) and Strep (100 mg/L) for approximately 4 h. A secondary culture of 1 L
M9 media was inoculated with 4 mL of the starter culture and grown at 37 °C with the
same concentrations of Amp and Strep. M9 minimal media was prepared as described
above. The culture was induced by the addition of Cnf (150 mg) followed by 0.5 mM of
IPTG when it reached an OD600 of 0.8 and allowed to grow at 37 °C overnight. Cells
were harvested at 5, 000 RPM using a GS3 rotor and Sorvall RC-5 centrifuge for 20 min
at 4 °C. After discarding the supernatant, the pellet was resuspended in 30 mL of
resuspension buffer: 40 mM Tris, 5 mM EDTA, pH 8.3, protease inhibitor cocktail, 1
mM phenylmethanesulfonyl fluoride (PMSF), and 10 units/mL DNAse1–Grade II. The
cells were lysed by sonication, and the lysate was centrifuged at 13, 900 RPM for 30 min
at 4 °C. The supernatant was then incubated with Ni-NTA resin for 1 h on ice. This slurry
was loaded into a column and the liquid allowed to flow though. The resin was washed
extensively, first with 15 mL of Wash Buffer A (50 mM HEPES, pH 7.0), then twice
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with 10 mL of Wash Buffer B (50 mM HEPES, 10 mM imidazole, pH 7.0. The protein
was eluted with five 2 mL portions of elution buffer (50 mM HEPES, 300 mM imidazole,
pH 7.0). The eluted fractions were combined and incubated with 400 mM sodium 2mercaptoethanesulfonate (MESNA) for thiolysis for 48 h, stirring at 4 °C. The protein
thioester was dialyzed against 20 mM Tris, pH 8.0 overnight, and incubated with NiNTA resin for 1 h on ice. The flow-through was collected, dialyzed against 20 mM
sodium citrate, pH 5.0, purified over HiTrap SP column using a 100 min NaCl gradient (0
to 0.5 M NaCl in sodium citrate, pH 5). The product fractions were pooled and dialyzed
against Milli-Q water overnight, dried in a vacuum centrifuge, and stored at - 80 °C until
further use.
Mass Spectrometry of Ac-αSFV3C9F*39.

Figure 3.46 MALDI MS analysis of Ac-αSFV3C9F*39.
Calcd m/z of Ac-αSFV3C9F*39:14494.7.

Ligation to Form αSFF*94C123A124. Protein thioester αSF1-122F*39 (1.5 equiv, 0.45 μmol,
1.5 mM) and C-terminal protein fragment αSF123-140C123A´124 (1 equiv, 0.3 μmol, 1 mM)
were dissolved in 300 μL of a freshly made, degassed ligation buffer (6 M Gdn•HCl, 200
mM Na2HPO4, 20 mM TCEP, and 1% v/v thiophenol, pH 7.0). The reaction solution was
placed in an incubator at 37 °C, shaking at 1000 RPM. The ligation progress was
monitored by MALDI MS, and allowed to react until all the protein thioester was either
consumed or hydrolyzed. Upon completion, the ligation solution was brought up to 1.5
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mL with water and dialyzed against 20 mM Tris, pH 8.0 for 4 h. Then, the ligated
product, αSFF*39C123A´124, was purified over a HiTrap™ Q HP column using a 100 min
NaCl gradient (0 to 0.5 M NaCl in 20 mM Tris, pH 8). The product fractions were
pooled, concentrated, and the buffer was exchanged for 20 mM Tris, 100 mM NaCl, pH
7.4 using an Amicon (Millipore) Ultra 0.5 mL 10 kDa spin column.
HPLC Analysis of αSFF*39 C123A124.

Figure 3.47 HPLC Analysis of αSFF*39 C123A124.
Peaks under bracket a correspond to thioamide peptide and thioamide peptide side products.
Unligated αS1-122F*39 (b) and ligated product αSFF*39C123A'124 (c) are represented by the blue and
red shaded regions, respectively.

FPLC Analysis of αSFF*39C123A124.

Figure 3.48 FPLC analysis of αSFF*39C123A124.
Peaks a, b, and c correspond to hydrolyzed αS1-122F*39SR (αS1-122F*39OH), TCEP, and protein
impurities in the 8-9 kDa range. Peaks d, e, and f, and g correspond to thioamide peptide side
products, αSFF*39C123A'124, thioamide peptide-ligated protein dimer, and thioamide peptide dimer.
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Absorbance Measurements of Thioacetamide in Trimethylamine Oxide. The
absorbance of thioacetamide (approximately 35 µM) was measured in Tris buffer (20
mM Tris, 100 mM NaCl, 1 mM BME, pH 7.5) and in Tris buffer containing 4M
trimethylamine oxide. This verified that TMAO did not alter the ability of the thioamide
to participate in FRET.

Figure 3.49 Thioacetamide Absorbance in Tris Buffer Compared to Thioacetamide
Absorbance in Tris buffer Containing 4M TMAO.

Fluorescence Measurements of Cnf in Trimethylamine Oxide. The fluorescence of 1
µM Cnf amino acid was measured in 20 mM Tris, 100 mM NaCl, pH 7.5 containing 0, 1,
2, 3, or 4M TMAO. A decrease in fluorescence is observed at higher TMAO
concentrations.

'
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Figure 3.50 Fluorescence Intensity of Cnf In Increasing Concentrations of TMAO.

Fluorescence Measurements of αS Mutants in Trimethylamine Oxide and Urea.
Prior to performing the experiment, the concentrations of all double-labeled proteins were
adjusted using the BCA assay to match their respective oxoamide (donor only) control
proteins. Tris buffers (20 mM Tris, 100 mM NaCl, 1 mM βME, pH 7.5) containing
trimethylamine oxide (TMAO) were prepared such that upon addition of protein (to a
final concentration of 1 µM), the final TMAO concentrations were 0 M, 1 M, 2 M, 3 M,
and 4 M. Buffers containing urea were similarly prepared such that upon addition of
protein, the final urea concentration was 6 M. Fluorescence spectra were measured
immediately following sample dilution in TMAO or urea buffer (to a final volume of 130
µL). All samples were prepared and measured in triplicate. The background fluorescence
of each buffer was independently measured and subtracted from the protein fluorescence
spectrum.
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Figure 3.51 Fluorescence Scans of Oxoamide and Thioamide-containing αS mutants in
Increasing Concentrations of TMAO.
αSFC9F*39 (a), Ac-αSFF4C9F*39 (b), αSFC9F*94 (c), Ac-αSFF4C9F*94 (d), αSFF*39 C123 (e), αSFF*39
C123A124 (f).
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Figure 3.52 Normalized Fluorescence Scans of Oxoamide and Thioamide-containing αS
Mutants in 0 and 6 M Urea.
Top: αSFC9F*39 and Ac-αSFF4C9F*39, Middle: αSFC9F*94 and Ac-αSFF4C9F*94, Bottom: αSFF*39
C123 and αSFF*39 C123A124.

Experimental Förster Distance Calculations (S). The Förster distance, R0, was
calculated as described above for CaM. Substituting J = 7.0×1012 ± 2×1011 M-1•cm-1•nm4
into equation (3.1), as well as 0.11 for the quantum yield of Cnf, 1.33 for the index of
refraction of water, and 2/3 for 2 gives R0 = 15.6 Å for SFC9F*39 constructs in 0 M
TMAO. For SFC9F*94 constructs, we use 0.049 as a quantum yield for Cnf, and
calculate R0 = 13.6 Å. For SFF*39C123 constructs, we use 0.045 as a quantum yield for
Cnf, and calculate R0 = 13.5 Å. In all cases data in 6 M urea were used to normalize oxo-
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and thio- fluorescence data to ensure that small deviations in concentration did not alter
data interpretation. Quantum yields for each mutant in different concentrations of TMAO
were determined by comparing the fluorescence output of the mutant relative to the
fluorescence of that mutant in 0 M TMAO using identical concentrations and fluorometer
settings. Comparison of SFC9F*39 fluorescence to free Cnf showed that no substantial
quenching occurred in this mutant in the absence of the thioamide (data not shown). As
for CaM, these values of R0 were then used in determining experimental chromophore
separations (RFRET) for each set of Cnf/thioamide probe locations according to equation
3.5 where EQ is defined by equation 3.6 as described in the main text. These calculations
are summarized in Table 3.9.
Table 3.9 RFRET Determination in α-Synuclein Refolding Assay.
[TMAO]
0
1
2
3
4

EQ

SE

EQ

SE

EQ

SE

0.13
0.14
0.24
0.48
0.59

0.02
0.01
0.02
0.03
0.03

-0.02
0.07
0.08
0.31
0.59

0.02
0.03
0.03
0.03
0.07

0.03
0.02
0.07
0.24
0.40

0.06
0.02
0.03
0.02
0.05

[TMAO]
0
1
2
3
4

RFRET

SE

RFRET

SE

RFRET

SE

21.3
20.5
17.9
15.2
14.4

0.7
0.4
0.4
0.3
0.3

20.8
19.2
14.8
12.6

1.7
1.5
0.4
0.6

24.5
20.1
15.8
14.1

4.2
1.4
0.3
0.5

[TMAO]
0
1
2
3
4

FOxo
282.2
243.9
204.7
220.8
257.5

FOxo
125.3
110.8
87.4
93.4
112.3

R0

FOxo

R0

15.6
15.2
14.8
15.0
15.4

13.6
13.4
12.8
13.0
13.4

115.9
106.2
90.2
93.2
102.0

13.5
13.3
12.9
13.0
13.2

R0

Parameters calculated as described in text. All distances in Å.
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Synthesis and Purification of Thioaspartate Precursor
α-N-Fmoc-L-aspartate-2-amino-5-nitroanilide. Fmoc-Asp(Ot-Bu)-OH (2.67 g, 6.50
mmol) was dissolved in 35 mL of tetrahydrofuran (THF) under argon flow and the
solution was cooled to - 10 °C in a 1:3 NaCl/ice bath. N-methylmorpholine (NMM, 0.72
mL, 6.5 mmol) and isobutyl chloroformate (IBCF, 0.85 mL, 6.5 mmol) were added
dropwise with stirring. After 15 min, 4-nitro-o-phenylenediamine (1.0 g, 6.5 mmol) was
added and the reaction was allowed to proceed with stirring under argon flow at - 10 °C
for 2 h. The reaction was then allowed to proceed for an additional six hours with stirring
at room temperature. The reaction mixture was dried by rotary evaporation, resuspended
in 20 mL of DMF, and then poured into 200 mL of a saturated potassium chloride
solution. The precipitated product was filtered and washed with cold water. The
precipitate was then dissolved in minimal ethyl acetate (EtOAc) and purified over a silica
gel column in 3:2 hexanes/EtOAc to afford the compound as a yellow solid in 88.9%
yield. Rf = 0.5 in 1:1 hexanes/EtOAc; 1H NMR (500 MHz, CDCl3): δ 8.07 (br. s, 2H),
7.95 (dd, J = 2.5, 9.0 Hz, 1H), 7.76 (dd, J = 3.6, 7.5 Hz, 2H), 7.57 (dd, J = 3.4, 7.4 Hz,
2H), 7.41-7.36 (m, 2H), 7.31-7.28 (m, 2H), 6.67 (d, J = 9.0 Hz, 1H), 5.94 (d, J = 8.2 Hz,
2H), 4.65 (br. s, 1H), 4.55-4.45 (m, 2H), 4.21 (t, J = 6.3 Hz, 2H), 2.99 (dd, J = 4.6, 17.2
Hz, 1H), 2.77 (d, J = 12.8 Hz, 1H) 1.46 (s, 9H); 13C NMR (125 MHz, CDCl3): δ 172.5
(no peak), 170.8 (no peak), 157.3 (no peak), 149.0 (no peak), 144.4 (no peak), 142.3 (no
peak), 139.6 (no peak), 128.8 (+), 128.2 (+), 125.9 (+), 125.4 (+), 124.5(+), 121.7 (no
peak), 121.1 (+), 115.9 (+), 83.6, 68.3 (-), 52.7 (+), 48.2 (+), 38.3 (-), 29.1 (+); HRMS
(ESI) m/z calcd for C29H30N4O7 [M + H]+ 547.219, found 547.218.
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α-N-Fmoc-L-thioaspartate-2-amino-5-nitroanilide. P4S10 (2.47 g, 5.56 mmol) and
anhydrous Na2CO3 (0.589 g, 5.56 mmol) were stirred in 30 mL of THF at room
temperature under argon flow until a clear yellow solution was obtained. After cooling
the solution to 0 ºC on ice, α-N-Fmoc-L-aspartate-2-amino-5-nitroanilide (3.04 g, 5.56
mmol) was added, and the reaction was carefully monitored by TLC. After approximately
1 h, the reaction was filtered through Celite® (Sigma-Aldrich) and dried by rotary
evaporation. The crude reaction material was dissolved in EtOAc and purified over a
silica gel column in 1:1 hexanes/EtOAc to afford α-N-Fmoc-L-thioaspartate-2-amino-5nitroanilide as a yellow foam (2.46 g, 78.6% yield). Rf = 0.7 in 1:1 hexanes/EtOAc; 1H
NMR (500 MHz, CDCl3): δ 9.84 (br. s, 1H), 8.07 (br. s, 1H), 7.96 (d, J = 8.4 Hz, 1H),
7.76 (d, J = 6.9, 2H), 7.52 (dd, J = 7.3, 19.6 Hz, 2H) 7.43-7.39 (m, 2H), 7.32-7.28 (m,
2H), 6.56 (d, J = 9.0 Hz, 1H), 6.06 (d, J = 8.2 Hz, 1H), 5.07 (br. s, 1H), 4.84 (br. s, 2H),
4.37 (br. s, 2H), 4.21-4.13 (m, 1H), 3.18-3.05 (m, 2H), 1.45 (s, 9H); 13C NMR (125 MHz,
CDCl3): δ 204.9 (no peak), 172.1 (no peak), 157.2 (no peak), 149.6 (no peak), 144.3 (no
peak), 142.2 (no peak), 139.0 (no peak), 128.8 (+), 128.1 (+), 126.5 (+), 125.9 (+), 125.8
(+), 122.8 (no peak), 121.0 (+), 115.6 (+), 83.5, 68.4 (-), 58.4 (+), 47.8 (+), 41.6 (-), 28.9
(+); HRMS (ESI) m/z calcd for C29H30N4O6 S1 [M + H]+ 563.196, found 563.197.
α-N-Fmoc-L-thioaspartate-nitrobenzotriazolide. α-N-Fmoc-L-thioaspartate-2-amino5-nitroanilide (1.00 g, 1.78 mmol) was added to glacial acetic acid diluted with 5% H2O
(25 mL). NaNO2 (0.16 g, 2.23 mmol) was added in small portions over 5 min with
constant stirring at room temperature. After 30 min, the reaction was quenched by the
addition of 500 mL ice water. The resulting pale orange precipitate was filtered, washed
extensively with ice water, and allowed to dry under vacuum. The final product was
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characterized and used in peptide synthesis without any further purification. Rf = 0.9 in
1:1 hexanes/EtOAc; 1H NMR (500 MHz, CDCl3): δ 9.64 (s, 1H), 8.46 (d, J = 8.6 Hz 1H),
8.33 (d, J = 8.7 Hz, 1H), 7.78-7.77 (m, 2H), 7.64-7.59 (m, 2H) 7.44-7.38 (m, 2H), 7.357.29 (m, 2H), 6.52-6.45 (m, 1H), 6.23 (d, J = 8.7 Hz, 1H), 4.54-4.48 (m, 1H), 4.41-4.34
(m, 1H), 4.26-4.21 (m, 1H), 3.15-3.07 (m, 1H), 2.97-2.86 (m, 1H), 1.42 (s, 9H);

13

C

NMR (125 MHz, CDCl3): δ 206.7 (no peak), 169.3 (no peak), 156.4 (no peak), 150.6 (no
peak), 149.9 (no peak), 144.6 (no peak), 142.3 (no peak), 132.8 (no peak), 128.7 (+),
128.0 (+), 126.0 (+), 123.2 (+), 122.6 (+), 121.0 (+), 113.6 (+), 83.4, 68.2 (-), 59.0 (+),
48.1 (+), 41.9 (-), 28.9 (+); HRMS (ESI) m/z calcd for C29H30N4O6 S1 [M + Na]+
596.158, found 596.158.
Peptide Synthesis and Purification. Peptide synthesis and selective cleavage from ClTrt resin was performed as previously described. 50 µmol of cleaved N-terminal peptide
(Ac-MetAsp'(Ot-BuValPhe-OH)

was

dissolved

in

THF,

and

methyl

3-

mercaptopropionate (16.6 µL, 150 µmol) was added to the solution. After stirring for 5
min, N,N-diisoproplethylamine (DIPEA, 26.2 µL, 300 µmol) and a solution of PyBOP,
78 mg, 150 µmol) dissolved in minimal DMF were added to the reaction mixture. The
solution was allowed to stir for 25 min at room temperature, at which point the solvent
was reduced to less than 1 mL by rotary evaporation. Next, the peptide was precipitated
with water and isolated by centrifugation. The aspartate protecting group was removed by
incubating the peptide for 10 min with a cleavage cocktail containing trifluoroacetic acid
(TFA), triisopropylsilane, thioanisole, and 1,2-ethanedithiol (47:1:1:1). Following
concentration of the cleavage solution by rotary evaporation, the peptide was dissolved in
a solution of water and acetonitrile (70:30) and purified by HPLC using a binary system
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of Buffer A (0.1% TFA/H2O) and Buffer B (0.1% TFA/CH3CN). Solvent gradients,
column descriptions, and retention times are listed in Tables 3.10 and 3.12. MALDI MS
calcd m/z (M + H)+ 671.2, found 671.2.
Table 3.10 Summary of HPLC Peptide Purification.
Gradient Retention Time
Description†
(min)

Peptide
Ac-MetAsp'ValPhe-SR
†

S7

27.5

Column
(Size: Brand)
Semi-prep: Vydac 218 TP
C18

Described in Table S2.

Table 3.11 Solvent Gradient Used for Peptide Purification.
Gradient

Time
(min)

Buffer A
(%)

S7

0:00

98

5:00

98

11:00

66

40:00

62

43:00

0

45:00

0

50:00

98

Construction of Recombinant pET16b αS Expression Plasmid. The generation of
pET16b-HisTag-αSF9-140C9TAG39, constructed for cysteine-mediated NCL at position 9,
has been described previously. In order to generate HisTag-αSF6-140TAG39, a primer was
designed to insert base pairs corresponding to residues K, G, and L with simultaneous
mutation of C9 back to S (Figure 3.54).

Figure 3.53 Construction of HisTag-αSF6-140TAG39.
A primer was designed to insert nucleotides corresponding to amino acid residues 6-8
(underlined) and mutate C9 to S (bolded) with a single round of Quikchange® mutagenesis.
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DNA Oligomers Used for αS QuikChange® Mutagenesis
Forward: 5' – GGCCATATCGAAGGTCGTAAAGGACTTTCAAAGGCCAAGG – 3'
Reverse: 5' – CCTTGGCCTTTGAAAGTCCTTTACGACCTTCGATATGGCC – 3'
Figure 3.54 Sequence of Forward and Reverse Primers Used in Mutagenesis.

Overexpression and Purification of HisTag-αSF6-140Cnf39. pET16b-HisTag-αSF6140TAG39

was transformed into competent E. coli BL21(DE3) cells harboring the

orthogonal tRNACUA and CnfRS pair. Transformed cells were selected on the basis of
ampicillin (Amp) and streptomycin (Strep) resistance. Single colonies were used to
inoculate 5 mL of LB media supplemented with Amp (100 µg/mL) and Strep (100
µg/mL). The primary 5 mL culture was incubated at 37 ºC with shaking at 250 rpm for 5
h. The primary culture was used to inoculate 1 L of a variant of M9 minimal media
described previously. When the OD600 of the secondary culture reached 0.8, Cnf was
added (150 mg, 0.8 mM final concentration), and the culture was incubated overnight at
37 ºC with shaking at 250 rpm. The cells were harvested at 5000 x g for 15 min and the
resulting pellet was re-suspended in Factor Xa cleavage buffer (20 mM Tris, 100 mM
NaCl, and 1 mM CaCl2, pH 8.0). Following sonication, the cell lysate was boiled for 20
min prior to centrifugation for 20 min at 30,000 x g, 4 ºC. The cleared lysate was
incubated with 2 mL of Ni-NTA resin for 1 h at room temperature and then applied to an
empty PD-10 column. The resin was washed with 20 mL of Factor Xa buffer followed by
a 20 mL wash with Factor Xa buffer containing 30 mM imidazole. The protein was
eluted from the column in eight 1.5 mL portions of Factor Xa buffer containing 250 mM
imidazole. Elution fractions were analyzed by SDS-PAGE, combined, and dialyzed
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against Factor Xa cleavage buffer overnight at 4 ºC. Protein expression yields ranged
from 4 to 6 mg per L of culture.
Factor Xa Cleavage and Purification of HisTag-αSF6-140Cnf39. Dialyzed HisTag-αSF6140Cnf39

was diluted to 0.5 mg/mL in Factor Xa cleavage buffer. Removal of the His11 tag

was achieved by incubating HisTag-αSF6-140Cnf39 with 8 µL of Factor Xa (1.05 mg/L). The
reaction progress was monitored by MALDI MS. When full-length protein was no longer
detected by MALDI MS, the protein was dialyzed into 20 mM Tris, pH 8.0 for 2 h. The
protein was then loaded onto a HighTrap Q HP (GE Healthcare) column and eluted over
a 120 min sodium chloride gradient (0 to 0.5 M NaCl in 20 mM Tris, pH 8.0). FPLC
fractions from ion-exchange chromatography were analyzed by SDS PAGE and MALDI
MS and then immediately exchanged into AaT ligation buffer (50 mM HEPES pH 8.0,
150 mM KCl, 10 mM MgCl2) using an Amicon (Millipore) Ultra 0.5 mL 3 kDa spin
column.

Figure 3.55 MALDI MS of αSF6-140Cnf39.
Calcd m/z (M + H)+ 13799, found 13800.

Enzymatic Transfer of Hcm to αSF6-140Cnf39. Aminoacyl transferase (AaT), L13G
methionyl tRNA synthetase (Met*RS), and Hcm were prepared as previously described.
αSF6-140Cnf39 (0.5 mg/mL) was incubated with Hcm (1 mM), 20 mg E. coli total tRNA,
ATP (2.5 mM) and 0.1 mg each E. coli Met*RS and AaT for 2 h at 37 ºC. Following the
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incubation period, the reaction buffer was exchanged (20 mM Tris, pH 8.0), and the
protein was loaded onto a HighTrap Q HP column, and eluted over a 120 min sodium
chloride gradient (0 to 0.5 M NaCl in 20 mM Tris, pH 8.0). Prior to native chemical
ligation, the buffer was exchanged against MilliQ H2O and the protein was dried in a
vacuum centrifuge.

Figure 3.56 MALDI MS of αSF5-140Hcm5Cnf39.
Calcd m/z (M + H)+ 13963, found 13962.

Ligation

of

Ac-MetAspValPhe-SR

to

αSF5-140Hcm5Cnf39

to

form

Ac-

αSFAsp'2Hcs5Cnf39. αSF5-140Hcm5Cnf39 (1 equiv, 0.072 µmol) was dissolved in 200 µL
of degassed ligation buffer (6 M guanidinium hydrochloride, 200 mM sodium phosphate,
20 mM tris(2-carboxyethyl)phosphine (TCEP), 1% v/v thiophenol, pH 7.5) and incubated
for 5 min. The reduced protein fragment was transferred to a microcentrifuge tube
containing 1.5 equiv of the dried N-terminal peptide thioester, purged with argon, and
allowed to incubate for 24 h at 37 ºC with shaking at 600 rpm. The ligation solution was
then thoroughly exchanged into 500 µL methylation reaction buffer (20 mM Tris, 20 mM
TCEP, pH 8.6).
Methylation of Ac-αSFAsp'2Hcs5Cnf39 to form Ac-αSFAsp'2Cnf39. Following exchange
into methylation reaction buffer, the ligation products were quantified using the
bicinchioninic acid assay. Methylation was performed by incubating the ligation reaction
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with 3,000 equiv methyl iodide for 10 min. The reaction was quenched by adding 10,000
equiv β-mercaptoethanol, diluted to 1 mL with MilliQ H2O, and immediately purified by
HPLC.
Table 3.12 Summary of Protein HPLC Purification.
Gradient Retention Time
Column
Description†
(min)
(Size: Brand)
Semi-prep: Vydac 218 TP
S8
25.2
Semi-prep: Vydac 218 TP
S8
26.7

Peptide

αSF5-140Hcs5Cnf39
αSF5-140Cnf39 (Met5)
Ac-αSFAsp'2Hcs5Cnf39
Ac-αSFAsp'2Cnf39 (Met5)
†

S8

34.8

Semi-prep: Vydac 218 TP

S8

35.9

Semi-prep: Vydac 218 TP

Described in Table 3.12.

Table 3.13 Solvent Gradient Used for Peptide Purification.
Gradient

Time
(min)

Buffer A
(%)

S8

0:00

98

5:00

98

10:00

67

50:00

56

55:00

0

60:00

0

65:00

98

190

215 nm

d

b
a

c

277 nm

Figure 3.57 HPLC Purification of One-Pot Ligation/Methylation Reaction to Form AcαSFAsp'2Cnf39..
Peaks: a) Unmethylated starting material (αSF5-140Hcs5Cnf39) b) Methylated starting material
(αSF5-140Cnf39) c) Unmethylated ligation product (Ac-αSFAsp'2Hcs5Cnf39) d) Methylated ligation
product (Ac-αSFAsp'2Cnf39).

Absorbance and Fluorescence Spectroscopy. UV-Vis spectra were acquired in quartz
cells with a 1.00 cm path length using an HP 8452A spectrometer. Corrected
fluorescence spectra were collected in triplicate using quartz fluorometer cells with path
lengths of 1.00 cm in a PTI Quantamaster 40 spectrometer with photon counting
detection. For all Cnf experiments, the excitation wavelength was 240 nm and emission
data were collected from 275 - 400 nm. The excitation and emission slit widths were 5
nm, the step size was 1 nm, and the data interval was 1 nm.
Fluorescence and UV Spectra of Ac-αSFAsp'2Cnf39. Primary UV and fluorescence
spectra were obtained in αS buffer (20 mM Tris, 100 mM NaCl, pH 7.5). Characteristic
thioamide absorbance (λmax = 272 nm) and Cnf fluorescence upon excitation with 240 nm
light are displayed in the spectra shown below.
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Figure 3.58 Absorbance and Fluorescence Spectra of Purified Ac-αSFAsp'2Cnf39.

Trypsin Digestion. Ac-αSFAsp'2Cnf39 (30 µg) was incubated with a 5 µL aliquot of
sequencing-grade modified trypsin (0.1 mg/mL) in 20 mM Tris, 100 mM NaCl, pH 7.5,
at 37 ºC for 1.5 h. An aliquot (1.0 µL) of the digestion reaction was removed from the
solution and analyzed by MALDI MS. An analysis of the thioamide-containing fragment
as well as the Cnf-containing fragment is described in the main text. Notably, alkylation
in the histidine-containing fragment of Ac-αSFAsp'2Cnf39 (44-58) was not observed.

Figure 3.59 MALDI MS of Ac-αSFAsp'2Cnf39 Trypsin Fragment 44-58.
Calcd m/z (M + H)+ 1525.8, found 1525.3. Asterisk indicates the absence of a peak
corresponding to methylated 44-58. Calcd m/z (M + H)+ 1539.8.

Overexpression and Purification of αSFCnf39 (Oxoamide Control). Overexpression
and purification of αSFCnf39 was performed as previously described. Briefly, αSFCnf39
was transformed into competent E. coli BL21(DE3) cells harboring the orthogonal
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tRNACUA and CnfRS pair. Single colonies were used to inoculate 5 mL of LB media
supplemented with Amp (100 ug/mL) and Strep (100 ug/mL). The primary 5 mL culture
was incubated at 37 ºC with shaking at 250 rpm for 5 h. The primary culture was used to
inoculate 1 L of a variant of M9 minimal media described previously. When the OD600 of
the secondary culture reached 0.8, Cnf was added (150 mg, 0.8 mM final concentration),
and the culture was incubated overnight at 37 ºC with shaking at 250 rpm. The cells were
harvested at 5000 x g for 15 min and the resulting pellet was re-suspended in 20 mM
Tris, pH 8.0. Following sonication, the cell lysate was boiled for 20 min prior to
centrifugation for 20 min at 30,000 x g, 4 ºC. The cleared lysate was dialyzed against 20
mM Tris pH 8.0, loaded onto a Superdex 200 column (25 cm) and eluted with 20 mM
Tris, pH 8.0. The fractions containing αSFCnf39 were then loaded onto a HighTrap Q HP
column and eluted over a 100 min sodium chloride gradient (0 to 0.5 M NaCl in 20 mM
Tris, pH 8.0). FPLC fractions from ion-exchange chromatography were dialyzed against
20 mM Tris, 100 mM NaCl, pH 7.5 and analyzed by MALDI MS and fluorescence
spectroscopy.

Figure 3.60 MALDI MS of αSFCnf39.
Calcd m/z (M + H)+ 14423, found 14420.

Fluorescence Spectrometry of αSFCnf39. Primary fluorescence spectra were obtained in
αS buffer (20 mM Tris, 100 mM NaCl, pH 7.5). Characteristic Cnf fluorescence upon
excitation with 240 nm light is displayed in the spectrum shown below.
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Figure 3.61 Fluorescence Spectrum of Purified αSFCnf39.

αS Refolding Assays. Prior to performing the experiment, the concentrations of AcαSFAsp'2Cnf39 and αSFCnf39 were adjusted to 10 µM. Tris buffers (20 mM Tris, 100 mM
NaCl, pH 7.5) containing trimethylamine oxide (TMAO) were prepared such that upon
addition of αS, the final TMAO concentrations were 0, 2, and 4 M. Fluorescence spectra
were obtained immediately following sample dilution (to a final concentration of 1 µM)
in TMAO buffer. All samples were prepared and measured in triplicate. The background
fluorescence of each buffer was independently measured and subtracted from the protein
fluorescence spectrum.
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Figure 3.62 Fluorescence Spectra of αSFCnf39 and Ac-αSFAsp'2Cnf39 in Increasing
Concentrations of TMAO.
Fluorescence Spectra of αSFCnf39 (a) and Ac-αSFAsp'2Cnf39 (b) in increasing concentrations of
TMAO.

Förster Distance Calculations. Förster distance calculations for double-labeled αS were
performed as described above. Quantum yields for each mutant in different
concentrations of TMAO were determined by comparing the fluorescence output of
αSFCnf39 relative to its fluorescence in 0 M TMAO. The value of R0 for αSFCnf39 mutants
in 0, 2, and 4 M TMAO was determined to be 15.6, 14.7, and 14.4 Å, respectively. The
experimental chromophore separation (RFRET) in Ac-αSFAsp'2Cnf39 was determined as
previously described.
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Table 3.14 RFRET Determination in αS Refolding Assay.
[TMAO]
0
2
4

a

EQ

SE

0.04
0.42
0.69

0.04
0.04
0.04
a

a

SE

[TMAO]

RFRET

0
2
4

26.2
15.4
12.6

[TMAO]

FOxo

R0

0
2
4

278856
190131
168416

15.6
14.7
14.4

b

7.8
0.4
0.4
a

Distances in Å. b Fluorescence intensity in counts
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Chapter 4 : Incorporation of Visible Wavelength Fluorescent Labels
into α-Synuclein for Aggregation and Disaggregation Studies
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§ 4.1 Strategies for Efficiently Incorporating Non-Perturbing Labels Into αSynuclein
Our understanding of the dynamics of protein folding, protein-protein
interactions, cellular trafficking, and the effects of protein post-translational
modifications can be facilitated by labeling proteins with appropriate reporters. Two
classes of proteins of particular current interest are intrinsically disordered proteins and
amyloidogenic proteins. These proteins, which are refractory to traditional structural
characterization techniques, can be labeled with fluorophores so that methods such as
Förster resonance energy transfer (FRET) or fluorescence quenching can be used to
monitor their conformations in vitro and in vivo.214,215 To do so, one must find a way to
selectively introduce multiple site-specific labels that can effectively report on protein
dynamics without being disruptive to the native fold of the protein. Here, we use the
unstructured and amyloidogenic protein α-synuclein (αS) to demonstrate effective
combinations of several methods for protein labeling. While we focus on αS, these
strategies should be broadly applicable to the protein folding community.
To be useful, protein labeling must be specific, either through direct genetic
incorporation of a label, or through the introduction of a chemoselective reactive handle
for further functionalization. Reactive groups that can be selectively modified in the
presence of other biomolecule functional groups are described as bioorthogonal.25 The
most well known reactions in this category are the Cu-catalyzed or strain-promoted
azide/alkyne cycloadditions commonly referred to as “click” reactions.29,216 The
simultaneous site-specific introduction of multiple functionalities into a protein further
requires that the labeling techniques be mutually orthogonal, or capable of being carried
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out sequentially. In order to frame our discussion of how the following labeling
techniques may be used together, we must first introduce them individually.
Several genetically controlled strategies currently exist for protein labeling. The
most time-tested method is Cys modification, which is typically done through reaction
with an alkyl halide or maleimide label.217 However, Cys modification will only be sitespecific if the protein contains no other Cys residues or if reaction conditions can be used
to suppress the reactivity of the undesired sites. The amber codon suppression method
developed by Schultz and co-workers can be used to site-specifically incorporate an
unnatural amino acid (Uaa) into a protein at an amber (UAG) stop codon.23 Efficient
incorporation into recombinant proteins is typically accomplished using evolved
orthogonal tRNA/aminoacyl tRNA synthetase (aaRS) pairs to generate the requisite UaatRNA for ribosomal incorporation of the Uaa. The Uaa can either feature an intrinsic
label such as a fluorophore, or a bioorthogonal reactive handle for further modification
such as an azide. The Uaa mutagenesis method has been expanded by Chin, Liu, and
others to enable the incorporation of multiple Uaas.35,46,218-222 Alternatively, Tirrell and
co-workers have demonstrated the utility of so-called auxotrophic organisms for
incorporating Uaas into proteins.223,224 Auxotrophic organisms are engineered to be
deficient in a specific natural amino acid. By taking advantage of the promiscuity of
endogenous RSs by supplying an isosteric Uaa during protein expression in an auxotroph,
one can achieve codon-specific Uaa incorporation. While auxotrophs could conceivably
be used in combination with other methods, we have not investigated them in depth, as
they would only permit site-specific labeling in unusual cases or through mutagenesis to
remove certain residues as the Davis group has done.225
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In addition to these co-translational methods, several post-translational
chemoenzymatic strategies exist for transferring labels onto proteins at unique
recognition motifs. Some enzymes, like sortase, can be used for conjugation to the
protein termini.16,17 Other enzymes, like biotin ligase and lipoic acid ligase, can be used to
attach labels to specific amino acid sidechains.16,19 However, sortase, biotin ligase, and
lipoic acid ligase all require the insertion of a 5-15 amino acid recognition motif that may
prove to be disruptive to protein folding. In contrast, E. coli aminoacyl transferase (AaT)
requires only a single amino acid for recognition. AaT is an enzyme in the N-end rule
pathway that transfers Leu, Phe, or Met from the corresponding aminoacyl tRNA to
proteins containing an N-terminal Lys or Arg.226 AaT is relatively promiscuous, so it can
be used to transfer a wide range of Uaas to the N-termini of peptides and proteins if the
appropriate aminoacyl tRNA donor or small molecule analog can be generated.227
Importantly, one can control the timing of AaT modification to introduce a second label
independently of a primary modification made co-translationally (e.g., by amber
suppression).
Finally, one of the most versatile and general methods for protein modification is
native chemical ligation (NCL).143 NCL reactions involve the reaction of a peptide with a
C-terminal thioester and a peptide with an N-terminal Cys residue. Thus, like AaT
modification, NCL requires only a single amino acid motif for synthesis, and through the
use of β-thiol Cys analogs and desulfurization, even this single amino acid motif can be
“erased.” The two sections of the protein can be generated either through synthesis or
recombinant expression, allowing one to produce semi-synthetic proteins where large
segments of unmodified protein are derived from cellular expression.162 NCL methods
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allow for essentially complete freedom in the synthetic portion of the protein since no
enzyme recognition requirements must be satisfied. The two primary drawbacks to the
use of NCL for protein modification are that the semi-synthesis process can be very labor
intensive and that refolding after synthesis is required, which may not be feasible for
some proteins. Thus, although one can conceivably introduce all desired modifications
through NCL, it is not always the optimal technique.
The ideal synthesis of a multiply labeled version of a protein is likely to involve a
judicious combination of techniques. Cys modification, amber codon suppression, AaT
N-terminal modification, and NCL are techniques that can be combined for protein
multifunctionalization using Uaas. While we stress that these are general techniques, we
will demonstrate all of them in syntheses of αS. αS is an intrinsically disordered 140
amino acid protein, aggregates of which are among the hallmarks of Parkinson’s
disease.44,51,78,145 Residues 61-95 of αS comprise the so-called non-amyloid-β component
(NAC) domain and drive the formation of β-sheet rich amyloidogenic aggregates. In vitro
aggregation studies suggest a nucleation-propagation mechanism for αS fibril assembly
that is highly sensitive to experimental conditions.154 Labeling of αS has been used
previously to investigate the mechanisms that drive αS fibril formation and cellular
toxicity. Macromolecular labeling of αS using either a yellow fluorescent protein (YFP)
fusion construct or immuno-tags has been used for monitoring protein aggregation in
vitro and in vivo.144 Imaging of fibrillization in living cells was accomplished by inserting
the CysCysProGlyCysCys motif at the C-terminus of αS and labeling using biarsenical
fluorophore reagents (i.e., FlAsH).228 These labeling techniques, which require the
insertion of a large protein label or the binding of a label molecule to a section of the
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protein, can be disruptive to the folding of αS. Thus, our laboratory and others have
focused on αS labeling through the modification of single amino acids.
Cys-maleimide fluorophore labeling was combined with Trp fluorescence to
generate a FRET pair to probe αS conformational dynamics just prior to aggregation.229
Alternatively, others groups have prepared doubly labeled αS using stochastically
controlled fluorophore-maleimide labeling of double Cys mutants.69,81 This leads to a
mixture of forms of singly and doubly labeled proteins, which can be difficult to separate.
Using Cys and pH-dependent N-terminal α-amine labeling, it was shown that a
conformational change precedes fibril formation and that fibril nucleation is
concentration dependent.103 However, it is difficult to achieve complete specificity for the
N-terminus in this way. Lashuel and Brik have used both semi-synthesis and total
synthesis through NCL to incorporate authentic post-translational modifications at many
sites in αS, including ubiquitination and phosphorylation.163,230 Pielak and coworkers
have used amber suppression to incorporate
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F NMR probes into αS for folding

studies.231
Recently, our laboratory has demonstrated the ability to incorporate a variety of
minimally perturbing probes into αS. Spectroscopic probes such as cyanophenylalanine
or acridonylalanine (Acd) have been incorporated using amber suppression.47,117 Double
labels, such as the fluorophore/quencher pair of fluorescein and a thioamide, have been
incorporated using sequential NCL and Cys modification.151 We have also combined
NCL and amber codon suppression to attach Cnf/thioamide pairs.117 We have further
combined these methods with AaT modification to enable the traceless incorporation of
N-terminal αS modifications.117 While these combinations of methods have allowed us to
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multiply label αS, due to the labor-intensive nature of the peptide synthesis in NCL, we
have continued to examine other combinations of techniques that can be used in a
straightforward manner to generate large quantities of protein for in vitro and in vivo
aggregation studies. Here, we compare combinations of a number of labeling methods to
generate homogeneous, multiply labeled versions of αS.

Figure 4.1 Methods for Amino Acid Incorporation and Modification.
Cysteine (Cys, C), acridonylalanine (Acd, ), benzoylphenylalanine (Bzf, ), azidophenylalanine
(Azf, Z), propargyl tyrosine (Ppy, ), azidohomoalanine (Aha, ), and thioglutamate (Glu, E) are
incorporated by simple mutation (Mut.), native chemical ligation (NCL), amber suppression
(UAG), or aminoacyl transferase (AaT) and may be modified with the reagents shown.

§ 4.2 Labeling Results and Discussion
In using combinations of labeling methods, it is important to consider whether
any given pair of methods satisfies the criteria for orthogonality and for sequential use.
We deem methods to be orthogonal if one type of reaction can be carried out in the
presence of a functional group for the other type of reaction; we do not require that they
be used in one pot. Some reactions are inherently sequential, such as the co-translational
incorporation of an intrinsic spectroscopic probe and the post-translational attachment of
a second probe. Other pairs of reactions could be carried out in either order, but we have
identified a preferred sequence. Techniques requiring click chemistry modification and
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Cys modification fall into this category. Finally, some combinations are only practical in
a certain order. We have generated at least one example of every labeling combination,
and for several examples, we have explored multiple strategies.

Of course, before

generating any doubly labeled constructs, we assessed the corresponding singly labeled
constructs. All purified, labeled proteins were characterized by whole protein matrixassisted laser desorption ionization mass spectrometry (MALDI MS) as well as trypsin
digest followed by MALDI MS to confirm the extent and specificity of labeling.
Cys Modification
While several types of reactions are available for Cys modification, including
radical-mediated

thiol-ene

coupling,

photochemically-controlled

reactions,

and

elimination/addition chemistry; simple SN2 or Michael additions are by far the most
common Cys reactions, with a great number of reagents commercially available.217 In
addition, we expected either reaction with the Cys nucleophile to be compatible with the
other labeling reactions considered here. Since αS has no endogenous Cys residues, we
easily generated two singly modified αS constructs by expressing αS-C9 and αS-C114,
labeled them in a semi-pure state with fluorescein-maleimide (Fam) to generate αS-CFam9
and αS-CFam114, and purified the products by high performance liquid chromatography
(HPLC). Analyses of the crude labeling reactions indicated that the yields of αS-CFam9
and αS-CFam114 were quantitative (see Section 4.7, Materials and Methods). Whole
protein MALDI MS and trypsin digest confirmed complete and site-specific labeling in
the purified products. Trypsin digestion also revealed that ring-opening hydrolysis of the
maleimide unit (corresponding to a mass increase of + 18 Da in the observed fragment)
occurred during the labeling and purification procedures.
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Figure 4.2 Single Labeling of αS-C9 with Fam Maleimide.
Top MALDI MS: Whole protein and trypsin digest MALDI MS data show that the purified protein is
homogeneously labeled. The asterisk (*) indicates a matrix adduct observed in all MALDI spectra
of αS (+207 Da). Bottom MALDI MS: Calcd m/z for trypsin fragment 7-10: 847.3, Obs 865.2 (+18
Da). The double asterisk (**) corresponds to the unmodified trypsin fragment 7-10; no peak is
observed. MALDI MS data for αS-C114 can be found in Materials and Methods.

Uaa Mutagenesis
Note: Performed by John Warner and Lee Speight and described in detail
elsewhere.47,232
For Uaa modification, we examined two types of Uaas: those with bioorthogonal
reactive handles (i.e., azides and alkynes) and intrinsic probes such as the fluorescent
amino acid acridonylalanine (Acd, δ). Acd is a blue wavelength fluorophore that can be
selectively excited in the presence of Trp and Tyr.47,113 Acd can function on its own as an
environmentally sensitive fluorescent probe, or it can be paired with a FRET acceptor
such as the quencher Dabcyl or the fluorophore BODIPY R6G. We expressed αS- δ39
and αS- δ94 using standard amber suppression protocols as described previously.47 First,
we inserted TAG codons at the appropriate positions in the αS gene.

We then

transformed each αS plasmid into E. coli cells along with a plasmid encoding a mutant
Methanococcus jannaschii (Mj) TyrRS/tRNA pair (pDULE2-Acd) and induced
expression along with addition of Acd to give αS-δ39 and αS-δ94 in ~3 mg/L yields. In
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this case, whole protein and trypsin digest MALDI MS were used to assess the fidelity of
Acd incorporation.
While intrinisic probes like Acd are valuable, they are often limited in their
functionality by their need to remain compatible with the translational machinery. Thus,
several RS/tRNA pairs derived from the Mj TyrRS/tRNA have been selected for Uaas
amenable to post-translational modification through click chemistry reactions, including
pXFRS for both azidophenylalanine (Azf, Z) and propargyltyrosine (Ppy, π). Selective
post-translational reactions with Azf and Ppy can be used to derivatize them with
virtually any type of label. Using the αS plasmid from above with the pDULE2-pXF
plasmid,

αS-Z94

was

expressed

and

labeled

with

tetramethylrhodamine-

dibenzocyclooctyne (Tco) to give αS-ZFco94. MALDI MS analysis of the crude labeling
mixture showed that the labeling yield was incomplete (see Section 4.7, Materials and
Methods).

Aryl azides such as Azf are subject to both chemical reduction and

photodegradation that could prevent complete labeling.233 Although light exposure is
easily limited by working in the semi-dark, some Azf reduction can occur in cells or
during handling of the proteins. Unfortunately, Azf-containing peptide fragments are
ionized to p-aminophenylalanine species during MALDI MS analysis, so it is difficult to
directly determine the extent of Azf reduction, and we infer it from the yields of reactions
with alkynes. Suspecting that the problem lay in the kinetics of the azide/cyclooctyne
reaction, we

subjected

αS-Z94 to

Cu-catalyzed

tetramethylrhodamine-alkyne (Tak) to give αS-ZFak94.

cycloaddition

reactions

with

We observed slightly higher

modification yields (by MALDI MS) than for stain-promoted cycloaddition with Fco, but
the labeling reaction did not go to completion (see Section 4.7, Materials and Methods).
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Unlike azides, which can be reacted with alkynes through either strain-promoted
cyclizations or Cu-catalyzed cyclizations, terminal alkynes like Ppy must be reacted with
azides using Cu catalysis. We expressed αS-39 and αS-94 using the αS plasmids and the
pDULE2-pXF plasmid, and derivatized the Ppy residues with tetramethylrhodamineazide (Raz) to give αSRaz39 and αS-Raz94. When the proteins were analyzed by MALDI
MS to confirm the extent and specificity of labeling, we observed near quantitative
labeling at both sites (see Section 4.7, Materials and Methods). We believe that the lower
labeling efficiency of Azf relative to Ppy under otherwise identical Cu-catalyzed
conditions is the result of reduction of some of the Azf residues. This is consistent with
our observations for other reactions with co-translationally incorporated Azf (see below).

Figure 4.3 Single Labeling of αS-Raz94 with Raz.
Top MALDI MS: Whole protein and trypsin digest MALDI MS data show that the purified protein is
homogeneously labeled. The asterisk (*) indicates a matrix adduct observed in all MALDI spectra
of αS (+207 Da). Bottom MALDI MS: Calcd m/z for trypsin fragment 81-96: 2047.0, Obs 2046.9.
The double asterisk (**) corresponds to the unmodified trypsin fragment 81-96; no peak is
observed. MALDI MS data for αS-Raz39 can be found in Materials and Methods.

AaT Modification
Note: Performed by John Warner and described in detail elsewhere.232
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We have previously shown that AaT is capable of modifying protein N-termini
with Uaas using semi-synthetic aminoacyl adenosine donors.227

Our laboratory and

others have also used RSs to generate aminoacyl tRNA substrates for AaT in
situ.203,210,227 Although aminoacyl adenosine donors are useful for screening the substrate
specificity of AaT, if an RS appropriate for the Uaa can be identified, the RS method is
more straightforward for most laboratories to implement.

Therefore, we sought to

develop RS/AaT protocols for labeling the αS N-terminus that could be combined with
other labeling methods. An αS construct with an N-terminal Lys was generated by
inserting a 10 His tag with a Factor Xa proteolysis site at the protein N-terminus, deleting
Met1, and making the mutation Asp2Lys (His10-αS2-140-K2). Following Ni-NTA affinity
purification, the His10 tag was cleaved with Factor Xa and the N-terminal Lys was
revealed. This construct, αS2-140-K2, could then be modified with a variety of Uaas using
an

RS/AaT

protocol,

including

Azf,

Ppy,

azidohomoalanine

(Aha,

)

or

homopropargylglycine (not shown). For example, Aha was transferred to αS2-140-K2
using a mutant E. coli MetRS (Met*RS), ATP, E. coli total tRNA, and AaT. Transfer
was complete within 2 h as monitored by MALDI MS. αS2-140-K2N was subsequently
modified with Fco or a dibenzylcyclooctyne–tetramethylrhodamine (Rco) fluorophore
using strain-promoted azide-alkyne cycloaddition.

Interestingly, nearly complete

labeling of the N-terminus was observed, in contrast to our results with Azf incorporated
through amber suppression. The purified proteins, αS2-140-K2FcoN and αS2-140-K2RcoN,
were characterized by MALDI MS and labeling was found to be selective, as expected.
In additional experiments in which we labeled the N-terminus with Azf using AaT, we
also observed complete labeling at the N-terminus with Fco. This indicates that the
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limited Fco reactivity observed for internal Azf modifications may be due to steric
hinderance not present at the terminus. Moreover, it shows that Azf is stable in the short
term after transfer by AaT, so that partial reduction observed elsewhere probably occurs
during growth and lysis of E. coli cells.
NCL then Cys Modification
We have previously shown that we can label αS with spectroscopic probes at
either the C-terminus or the N-terminus through NCL. While there are a great many
modifications possible, here we restrict ourselves to thioamide fluorescence quenching
probes since there is no equivalent way of installing these backbone modifications
through any of the other labeling methods. We examined two modifications, Asp2 and
Glu137, where we denote the presence of the thioamide by adding a prime symbol to the
one or three letter code for the corresponding natural amino acid. To insert the Asp2
modification, we expressed the truncated construct His10-αS9-140-C9, cleaved the Nterminal His10 tag with Factor Xa, and ligated the resulting αS9-140-C9 fragment to the
synthetic thioester peptide αS1-8-D2-SR in quantitative yield (MALDI analysis, see
Section 4.7, Materials and Methods). We have previously described insertion of the
Glu137 modification, where we expressed the intein fusion construct αS1-113-IntH6,
cleaved the C-terminal intein with mercaptoethanesulfonate (MESNA), and ligated the
resulting thioester fragment αS1-113-SR to the synthetic peptide αS114-140-C114E137.151 The
crude proteins, αS-D2C9 and αS-C114E137, were taken forward to the second labeling step
where they were incubated with Fam. The doubly labeled proteins αS-D2CFam9 and αSCFam114E137 were then purified and characterized by MALDI MS.
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Figure 4.4 NCL and Cys Modification to Generate Ac-αS-D2CFam9.
His10-IEGR-αS9-140-C9 was cleaved using Factor Xa and subject to NCL with Ac-αS-D2-SR to
generate Ac-αS-D2C9. Top MALDI MS: Following the ligation reaction, Ac-αS-D2C9 was labeled
with Fam to yield the doubly-labeled protein. The asterisk (*) indicates a matrix adduct observed
in all MALDI spectra of αS (+207 Da). Middle MALDI MS: Calcd m/z for trypsin fragment 1-8:
828.3, Obs 828.3. The double asterisk (**) corresponds to the unmodified trypsin fragment 1-8;
no peak is observed. Calcd m/z for trypsin fragment 7-10: 847.3, Obs 865.2 (+18 Da). The double
asterisk (**) corresponds to the unmodified trypsin fragment 7-10; no peak is observed.

Cys Modification and Uaa Mutagenesis
Cys modification and Uaa mutagenesis are perhaps the most versatile and obvious
combination of methods for doubly labeling a protein. In spite of this, there are relatively
few examples of their use together.21,28,31 For both methods, many substitutions are
possible. To produce doubly-labeled proteins for fluorescence experiments, we began
with Cys modification of a Ppy-labeled protein. TAG mutations were introduced into the
Cys mutant plasmids at positions 39 and 94, then αS-C994, and αS-39C114 were
expressed using the standard amber suppression protocols with pDULE2-pXF.

We

performed the Cys modification with Fam first, and then the Cu-catalyzed addition of
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Raz to Ppy. We found that both reactions occurred in high yields to give αS-CFam9Raz94
and αS-Raz39CFam114.

Figure 4.5 Double Labeling of αS-C994 with Fam and Raz.
Top MALDI MS: Whole protein and trypsin digest MALDI MS data show that the purified protein is
homogeneously labeled. The asterisk (*) indicates a matrix adduct observed in all MALDI spectra
of αS (+207 Da). Middle MALDI MS: Calcd m/z for trypsin fragment 7-10: 847.3, Obs: 865.3 (+18
Da). The double asterisk (**) corresponds to the unmodified trypsin fragment 7-10; no peak is
observed. Bottom MALDI MS: Calcd m/z for trypsin fragment 81-96: 2047.0, Obs: 2046.9. The
double asterisk (**) corresponds to the unmodified trypsin fragment 81-96; no peak is observed.
MALDI MS data for αS-C39114 can be found in Materials and Methods.

Uaa Mutagenesis then AaT
Note: Performed by John Warner and described in detail elsewhere.232
Many of the examples of amber suppression and AaT modification considered
thus far have involved bioorthogonal chemistry. Because one can control the timing of
the AaT modification, azide/alkyne cycloadditions can easily be used for both
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modification steps when combining AaT and amber suppression. To develop procedures
for these modifications, we generated two constructs by introducing amber codons into
the His10-αS2-140K2 construct at either Tyr39 or Phe94. As before, Azf was incorporated
during expression in E. coli cells using the pDULE2-pXF plasmid to produce His10-αS2140-K2Z39

and His10-αS2-140-K2Z94, and the proteins were purified using the His tags.

Labeling of Azf at either residue 39 or 94 was performed with Rco to give His10-αS2-140K2ZRco39 and His10-αS2-140-K2ZRco94. Factor Xa proteolysis was then used to reveal the Nterminal Lys for subsequent transfer of Aha to the N-terminus. Addition of Aha to αS2Rco
140-K2NZ
39

and αS2-140-K2NZRco39 proceeded in quantitative yields to give αS2-140-

K2NZRco39 and αS2-140-K2NZRco94. The N-terminal Aha was then modified with Fco for
both constructs producing αS2-140-K2FcoNZRco39 and αS2-140-K2FcoNZRco94 in quantitative
yields. The proteins were purified by reverse phase HPLC and characterized by MALDI
MS and trypsin digest followed by MALDI MS.
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Figure 4.6 Double Labeling Using Amber Suppression and N-Terminal AaT Transfer.
Azf was incorporated into αS and modified with tetramethylrhodamine-dibenzocyclooctyne (Rco).
Then Aha was attached by AaT-mediated transfer and modified with fluoresceindibenzocyclooctyne (Fco). The asterisk (*) indicates a matrix adduct observed in all MALDI
spectra of αS (+207 Da).

In our efforts towards αS2-140-K2FcoNZRco39 and αS2-140-K2FcoNZRco94, we
observed incomplete labeling of Azf at residues 39 or 94, similar to what was seen in
using Cys modification together with Uaa mutagenesis. We again attributed this to azide
reduction, although in this case relatively low levels of thiol were present (AaT can be
handled with β-mercaptoethanol concentrations as low as 5 µM).

To address the

limitation of incomplete Azf labeling, we incorporated Ppy at position 39 to give His10αS2-140-K239. The extent of protein labeling of Azf versus Ppy was compared using Cucatalyzed fluorophore labeling. The Azf protein (His10-αS2-140-K2Z39) was incomplete
whereas labeling of the Ppy protein (His10-αS2-140-K239) occurred in near quantitative
yields. Thus, as before, the incomplete Azf labeling observed with Fco and Rco seems to
be due to instability of the Azf residue, not a limitation of the cyclooctyne chemistry. In
general, Cu-catalyzed reactions with Ppy should be used for in vitro labeling unless the
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reaction conditions are detrimental to protein stability.

For combinations of Uaa

mutagenesis and AaT N-terminal labeling, one should label the internal Ppy first, and
then attach either Aha or Hpg using AaT. Since no azide stability issues were observed
at the N-terminus in either singly or doubly labeled constructs, cyclooctyne chemistry can
be used with N-terminal Aha, if desired, or Cu-catalyzed reactions could be used with
Hpg.
§ 4.3 Monitoring αS Dynamics using Fluorescence Polarization
Misfolding of the intrinsically disordered neuronal protein αS has been implicated
in the pathogenesis of several debilitating neurodegenerative disorders including
Parkinson’s disease (PD).234 Although it is well established that misfolding of αS leads to
the formation of β-sheet rich fibrils, the molecular mechanisms underlying the conversion
of αS into neurotoxic species remain poorly understood. Commonly used amyloid
binding dyes, such as Thioflavin T (ThT) and Congo Red (CR), can be used to detect the
presence of αS fibrils.174 Although extrinsic dyes are routinely employed to monitor the
kinetics of amyloid formation, the structural information obtained from these experiments
is limited.
It has recently been shown that pre-formed fibrils can recruit native αS and
convert it into a pathogenic form in vivo.56 Accordingly, small molecules that can
remodel and/or disaggregate αS fibrils into less toxic species are being investigated as
potential therapeutics to combat the spread of PD.235-241 Amyloid dyes cannot be used to
reliably detect morphological changes of αS induced by small molecules, as it is possible,
even likely, that these compounds compete for similar binding sites. Moreover, the
optical properties of fluorescence-based amyloid dyes are extremely sensitive to the
presence of additional compounds. Improved methods for monitoring the aggregation and
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disaggregation of αS that yield meaningful structural information would greatly facilitate
our understanding of these crucial processes.
Fluorescence polarization (FP) spectroscopy is a powerful technique for
monitoring changes in the conformational mobility of fluorescently-labeled molecules.160
Upon irradiation with plane polarized light, fluorophores that have their absorption dipole
transition moments oriented along the incoming electric field vector are preferentially
excited. If the fluorophore remains relatively immobile for the duration of its excited state
lifetime (typically 1-10 ns), its emission will be polarized along the same direction. If the
fluorophore is able to rotate freely in solution, its emission will become depolarized with
respect to the incident excitation vector. In a typical FP experiment, the extent of
polarization is determined by measuring the fluorescence emission intensities parallel and
perpendicular to the plane of the linearly polarized excitation light. Quantitatively,
polarization is expressed as the difference in the parallel and perpendicular emission
intensities normalized by the total fluorescence intensity (Equation 4.1).160

P

∥
∥

(Eq. 4.1)

The ability of a fluorescently-labeled molecule to rotate in solution is dependent
on its conformation, its average molecular mass, and on the viscosity of its local
environment. By incorporating a fluorescent label into a protein, one can use FP
spectroscopy to obtain a wide range of dynamic information. Since the degree of
polarization is independent of the total observed intensity, FP measurements are generally
insensitive to fluctuations in sample concentration and/or to the presence of fluorescence
quenchers.242
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In 2007, the Lee laboratory demonstrated that FP can be used to monitor the
aggregation of αS.243 In this study, fluorescently-labeled αS was generated by treating
purified recombinant αS with succinimidyl esters of either Oregon Green 488 or Alexa
Fluor 594. Succinimidyl esters react with free amino groups (such as the -amino group
of lysine residues or the N-terminus) to form an amide linkage.244 To avoid attaching
multiple fluorophores to αS, the ratio of dye to protein used in the labeling reaction was
kept low (1:10). However, since αS contains up to 16 sites that can be labeled by
succinimidyl esters, the material that was ultimately produced by this method likely
consisted of a complex mixture of labeled proteins. Regardless, aggregation reactions
containing WT αS doped with a small percentage of labeled αS generated fibrils that
were morphologically indistinguishable from WT fibrils by electron microscopy (EM).
Over the course of aggregation, FP values of the labeled protein increased in a
manner that was consistent with a nucleation-dependent process characteristic of αS
assembly.154 In order to compare the observed changes in FP to amyloid formation, the
aggregation reaction was independently monitored using ThT as well as another wellknown amyloid dye, K114. The observed increase in polarization preceeded fibril
detection by ThT or K114, suggesting that FP can be used to detect the formation of early
oligomeric intermediates. Next, the authors performed FP aggregation assays in the
presence of small molecules that had previously been shown to prevent fibril formation.
Norepinephrine, epinephrine, dopamine, and L-DOPA were added to aggregation
reactions containing labeled αS. In the presence of each compound, only a modest
increase in FP was detected. Sedimentation and EM analyses confirmed that the majority
of αS remained soluble under these conditions. Together, these studies confirm that FP
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can be used to analyze the conformational state of aS and that FP assays can be
performed in solutions containing extraneous compounds.
Although this initial report demonstrates the utility of FP for monitoring αS
aggregation, the proteins used in these studies consisted of heterogeneous mixtures of
labeled constructs. Therefore, we sought to determine whether site-specifically labeled
αS could be used in conjunction with FP to distinguish local conformational
rearrangements that occur during folding and misfolding of αS. Although several small
molecules have been reported to remodel and/or disaggregate pre-formed αS fibrils,
robust methods for examining this process in real-time are currently lacking. Here, we
show that we can use FP to monitor the conformational remodeling of αS fibrils by small
polyphenolic compounds and demonstrate that site-specific labels yield insight into their
mechanism of action.
§ 4.4 Fluorescence Polarization Results and Discussion
In order to produce site-specifically labeled αS for FP studies, we expressed
constructs containing single Cys mutations at positions 9, 114, and 136. Whereas
positions 9 and 136 can be used to monitor local dynamics of the protein termini, position
114 was selected for its proximity to the fibril core. Following disulfide bond reduction
by TCEP, Cys labeling was performed by incubating the protein with an excess of Fam
for 8 hours at 37 ºC. HPLC purified proteins were characterized by MALDI-MS and
PAGE analysis. MALDI-MS of trypsin digestion fragments confirmed that the labeling
of αS proceeded in a quantitative and highly specific manner (See Section 4.7, Materials
and Methods).
We began our studies by measuring the polarization values associated with each
labeled protein in its monomeric state. In order to avoid intermolecular fluorophore
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interactions (such as homoFRET, which may lead to a decrease in polarization245) labeled
αS was diluted into a solution of WT αS in a 1:99 molar ratio for all FP measurements.
Since αS is intrinsically disordered, we expected that FP values corresponding to
monomeric αS would be similar for each labeled mutant. Intriguingly, we found that the
polarization of the Fam label was dependent on its location within the αS sequence.
Whereas the FP values corresponding to αS-CFam9 and αS-CFam114 were similar, a lower
FP value was observed for αS-CFam136 (Figure 4.7). These results are consistent with
NMR studies suggesting that the residues in the C-terminal tail exhibit greater
conformational freedom in comparison to those residing in the N-terminal and NAC
domains.246
To further demonstrate that site-specific labels can yield information on local
dynamics, we obtained FP measurements of each αS mutant bound to sodium dodecyl
sulfate (SDS) micelles. Previous NMR and fluorescence studies have shown that, upon
binding to SDS, the first 98 residues of αS fold into a pair of curved antiparallel helices
that are connected by a short linker region spanning residues 38-44.82,247 The helical pair
is followed by a predominantly disordered C-terminal tail consisting of residues 98140.247 In the presence of SDS, the FP value of αS-CFam9 increased, consistent with the
observation that the N-terminal domain of αS folds on the surface of SDS micelles. FP
values of αS-CFam114 and αS-CFam136 show a modest decrease upon binding to SDS
micelles, indicating that the C-terminal domain is somewhat more dynamic in the SDSbound conformation. In the disordered ensemble, the C-terminal domain participates in
long-range intramolecular contacts that result in compaction of the protein.65,66,68
Therefore, the observed decreases in FP for αS-CFam114 and αS-CFam136 likely result from
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release of these interactions on binding of the N-terminal and NAC domains to SDS
micelles, so that the C-terminus moves freely in bulk solvent.

Figure 4.7 Fluorescence Polarization Values of Monomeric Labeled αS.
Left: FP values of Fam-labeled αS in buffer. Right: FP values of monomeric αS in the presence of
1 mM SDS.

Next, we used FP to monitor the assembly of αS into amyloid fibrils. Aggregation
reactions were carried out by diluting each labeled construct into a mixture of WT αS in a
1:99 molar ratio and agitating the solution at 1500 rpm. Periodically, separate aliquots of
the aggregation reaction were removed for FP and CR analysis. CR binding assays
demonstrated that the kinetic profiles of aggregation assays containing fluorescentlylabeled αS are indistinguishable from those obtained using WT alone (Figure 4.9). Both
FP and CR measurements generated sigmoidal curves typical of a nucleation-dependent
mechanism of amyloid aggregation. However, the kinetic profiles obtained using FP
varied based on the position of the incorporated label (Figure 4.8, see Section 4.7,
Materials and Methods for raw data). Although further studies will be required to fully
understand this phenomenon, these preliminary results suggest that rigidification of the
C-terminus occurs concurrenty with overall αS aggrgegation and that rearrangement of
the N-terminal domain is slightly delayed.
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Figure 4.8 Aggregation of αS-CFam9, αS-CFam114 and αS-CFam136 Monitored by Fluorescence
Polarization.
Aggregation reactions containing 1% labeled αS in a solution of WT αS were performed in
triplicate. At the indicated time points, aliquots were removed from the aggregation reaction,
diluted 10-fold in buffer, and assessed using FP. The kinetic profiles of the aggregation reactions
varied depending on the position of the incorporated label.

Figure 4.9 Aggregation of αS-CFam9, αS-CFam114 and αS-CFam136.
Monitored by CR Binding. Aggregation reactions containing 1% labeled αS in a solution of WT αS
were performed in triplicate. At the indicated time points, aliquots were removed from the
aggregation reaction, diluted 20-fold in 20 µM CR, and assessed by UV-Vis absorbance. The
kinetic profiles of the aggregation reactions were similar for WT and each labeled mutant.
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Figure 4.10 Summary of t1/2 Values Determined by FP and CR. Normalized data were fit to a
sigmoidal expression to estimate the t1/2 of aggregation associated with each mutant (See Section
4.7, Materials and Methods for details).

Having shown that FP can be used to monitor amyloid assembly, we next chose to
examine whether we could use this technique to monitor the disaggregation of αS fibrils.
αS fibrils containing each labeled construct were agitated for 36 hours and separated from
the aggregation reaction by centrifugation. Freshly re-suspended fibrils were then treated
with excess SDS, boiled for 5 min, and allowed to cool to room temperature. Following
the disaggregation procedure, the FP values uniformly decreased to those corresponding
to the SDS-bound conformation (Figure 4.11). Sedimentation PAGE analyses confirmed
that αS fibrils were efficiently dissolved following treatment with SDS (data not shown).
These studies demonstrate that we can use FP to monitor conformational changes in αS
fibrils without the addition of any exogenous small molecule probe.

Figure 4.11 Disaggregation of αS-CFam9, αS-CFam114 and αS-CFam136 Fibrils Monitored by FP.
The darker bars (on the left of each graph) represent the FP values corresponding to αS fibrils
containing 1% of the labeled protein.The lighter bars (on the right of each graph) represent the FP
values after boiling in excess SDS for 5 min.
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Several small molecules have been shown to remodel and/or disaggregate preformed αS fibrils. However, the molecular details underlying these structural changes are
poorly understood. Dopaminergic nerve cell death is one of the pathological hallmarks of
PD.234 Thus, several groups have examined the effect of dopamine (Dop) and its oxidized
derivatives on the assembly of αS.248-252 In 2004, Li et al. reported that dopamine
treatment led to the disaggregation of pre-formed αS fibrils.235 In this study, the
disaggregation of αS was monitored using ThT fluorescence, dynamic light scattering
(DLS), atomic force microscopy (AFM), and EM. Surprisingly, the Dop-mediated
disaggregation of αS fibrils has not been described in the literature since this initial
report.
In the following years, several aromatic compounds containing vicinal hydroxyl
groups have been identified as efficient amyloid remodeling agents. Among the most
well-studied examples is epigallocatechin gallate (EGCG), a flavonoid that is found in
high concentrations in green tea. In 2008, Bieschke et al. demonstrated that EGCG
transforms αS fibrils into smaller species that are nontoxic to mammalian cells.237 Timeresolved EM and AFM imaging revealed that EGCG converts αS fibrils into poorly
defined amorphous aggregates. CD spectroscopy experiments showed a progressive loss
of β-sheet content in the presence of EGCG, demonstrating that binding of the compound
lead to a significant alteration of αS secondary structure. ThT binding measurements
were consistent with decreasing amyloid content. However, EGCG and ThT may
compete for similar binding sites, and these studies do not shed any light on local
structural changes induced by EGCG.
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Mature αS fibrils have a tendency to enhance the rate of αS assembly in a process
that is commonly referred to as seeding. EGCG-treated fibrils were unable to seed the
aggregation of αS in vitro, suggesting that the compound may reduce fibril toxicity in
vivo. HEK-293 cells overexpressing WT αS were transfected with pre-formed αS fibrils
and evaluated using a standard lactate dehydrogenase (LDH) assay after three days.
Whereas transfection with αS fibrils led to a 2.5-fold increase in LDH activity, no such
effect was observed when the cells were treated with EGCG. This result was reproducible
in an alternative pheochromocytoma (PC12) cell model. Overall, these studies reveal that
EGCG remodels αS fibrils in a manner that leads to a significant reduction of their
inherent pathogenicity.
Having shown that we can use FP to monitor αS folding, aggregation, and
disaggregation, we reasoned that we could use this technique to gain insight into the
mechanism by which small molecules remodel αS fibrils. Here, we chose to examine the
remodeling

capacity

of

dopamine,

EGCG,

and

an

additional

flavonoid,

nordihydroguiaretic acid (NDGA). Previously, NDGA has been shown to inhibit αS
aggregation and to disassemble αS oligomers that form in the presence of FeCl3.241 Prior
to this work, the effect of NDGA treatment on the structure of αS fibrils has not been
described.

Figure 4.11 Chemical Structures of Dop, EGCG, and NDGA.
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Pre-formed fibrils containing each labeled mutant were treated with Dop, EGCG,
and NDGA and continuously monitored using FP (Figure 4.12). Note: At this time, these
experiments have not been performed with αS-CFam136. Prolonged incubation with
stoichiometric or excess amounts of Dop had no effect on the observed FP values for any
of the labeled mutants tested. Treatment of pre-formed fibrils with stoichiometric
quantities of EGCG also failed to produce any significant changes in FP. When a 10-fold
molar excess EGCG was added to pre-formed fibrils containing αS-CFam114, we observed
a significant decrease in FP over time. However, only a small change in FP was observed
when αS-CFam9 fibrils were treated with excess EGCG. Together, these studies suggest
that EGCG binds to and preferentially remodels the C-terminus of αS. These data are
consistent with earlier reports suggesting that EGCG preferentially interacts with the Cterminus of αS monomers.253,254 Remarkably, treatment with excess NDGA produced a
significant change in FP for both αS-CFam9 and αS-CFam114-containing fibrils. These
preliminary results suggest that NDGA is a potent amyloid remodeling agent.
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Figure 4.12 Small Molecule Remodeling of αS-CFam9 and αS-CFam114 Monitored by FP.
Dopmaine, EGCG, and NDGA were added to pre-formed αS fibrils (10 µM, relative to monomer
concentration) and continuously monitored by FP.

§ 4.5 Conclusions
Since αS and other amyloidogenic proteins are generally not amenable to
traditional structural studies, many laboratories are interested in functionalizing these
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proteins in order to study the aggregation process in vitro and in vivo. Here, we have
employed several strategies to multifunctionalize αS with fluorophores using various
combinations of conventional Cys modifications, amber codon suppression, AaT
mediated N-terminal modification, and NCL. The combinations of techniques considered
here fulfill the requirements of being either mutually orthogonal or able to be carried out
sequentially. We have shown that several combinations are practical for site-specific
double labeling of αS. Cys modification can be used in combination with amber codon
suppression, and this pair of techniques is applicable to αS, but may not be feasible in
proteins with multiple Cys residues.

Since AaT modification takes place post-

translationally, when one uses it in combination with amber suppression, one can use the
same types of bioorthogonal reactions and control the position of the labels by reaction
sequence.
A variety of in vitro and in vivo experiments can be performed using
fluorescently-labeled αS. Here, we have shown that site-specifically labeled αS can be
used in conjunction with FP to monitor various processes including SDS-induced folding,
fibril formation, disaggregation, and fibril remodeling induced by exogenous small
molecules. Additionally, we have shown that site-specific Fam labels yield local dynamic
information. Although other groups have shown that certain small molecules can remodel
αS fibrils into amorphous, non-toxic species, the molecular basis for this effect is poorly
understood. Our preliminary results suggest that EGCG and NDGA preferentially bind to
and remodel the C-terminus of αS. In the future, we will combine FP with FRET studies
using doubly-labeled proteins to characterize these conformational changes in rigorous
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detail. Additionally, we will continue to use FP to screen synthetic derivatives of NDGA
in efforts to discover new compounds with enhanced therapeutic potential.
§ 4.6 Materials and Methods
General Information. Azf was purchased from Bachem (Torrance, CA). 5(6)’carboxytetramethylrhodamine was purchased from Novabiochem, EMD Millipore
(Darmstadt, Germany). Fluorescein-5-maleimide was purchased from TCI America
(Portland, Oregon). TAMRA-azide, 5-isomer was purchased from Lumiprobe
(Hallandale Beach, Florida). Dibenzylcyclooctyne-amine and carboxyrhodamine110azide were purchased from ClickChemistryTools (Scottsdale, AZ). Ni-NTA resin was
purchased from Qiagen (Valencia, CA). E. coli BL21(DE3) cells were purchased from
Stratagene (La Jolla, CA). (-)-Epigallocatechin gallate (EGCG) was purchased from
Caymen Chemical (Ann Arbor, Michigan). Nordihydroguaiaretic acid (NDGA) was
purchased from Sigma-Aldrich (St. Louis, MO). Sequencing-grade trypsin was purchased
from Promega (Madison, WI). Bovine Factor Xa protease was purchased from
Haematologic

Technologies

(Esses

Junction,

VT).

QuikChange®

site-directed

mutagenesis kits were purchased from Stratagene. DNA oligomers were purchased from
Integrated DNA Technologies, Inc (Coralville, IA). All other reagents were purchased
from Fisher Scientific (Pittsburgh, PA). MilliQ filtered (18 MΩ) water was used for all
solutions (Millipore, Billerica, MA). The pEG6 plasmid, containing His10-tagged E. coli
AaT, was a gift from Alexander Varshavsky (California Institute of Technology). The
pDULE2 plasmid was a gift from Ryan Mehl (Oregon State University). Matrix-assisted
laser desorption/ionization (MALDI) mass spectra were collected with a Bruker Ultraflex
III MALDI-TOF/TOF mass spectrometer (Billerica, MA). UV/vis absorbance spectra
were obtained with a Hewlett-Packard 8452A diode array spectrophotometer (Agilent
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Technologies, Santa Clara, CA). NMR spectra, 1H and 13C, were collected with a Bruker
DRX 500 MHz instrument (Billerica, MA). Gel images were obtained with a Typhoon
FLA 7000 (GE Lifesciences, Princeton, NJ). Fluorescence spectra were collected with a
Tecan M1000 plate reader. Fluorescence polarization data were collected with a Tecan
F200 plate reader (Mannedorf, Switzerland).
Construction of pRK αS Cys Mutant Expression Plasmids. A plasmid containing the
human wild-type αS gene cloned between NdeI and HindIII in the expression vector
pRK172 was provided by Dr. Virginia Lee (Perelman School of Medicine, University of
Pennsylvania). QuikChange® mutagenesis was used to mutate Ser9 to Cys9, Glu114 to
Cys114 and Tyr136 to Cys136 in the pRK172 construct to yield pRK172-αS-C9,
pRK172-αS-C114 and pRK172-αS-C136, respectively. The sequence of the mutant plasmid
was confirmed by DNA sequencing analysis. DNA primers for each mutagenesis step are
shown in Figure 4.13.
Construction of pT-T7 αS TAG Expression Plasmids. A plasmid containing the
human wild-type αS gene cloned between NdeI and HindIII in pT7-7 vector was
provided by Dr. Elizabeth Rhoades (Department of Molecular Biophysics and
Biochemistry, Yale University).

Higher yields were observed for Uaa-containing

proteins when expressed from the pT-T7 vector in comparison to Uaa expression from
αS pRK vectors. Thus, all TAG-containing mutant constructs were generated in pT-T7.
QuikChange® mutagenesis was used to mutate Tyr39 to TAG, and Phe94 to TAG in the
pT-T7 construct to yield pT-T7-αS-TAG39, and pT-T7-αS-TAG94 respectively. A second
round of QuikChange® mutagenesis reactions was performed to mutate pT-T7TAG94 to
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pT-T7-αSC9TAG94 and pT-T7-αS-TAG39 to pT-T7-αS-TAG39-C114. DNA primers for
each mutagenesis step are shown in Figure 4.13.
DNA Oligomers Used for αS QuikChange® Mutagenesis.
i.

Mutation S9C in αS
Forward: 5' – GTATTCATGAAAGGACTTTGCAAGGCCAAGGAGGGAGTTG – 3'
Reverse: 5' – CAACTCCCTCCTTGGCCTTGCAAAGTCCTTTCATGAATAC – 3'

ii.

Mutation E114C in αS
Forward: 5' – CCCCACAGGAAGGAATTCTGTGCGATATGCCTGTGGATCCTGA – 3'
Reverse: 5' – TCAGGATCCACAGGCATATCGCACAGAATTCCTTCCTGTGGGG – 3'

iii.

Mutation Y136C in αS
Forward: 5' – TCTGAGGAAGGGTATCAAGACTGCGAACCTGAAGC – 3'
Reverse: 5' – GCTTCAGGTTCGCAGTCTTGATACCCTTCCTCAGA – 3'

iv.

Mutation Y39TAG in αS
Forward: 5' – AAAAGAGGGTGTTCTCTAGGTAGGCTCCAAAACCAA – 3'
Reverse: 5' – TTGGTTTTGGAGCCTACCTAGAGAACACCCTCTTTT – 3'

v.

Mutation F94TAG in αS
Forward: 5' – GCATTGCAGCAGCCACTGGCTAGGTCAAAAAGGACCAGTTGGG – 3'
Reverse: 5' – CCCAACTGGTCCTTTTTGACCTAGCCAGTGGCTGCTGCAATGC – 3'

Figure 4.13 DNA Oligomers Used for Quikchange® Mutagenesis.

Overexpression and Purification of Full-length WT αS and αS Cys Mutants. pRKαS, pRK-αS-C9, prK-αS-C114, and pRK-αS-C136 were transformed into competent E. coli
BL21(DE3) cells. Single colonies were used to inoculate 5 mL of LB media
supplemented with ampicillin (Amp, 100 μg/mL). The primary culture was incubated at
37 °C with shaking at 250 rpm for 4 h. The primary culture was used to inoculate 1 L of
LB media containing Amp (100 μg/mL) which was then grown overnight at 37 °C with
shaking at 250 rpm. The cells were harvested by centrifugation at 5000 x g for 15 min,
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and

the

resulting

pellet

was

re-suspended

tris(hydroxymethyl)aminomethane (Tris), 5 mM

in

lysis

buffer

(40

mM

ethylenediaminetetraacetic acid

(EDTA), pH 8.2) supplemented with 1 mM phenylmethanesulfonyl fluoride (PMSF) and
10 units/mL DNase I – Grade II. The cells were lysed by sonication, boiled for 20 min at
100 °C, and centrifuged for 20 min at 14,200 x g at 4 °C. The clear supernatant was
dialyzed against purification buffer (20 mM Tris, pH 8.0) overnight at 4 °C. The resulting
solution was purified by gel filtration over a Superdex 75 16/600 column followed by
ion-exchange chromatography using a HiTrap Q HP column (5 mL) on an ÄKTA FPLC
using a 100 min NaCl gradient (0 to 500 mM NaCl in 20 mM Tris, pH 8.0). The fractions
containing the product were identified by MALDI MS, pooled, and dialyzed against αS
buffer (20 mM Tris, 100 mM, pH 7.5) overnight.
Labeling of αS-C9, αS-C114, and αS-C136 with Fam. Prior to performing the labeling
reactions, the concentration of each protein (αS-C9, αS-C114, and αS-C136) was adjusted to
approximately 1.0 mg/mL and incubated with αS buffer containing TCEP (1 mM) for 10
min at room temperature. Fluorescein-5-maleimide (5 equiv) was then added to the
protein from a fresh 10 mM stock solution prepared in DMSO. The reaction was carried
out at 37 °C for 4 h without shaking. After the first 4 h, an additional 5 equiv were added
and the reaction was allowed to incubate for an addition 2-4 hours at 37 ºC until
quantitative conversion was observed by MALDI MS. The resulting fluorescein-labeled
protein was dialyzed against purification buffer (20 mM Tris, pH 8.0) and purified over a
HiTrap Q HP column on an ÄKTA FPLC using a 100 min NaCl gradient (0 to 500 mM
NaCl in 20 mM Tris, pH 8.0). The fractions containing the product were identified by
MALDI MS and dialyzed against water overnight at 4 °C. The dialyzed, labeled proteins

230

were further purified by reverse-phase HPLC on a Vydac 218TP C4 semi-prep column
using the following gradient: isocratic at 95% aqueous phase for 5 min, and then ranging
from 95% to 75% aqueous phase over 5 min, then to 40% over 20 min, then to 0%
aqueous phase over 5 min, then returning to 95% aqueous phase during a 5 min wash out
period. The purified protein was then concentrated using an Amicon (Millipore) Ultra 0.5
mL 3 kDa spin column, exchanged into αS buffer, and stored at – 80 ºC until further use.
Mass Spectrometry Analysis of Fam Labeling Reactions. Fam labeling was
periodically monitored using MALDI MS. Complete labeling was consistently observed
within 8 hours.

Figure 4.14 MALDI MS Traces of Crude Fam Labeling Reactions.
Blue trace: Cys mutant prior to the labeling reaction. Red trace: Crude reaction mixture post
labeling with 10 equiv of Fam maleimide. The asterisk (*) indicates a matrix adduct observed in all
MALDI spectra of αS (+207 Da).

MALDI Analysis of HPLC Purified αS-CFam9, αS-CFam114 and αS-CFam136. MALDI
MS of the purified proteins consistently yielded masses that were 15-20 Da higher than
the expected mass. MALDI MS analysis of trypsin fragments suggest that this increase in
mass corresponds to hydrolytic ring-opening of the maleimide group (see below).
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Figure 4.15 MALDI Traces of HPLC Purified αS-CFam9, αS-CFam114 and αS-CFam136.
Expected [M+H]+ of αS-CFam9, αS-CFam114, and αS-CFam136 are 14906, 14864, and 14830,
respectively. Expected [M+H]+ of maleimide ring-opened αS-CFam9, αS-CFam114, and αS-CFam136
are 14924, 14882, and 14848, respectively. The asterisk (*) indicates a matrix adduct observed in
all MALDI spectra of αS (+207 Da).

Trypsin Digestion of αS-CFam9, αS-CFam114 and αS-CFam136. αS mutants (10−50 μg)
were incubated with 5−10 μL aliquots of sequencing-grade modified trypsin (0.1 mg/mL)
in 20 mM Tris, 100 mM NaCl, pH 7.5, at 37 °C for 4 h. An aliquot (1.0 μL) of the
digestion reaction was taken and analyzed by MALDI MS.

Figure 4.16 MALDI MS of Trypsin Fragments of αS-CFam9, αS-CFam114 and αS-CFam136.
Expected [M+H] + of αS-CFam9 Frag. 7-10, αS-CFam114 Frag. 103-140 and αS-CFam136 Frag. 103140 are 847.3, 4687.6, and 4652.8, respectively. Expected [M+H] + of maleimide ring-opened αSCFam9 Frag. 7-10, αS-CFam114 Frag. 103-140 and αS-CFam136 Frag. 103-140 are 865.3, 4705.6, and
4670.1, respectively. The double asterisk (**) corresponds to the unmodified trypsin fragment.
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MALDI MS analysis of the trypsin fragments show that Fam labeling is site-specific and
quantitative. In each labeled fragment, a mass adduct of approximately +18 Da was
observed. This increase in mass is consistent with hydrolytic ring-opening of the
maleimide group.
Overexpression and Purification of αS-Z94, αS-39, αS-94, αS-C994 and αS--39C114.
pT-T7-αS-TAG39 and pT-T7-αS-TAG94 were transformed into competent E. coli
BL21(DE3) cells harboring the orthogonal tRNACUA and pXF-tRNA synthetase pair.
Transformed cells were selected on the basis of Amp and streptomycin (Strep) resistance.
Single colonies were used to inoculate 5 mL of LB media supplemented with Amp (100
ug/mL) and Strep (100 ug/mL). The primary 5 mL culture was incubated at 37 ºC with
shaking at 250 rpm for 5 hours. The primary culture was used to inoculate 1 L of a
variant of M9 minimal media. To an autoclaved 1L solution containing 6 g Na2HPO4, 3 g
KH2PO4, .5 g NaCl and 1 g NH4Cl, the following autoclaved solutions were added: 1 mL
of 2 M MgSO4, 1 mL of 15 mg/mL FeCl2 (in 1.0 M HCl), 1 mL of 15 mg/mL ZnCl2 (in
acidified H2O), 2 mL of 10% Bacto™ Yeast Extract 12.5 mL 40% glucose (w/v), and 1
L of 1 M CaCl2. When the OD600 of the secondary culture reached 0.8, the
corresponding Uaa was added (220 mg for Ppy or 206 mg for AzF, final concentration of
1 mM), and the culture was incubated overnight at 37 ºC with shaking at 250 rpm. The
cells were harvested at 5000 x g for 15 min and the resulting pellet was resuspended in 20
mM Tris, pH 8. Following sonication, the cell lysate was boiled for 20 minutes prior to
centrifugation for 20 minutes at 30,000 x g, 4 ºC. The cleared lysate was dialyzed against
20 mM Tris pH 8.0 overnight. Next, the lysate was loaded onto a HiLoad 16/600
Superdex 75 column and eluted with 20 mM Tris, pH 8. FPLC fractions from size233

exclusion chromatography were analyzed by SDS PAGE. The fractions containing αS
were then loaded onto a HighTrap Q HP column and eluted over a 100 minute sodium
chloride gradient (0 to 0.5M NaCl in 20 mM Tris, pH 8). Following FPLC purification of
αS-Z94, αS-39, and αS-94, the fractions were analyzed by MALDI-MS and pooled prior
to click labeling. Following FPLC purification of αS-C994 and αS-39C114, the proteins
were dialyzed into αS buffer overnight for Fam labeling.
Click Labeling of αS-39 and αS-94 with Raz. Prior to performing the labeling
reactions, the concentration of FPLC-purified αS-39 and αS-94 was adjusted to 1.0
mg/mL. The catalyst mixture was separately prepared by combining (for each mL of
reaction)

1.25

µL

of

80

mM

Cu2SO4,

30

µL

of

50

mM

Tris-

(hydroxypropyltriazolylmethyl)amine (THPTA) and 30 µL of 100 mM sodium ascorbate.
This mixture was allowed to incubate at room temperature for 5 min. After adding 5
equiv of 5-TAMRA (Raz) azide to the protein solution, the Cu(I)-containing catalyst
mixture was added, and the reaction was allowed to incubate for 4 hours at 37 ºC.
Following the labeling reaction, excess dye was removed by performing buffer exchange
using using an Amicon (Millipore) Ultra 0.5 mL 3 kDa spin column. Next, the protein
was purified by reverse-phase HPLC as previously described. The purified protein was
then concentrated, exchanged into αS buffer, and stored at – 80 ºC until further use.
Mass Spectrometry Analysis of Raz Labeling Reactions. Click labeling was
periodically monitored using MALDI MS. Following treatment with a total of 5
equivalents of Raz azide in the presence of Cu(I), near quantitative labeling was observed
within 4 h.
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Figure 4.17 MALDI Traces of Crude Raz Labeling Reactions.
Blue trace: Cys mutant prior to the labeling reaction. Red trace: Crude reaction mixture post
labeling with 5 equiv of Raz in the presence of Cu(I). The asterisk (*) indicates a matrix adduct
observed in all MALDI spectra of αS (+207 Da).

MALDI Analysis of Purified αSRaz39 and αSRaz94.

Figure 4.18 MALDI Traces of HPLC Purified αS-Raz39 and αS-Raz94.
Expected [M+H] + of αS-Raz39 and αS-Raz94 are 15013 and 15029, respectively. The asterisk (*)
indicates a matrix adduct observed in all MALDI spectra of αS (+207 Da).

Trypsin Digestion of αSRaz39 and αSRaz94. Trypsin digestion was performed as
previously described. MALDI MS analysis of the trypsin digestion fragments show that
Raz labeling is quantitative and site-specific.

Figure 4.19 MALDI MS of Trypsin Fragments of αS-Raz39 and αS-Raz94.
Expected [M+H] + of αS-Raz39 Frag. 35-43 and αS-Raz94 Frag 81-96 are 1503.8 and 2047.0,
respectively. The double asterisk (**) corresponds to the unmodified trypsin fragment.
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Click Labeling of αS-Z94 with Tco and Raz. Prior to performing the labeling reactions,
the concentration of FPLC-purified αS-Z94 was adjusted to 1.0 mg/mL. αS-Z94 was
incubated with 5 equivalents of Tco for 4 h at 37 ºC. Following the 4 h incubation period,
incomplete labeling was observed by MALDI MS. After adding additional equivalents of
Tco, the labeling yield did not improve. Incomplete labeling is likely due to reduction of
Z to the unreactive amine during protein expression and purification. Raz labeling of αSZ94 was performed as described above. Although we observed a slightly higher
modification yield by MALDI MS, the labeling reaction did not go to completion. Shown
below are representative crude MALDI traces demonstrating that labeling of αS-Z94 using
Tco or Raz fails to go to completion.

Figure 4.20 MALDI MS Analysis of Tco and Raz Labeling of αS-Z94. The asterisk (*) indicates
a matrix adduct observed in all MALDI spectra of αS (+207 Da).

Double-Labeling of αS-C994 and αS--39C114. First, αS-C994 and αS--39C114 were
labeled with Fam as described above. The resulting fluorescein-labeled proteins were
then dialyzed against purification buffer (20 mM Tris, pH 8.0) and purified over a HiTrap
Q HP column on an ÄKTA FPLC over a 120 min NaCl gradient (0 to 1 M NaCl in 20
mM Tris, pH 8.0). The fractions containing the product were identified by MALDI MS
and pooled. Next, Cu-catalyzed click labeling with Raz azide was performed as described
above. Following the click reaction, excess dye was removed by performing buffer
exchange using an Amicon (Millipore) Ultra 0.5 mL 3 kDa spin column. The doubly-
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labeled proteins were purified by reverse-phase HPLC as previously described. The
purified proteins were then concentrated, exchanged into αS buffer, and stored at – 80 ºC
until further use.
Mass Spectrometry Analysis of Double-Labeling. Each labeling step was monitored
using MALDI MS. Near quantitative labeling was observed at each step for both
reactions. Representative MALDI MS data corresponding to each labeling step of αS39C114 are shown below.

Figure 4.21 MALDI Traces of Crude Double Labeling Reactions.
Blue trace: αS-39C114 prior to the labeling reaction. Red trace: Crude reaction mixture post
labeling with 10 equiv of Fam maleimide. Green trace: Crude reaction mixture post labeling with 5
equiv of Raz azide in the presence of Cu(I). The asterisk (*) indicates a matrix adduct observed in
all MALDI spectra of αS (+207 Da).

Mass Spectrometry Analysis of HPLC Purified αS-CFam994 and αS--Raz39C114.

Figure 4.22 MALDI MS Traces of HPLC Purified αS-CFam9Raz94 and αS-Raz39CFam114.
Expected [M+H] + of αS-CFam9Raz94 and αS-Raz39CFam114. are 15474 and 15416, respectively.
Expected [M+H] + of maleimide ring-opened αS-CFam9Raz94 and αS-Raz39CFam114. are 15492 and
15434, respectively. The asterisk (*) indicates a matrix adduct observed in all MALDI spectra of
αS (+207 Da).
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Trypsin Digestion of αS-CFam994 and αS--Raz39C114. Trypsin digestion was performed
as previously described. MALDI MS analysis of the trypsin digestion fragments show
that Fam and Raz incorporation are site-specific and quantitative. In each Fam labeled
fragment, a mass adduct of +18 Da was observed. This increase in mass is consistent with
hydrolytic ring-opening of the maleimide group.

Figure 4.23 MALDI MS of Trypsin Fragments of αS-CFam9Raz94.
Expected [M+H] + of Frag. 7-10 and Frag 81-96 are 847.3 and 2047.0, respectively. The double
asterisk (**) corresponds to the unmodified trypsin fragment.

Figure 4.24 MALDI MS of Trypsin Fragments of αS-Raz39 CFam114.
Expected [M+H] + of Frag. 35-43 and Frag 103-140 are 1503.8 and 4687.6, respectively. The
double asterisk (**) corresponds to the unmodified trypsin fragment.

Synthesis αS-D2CFam9. Protein fragment αS9-140-C9 and the synthetic thioester peptide
Ac-αS1-8-D2-SR were prepared in accordance with previously described protocols.116,117
αS9-140-C9 (1 equiv, 0.10 µmol) was dissolved in 200 µL of degassed ligation buffer (6 M
guanidinium hydrochloride, 200 mM sodium phosphate, 20 mM TCEP, 1% v/v
thiophenol, pH 7.5) and incubated for 5 min. The reduced protein fragment was
transferred to a microcentrifuge tube containing 2 equiv of the dried N-terminal peptide
thioester Ac-αS1-8-D2-SR, purged with argon, and allowed to incubate for 24 h at 37 ºC
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with shaking at 600 rpm. MALDI MS analysis of the crude ligation reaction showed
quantitative conversion to the full length product Ac-αSD2C9 (see below). Following
ligation, the reaction solution was dialyzed into αS buffer. Next, the ligated protein was
labeled with Fam as previously described. MALDI MS analysis of the crude reaction
showed nearly quantitative conversion to the Fam-containing product (see below).
Following the labeling reaction, excess dye was removed by performing buffer exchange
using an Amicon (Millipore) Ultra 0.5 mL 3 kDa spin column. The doubly-labeled
protein was purified by reverse-phase HPLC as previously described. The purified
protein was then concentrated, exchanged into αS buffer, and stored at – 80 ºC.
Mass Spectrometry Analysis of αS-D2CFam9 Synthesis.

Figure 4.25 MALDI Traces of Crude NCL and Fam Labeling Reactions Towards αS-D2CFam9.
Blue trace: αS9-140-C9. Red trace: Formation of αS-D2C9 following ligation of αS9-140-C9 with AcαS1-8-D2-SR. Green trace: Post Fam labeling of αS-D2C9 to generate αS-D2CFam9. The asterisk
(*) indicates a matrix adduct observed in all MALDI spectra of αS (+207 Da).

Mass Spectrometry Analysis of HPLC Purified αS-D2CFam9.

Figure 4.26 MALDI MS Trace of HPLC Purified αS-D2CFam9.
Expected [M+H] + of αS-D2CFam9 is 14962. Expected [M+H] + of maleimide ring-opened αSD2CFam9 is 14980. The asterisk (*) indicates a matrix adduct observed in all MALDI spectra of αS
(+207 Da).
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Fluorescence Polarization Measurements of αS-CFam9, αS-CFam114 and αS-CFam136.
The concentrations of HPLC purified Fam-labeled proteins were determined by UV-Vis
absorbance using a molar extinction coefficient of 68,000 M-1cm-1 at 494 nm. The
concentration of WT αS was also determined using UV-Vis absorbance using a molar
extinction coefficient of 5,600 M-1cm-1 at 277 nm. Prior to obtaining FP measurements,
the Fam-labeled mutants were diluted into a solution of WT αS in a 1:99 molar ratio to
achieve a final total protein concentration of 100 µM (1 µM Fam mutant to 99 µM WT).
100 µL of 10 µM samples were prepared in triplicate by diluting the concentrated stock
into αS buffer (20 mM Tris, 100 mM NaCl, pH 7.5). Each sample was then gently
vortexed and pipetted into a clear-bottomed, black-walled 96-well plate. FP
measurements were obtained using a Tecan Infinite® F200 Pro microplate reader
equipped with excitation (485 ± 20 nm) and emission (535 ± 25 nm) filters for Fam
fluorescence.
Fluorescence Polarization Measurements of αS-CFam9, αS-CFam114 and αS-CFam136
with SDS. In order to measure the FP values of each mutant in the presence of SDS, 10
µM samples containing 1 mM SDS were prepared in triplicate by combining 10 µL of the
protein stock solution (prepared as described above) with 80 µL of aggregation buffer
and 10 µL of 10 mM SDS. The samples were then gently vortexed, pipetted into a 96well plate and immediately assessed on the microplate reader.
Aggregation Assays. Aggregation reactions were carried out by diluting each labeled
construct into a mixture of WT αS in a 1:99 molar ratio to a final concentration of 100
µM as described above. Aggregation reactions were assembled in triplicate. Aggregation
was initiated by shaking the solution at 1500 rpm on an IKA MS3 digital orbital shaker in
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parafilm-sealed Eppendorf tubes. Periodically, aliquots were removed from the
aggregation reaction and assessed by FP and CR absorbance in separate assays. For FP
measurements, 10 µL of the aggregation solution was diluted to 100 µL using αS buffer.
The samples were gently vortexed and transferred to a 96-well plate. For CR
measurements, 10 µL of the aggregation solution was diluted to 200 µL using 20 µM CR
dissolved in αS buffer. The samples were allowed to sit at room temperature for 15
minutes prior to being transferred to a 96-well plate and measured by FP and UV-Vis.
Normalized data is shown in Section 4.5. Raw data corresponding to FP and CR
measurements are shown below. Note that free fluorescein has an FP value of ~20 mP
under the same conditions (data not shown).

Figure 4.27 FP Measurements Corresponding to αS-CFam9, αS-CFam114 and αS-CFam136
Aggregation.
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Figure 4.28 CR Absorbance Measurements Corresponding to αS-CFam9, αS-CFam114 and αSCFam136 and Wild-Type Aggregation Assays.

Estimation of t1/2. The times corresponding to the half-maximum of the kinetics curves
(t1/2, based on FP and CR measurements) were determined by fitting the data to a
sigmoidal equation (Eq. 4.2) of the form:
1
1
in Kaleidagraph, where m1 defines the upper baseline of the sigmoidal curve (normalized
to 1) and σ represents a fitting parameter. Measurements of t1/2 that correspond to each
mutant are listed in Section 4.4.
SDS Disaggregation Assays. Fibrils for disaggregation assays were prepared by
combining labeled αS in a 1:99 molar ratio with WT αS (300 µL total) and agitating the
solution at 1500 rpm at 37 ºC for a total of 36 hours. Following the aggregation reaction,
fibrils were isolated from the solution by centrifuging the samples for 1 h at 13,200 rpm
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on a desktop centrifuge. After removing the supernatant, the fibrils were re-suspended in
the same starting volume, such that the approximate protein concentration was 100 µM
(relative to monomeric αS). The fibrils were re-suspended by gently pipetting αS buffer
over the fibrils, and then vortexing at high speeds for 10 s intervals for a total of 4 times.
Typically, FP values following re-suspension were between 310-350 mP units for each
mutant. In order to obtain FP measurements of αS fibrils, 10 µL aliquots were removed
from the re-suspended samples and diluted into 90 µL of αS buffer. Disaggregation
reactions were performed by combining 10 µL of fibrils, 80 µL of αS buffer, and 10 µL
of 10 mM SDS and boiling the solution for 5 min in parafilm-sealed Eppendorf tubes.
The samples were allowed to cool to room temperature prior to being gently vortexed and
transferred to a 96-well plate for FP measurements.
Small Molecule Remodeling Assays. Fibrils containing each labeled mutant were
prepared for small molecule remodeling assays as described above. Stock solutions of
500 µM dopamine, 500 µM EGCG, and 500 µM NDGA were freshly prepared prior to
performing each remodeling assay. NDGA stock solutions were prepared with 20%
EtOH. Remodeling assays were performed in triplicate by treating three independent
samples of 10 µM αS fibrils with stoichiometric (10 µM) or excess (100 µM) amounts of
dopamine, EGCG, and NDGA. Prior to adding the small molecule solution to the αS
fibrils, the solutions containing the fibrils were transferred to a 96-well plate. Each small
molecule was then quickly added to the plate prior to continuously monitoring the
reactions using FP. FP measurements were obtained at 1 min intervals with 2 s of shaking
performed prior to each reading at room temperature.
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